

(19)



(11) Publication number:

SG 191124 A1

(43) Publication date:

31.07.2013

(51) Int. Cl:

**C12N 15/09, C12N 5/10, C12P
21/02, C12P 21/08;**

(12)

Patent Application

(21) Application number: **2013045265**

(71) Applicant:

(22) Date of filing: **14.12.2011**

(30) Priority: **JP 2010-279849 15.12.2010**

**INTER-UNIVERSITY RESEARCH
INSTITUTE CORPORATION RESEARCH
ORGANIZATION OF INFORMATION
AND SYSTEMS 10-3, MIDORI-CHO,
TACHIKAWA-SHI, TOKYO 1900014 JP
KYOWA HAKKO KIRIN CO., LTD. 1-6-1,
OHEMACHI, CHIYODA-KU, TOKYO
1008185 JP**

(72) Inventor:

**KAWAKAMI KOICHI
KUROKAWA MEGUMI
YAMAGUCHI KEINA
OGAWA RISA
TSUKAHARA MASAYOSHI
HAYASHI YOKO**

(54) **Title:**

PROTEIN PRODUCTION METHOD

(57) **Abstract:**

PROCESS FOR PRODUCTION OF PROTEIN Abstract
[Abstract] The present invention relates to a method for integrating a gene fragment 5 inserted between a pair of transposon sequences into a chromosome of a mammalian cell, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; and a method for producing the protein of interest comprising 10 suspension-culturing a suspension mammalian cell which produces the protein of interest; and an a suspension mammalian cell which expresses the protein of interest.

PROCESS FOR PRODUCTION OF PROTEIN

Abstract

[Abstract]

5 The present invention relates to a method for integrating a gene fragment
inserted between a pair of transposon sequences into a chromosome of a mammalian
cell, comprising introducing at least one expression vector which comprises a gene
fragment comprising a DNA encoding a protein of interest and also comprises a pair of
transposon sequences at both terminals of the gene fragment, into a suspension
mammalian cell; and a method for producing the protein of interest comprising
10 suspension-culturing a suspension mammalian cell which produces the protein of
interest; and an a suspension mammalian cell which expresses the protein of interest.

Fig. 1

DESCRIPTION

Title of Invention: PROCESS FOR PRODUCTION OF PROTEIN

5 Technical Field

[0001]

This invention relates to a method for integrating a gene fragment inserted between a pair of transposon sequences into a chromosome of a mammalian cell, comprising introducing at least one expression vector which comprises a gene fragment
10 comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; and a method for producing the protein comprising suspension-culturing a suspension mammalian cell which produces the protein, a suspension mammalian cell which expresses the protein; and an expression vector
15 which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment.

Background Art

[0002]

20 Production of exogenous proteins by recombinant DNA techniques is used in various industries such as pharmaceutical industry and food industry. In most cases, production of recombinant proteins is carried out by introducing an expression vector comprising a nucleotide sequence encoding a protein of interest into a host, such as *Escherichia coli*, yeast, insect cell, plant cell, and animal cell, selecting a transformant
25 in which the expression vector is integrated into the chromosome, and further culturing the transformed cell line under appropriate culture conditions.

[0003]

However, in order to develop a host which can produce an exogenous protein efficiently, it is necessary to select a host cell having good productivity for each protein
30 of interest, so that a further technical innovation is desired on the exogenous protein production techniques for each host.

[0004]

In the bacteria systems, such as *Escherichia coli*, and yeast systems, different from animal cells, post-translational modifications, such as sugar chain modification,
35 are difficult to attain in many cases and thus cause a problem in producing a protein having its activity.

[0005]

Since the produced protein is subject to a post-translational modification such as phosphorylation and addition of sugar chains in the insect system, this system has a merit that the protein having its original physiological activity can be expressed. However, since the sugar chain structure of the secreted protein is different from that of mammals-derived cells, antigenicity and the like become a problem when the protein is applied to pharmaceutical use.

[0006]

In addition, since a recombinant virus is used in the insect cell system when an exogenous gene is introduced, there is a problem that its inactivation and containment of the virus are required from the viewpoint of safety.

[0007]

In the animal cell system, post-translational modifications, such as phosphorylation, sugar chain addition, and folding, can be conducted to proteins derived from higher animals including human, in more similar manner to those produced in the living body. Such accurate post-translational modifications are necessary for recreating the physiological activity originally possessed by a protein in its recombinant protein, and a protein production system in which a mammalian cell is used as a host is usually applied to pharmaceutical products and the like that requires such physiological activity.

[0008]

However, a protein expression system in which a mammalian cell is used as the host is generally low in productivity, and also causes a problem of the stability of introduced genes in many cases. Improvement of productivity of a protein using a mammalian culture cell as a host is not only very important in producing medicaments for treatment, diagnostic agents and the like, but also greatly contributes to research and development of them. Thus, it is urgent to develop a gene expression system which easily makes it possible to obtain a cell line of a high productivity using a mammalian culture cell, particularly Chinese hamster ovary cell (CHO cell), as the host.

[0009]

A transposon is a transposable genetic element which can move from one locus to other locus on the chromosome. A transposon is a strong tool for the study on molecular biology and genetics and used for a purpose, such as mutagenesis, gene trapping, and preparation of transgenic individuals, in insects or nematode (e.g., *Drosophila melanogaster* or *Caenorhabditis elegans*) and plants. However, development of such a technique has been delayed for vertebral animals including mammalian cells.

[0010]

In recent years, however, transposons which have activities also in vertebral animals have been reported, and some of them were shown to have an activity in mammalian cells, such as cell derived from mouse and human. Typical examples include transposons Tol1 (Patent Reference 1) and Tol2 (Non-patent Reference 1) which are cloned from a medaka (killifish), Sleeping Beauty reconstructed from a non-autonomous transposon existed in *Onchornhynchus* fish genome (Non-patent Reference 2), an artificial transposon Frog prince (Non-patent Reference 3) which is derived from frog and a transposon piggyBac (Non-patent Reference 4) which is derived from insect.

[0011]

These DNA transposons have been used for mutagenesis, gene trapping, preparation of transgenic individuals, expression of drug-resistant proteins, and the like, as a gene introduction tool for bringing a new phenotype in a genome of a mammalian cell (Non-patent References 5 to 12).

[0012]

In the case of insects, a method in which an exogenous gene is introduced into silkworm chromosome using the transposon piggyBac derived from a *Lepidoptera* insect to express the protein encoded by said exogenous gene has been studied, and a protein production method using the above techniques was disclosed (Patent Reference 2).

[0013]

However, since protein of interest is not expressed at sufficient levels and is produced in the whole body of silkworm, it causes an economical problem due to the necessity of an advanced purification technique for recovering the expressed exogenous protein in a highly purified form from the body fluid including a large amount of contaminated proteins.

[0014]

In addition, an example in which a protein relating to G418 resistance is expressed in a mammalian cell using the medaka-derived transposon Tol2 (Non-patent References 12 and 13) is known.

[0015]

In the case of producing a protein drug for medical use using a mammal-derived cultured cell, it is important that an animal-derived component is not contained during its production process in order to prevent unexpected contamination of an unknown virus or pathogenic polypeptide. CHO cell is most frequently used as an animal cell for producing a protein drug, and due to the studies of recent years, a suspension CHO cell line capable of culturing in a safe medium which does not use a

serum or animal-derived component has also be established. However, productivity of a cell line into which a gene was introduced under a serum-free or protein-free condition is limited to half that of the cell line into which a gene was introduced under a serum-used condition (Non Patent Literature 14). It is shown that gene transduction under a serum-free or protein-free condition is technically difficult.

[0016]

It is general that a selectable marker for screening a cell expressing a protein of interest is arranged on the same gene expression vector. This is based on a hypothesis that there are a region where a gene existing in the genome is easily expressed and a region where a gene existing in the genome is hardly expressed (called as position effects, Non Patent Literature 15), and that the protein of interest is also expressed when the selectable marker is expressed.

[0017]

On the other hand, when a protein of interest, is comprised of two or more polypeptides such as an antibody and the like, it is also known that each polypeptide is expressed using different vectors. In the case of an antibody, it has been shown that the productivity is higher when expression of heavy chain of the antibody is higher than the expression of light chain (Non Patent Literature 16). Since it is predicted that expressions of heavy chain and light chain become constant on the same vector. It becomes possible to obtain a cell line which expresses the heavy chain and light chain at an optimum ratio by intentionally expressing the heavy chain and light chain using different vectors for the purpose of obtaining high productivity. However, when a protein is expressed using two or more different vectors, two or more selectable marker genes are also necessary.

[0018]

As a way for overcoming this, it was reported a case in which a dhfr gene originally consisting of one polypeptide chain was divided into two polypeptide chains and one of them was arranged on a heavy chain expression vector, and the other was arranged on a light chain expression vector (Non Patent Literature 17).

[0019]

However, the cell described in the Non Patent Literature 17 is a CHO cell in which the cell is dependent on the protein component added to the medium, and as described in the above, there is a possibility that the gene introduction efficiency is high different from the case of the gene introduction under a serum-free or protein-free condition. It is predicted that selecting a cell of high productivity is still difficult when a gene is introduced under a serum-free or protein-free condition having high safety and free from the danger of viral infection and the like.

[Citation List]

[Patent Literature]

[0020]

[Patent Literature 1] WO2008/072540

5 [Patent Literature 2] Japanese Published Unexamined Patent Application No. 2001-532188

[Non Patent Literature]

[0021]

[Non Patent Literature 1] *Nature* 383, 30 (1996)

10 [Non Patent Literature 2] *Cell* 91, 501-510 (1997)

[Non Patent Literature 3] *Nucleic Acids Res*, 31, 6873-6881 (2003)

[Non Patent Literature 4] *Insect Mol. Biol.* 5, 141-151 (1996)

[Non Patent Literature 5] *Genetics*.166, 895-899 (2004)

[Non Patent Literature 6] *PLoS Genet*, 2, e169 (2006)

15 [Non Patent Literature 7] *Proc. Natl. Acad. Sci. USA* 95, 10769-10773 (1998)

[Non Patent Literature 8] *Proc. Natl. Acad. Sci. USA* 98:6759-6764 (2001)

[Non Patent Literature 9] *Nature* 436,221-22 6 (2005)

[Non Patent Literature 10] *Nucleic Acids Res.*, 31, 6873-6881 (2003)

[Non Patent Literature 11] *Nucleic Acids Res.*, 35, e87 (2007)

20 [Non Patent Literature 12] *Proc Natl. Acad. Sci. USA*, 103, 15008-15013 (2006)

[Non Patent Literature 13] *Plos Genetics*, 2,1715-1724(2006)

[Non Patent Literature 14] *Biotech. Bioeng.* 96, 1118-1126

(2007)

[Non Patent Literature 15] *Nature Biotech.* 22, 1393-1398

25 (2004)

[Non Patent Literature 16] *Biotech. Bioeng.* 96, 337-348 (2007)

[Non Patent Literature 17] *Biotech. Bioeng.* 84, 439-444 (2003)

Disclosure of Invention

30 Problems to be Solved by the Invention

[0022]

In order to produce and analyze a protein of interest, it is necessary to select a cell line which stably and highly expresses a protein of interest, using a mammalian-derived culture cell. However, preparing and culturing the cell that
35 produces the protein of interest require considerable effort and time.

[0023]

In addition, though it is known that a protein of interest is expressed in a

mammalian cell using a transposon sequence, preparation of a cell which can highly express a protein of interest and thus can be used as a protein production system by using a transposon sequence; a preparation method of a mammalian cell which can highly produce a protein of interest by using a transposon sequence; and a production method of a protein using the cell are not known.

[0024]

As described in the above, the expression of a protein of interest in a large amount by establishing a protein production system which can highly produce a protein of interest using a mammalian culture cell efficiently and within a short period has been required. In addition, establishment of a producing cell which does not require any components derived from an animal from the gene introduction to establishment of a producing cell has been desired.

[0025]

Thus, the objects of the invention are to provide a cell capable of highly expressing a protein of interest which can be efficiently established, and a method for producing the protein of interest using the cell.

Means for Solving the Problems

[0026]

To solve the above-mentioned problems, the present inventors have conducted intensive studies and found as a result that a protein of interest can be efficiently produced by introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; and integrating the gene fragment inserted between a pair (two) of the transposon sequences into a chromosome of the mammalian cell. In addition, it was found that the protein of interest can be produced efficiently by using the cell, and thereby the invention was accomplished.

[0027]

Specifically, the invention relates to the followings:

1. A method for producing a protein of interest, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment comprising the DNA encoding the protein of interest inserted between a pair of the transposon sequences into a chromosome of the mammalian cell to obtain a mammalian cell which expresses the protein of interest; and suspension-culturing the mammalian

cell;

2. A method for producing a protein of interest, comprising the following steps (A) to (C):

(A) a step of simultaneously introducing the following expression vectors (a) and (b) into a suspension mammalian cell:

(a) at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(b) an expression vector which comprises a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome,

(B) a step of obtaining a suspension mammalian cell which expresses the protein of interest by expressing transiently the transposase from the expression vector which is introduced into the suspension mammalian cell in the step (A) to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome of the mammalian cell, and

(C) a step of suspension-culturing the suspension mammalian cell which expresses the protein of interest obtained in the step (B) to produce the protein of interest;

3. A method for obtaining a suspension mammalian cell which expresses a protein of interest, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises transposon sequences at both terminals of the gene fragment into a suspension mammalian cell, and integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell;

4. The method described in any one of the above items 1 to 3, wherein at least one of the expression vectors which comprises a gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment is an expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment;

5. The method described in any one of the above items 1 to 4, comprising introducing an expression vector which comprises a gene fragment comprising a selectable marker and comprises a pair of transposon sequences at both terminals of the gene fragment into a mammalian cell in addition to the expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment,;

6. The method described in any one of the above items 1 to 5, wherein the DNA encoding the protein of interest is a DNA encoding an antibody.

7. The method described in any one of the above item 6, wherein the DNA encoding an antibody is at least one of a DNA encoding an H chain of the antibody and
5 a DNA encoding a L chain of the antibody;

8. The method described in any one of the above items 4 to 7, wherein an expression vector selected from the following (a) to (d) is introduced into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA
10 encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also
15 comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an
20 antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
25 vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also
30 comprises a pair of transposon sequences at both terminals of the gene fragment;

9. The method described in any one of the above items 1 to 8, wherein the suspension mammalian cell is a cell capable of surviving and proliferating in a serum-free medium;

10. The method described in any one of the above items 1 to 9, wherein the
35 suspension mammalian cell is at least one selected from a suspension CHO cell in which a CHO cell is adapted to suspension culture, a PER.C6 cell, a rat myeloma cell

YB2/3HL.P2.G11.16Ag.20 (or also called YB2/0) and a suspension mouse myeloma cell NS0 adapted to suspension culture;

11. The method described in the above item 10, wherein the CHO cell is at least one selected from CHO-K1, CHO-K1SV, DUKXB11, CHO/DG44, Pro-3 and CHO-S;

12. The method described in any one of the above items 4 to 11, wherein the selectable marker gene is a cycloheximide resistance gene;

13. The method described in any one of the above item 12, wherein the cycloheximide resistance gene is a ribosome protein;

14. The method described in any one of the above items 1 to 13, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of DNA-type transposons which function in a mammalian cell;

15. The method described in the above item 14, wherein the nucleotide sequences derived from a pair of DNA type transposons are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons;

16. The method described in the above item 15, wherein the nucleotide sequences derived from a pair of Tol2 transposons are a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3;

17. The method described in the above item 15, wherein the nucleotide sequences derived from a pair of Tol1 transposons are the nucleotide sequences shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15.

18. A suspension mammalian cell, which has a chromosome into which a gene fragment inserted between a pair of the transposons is integrated and which produces a protein of interest obtainable by simultaneously introducing at least one of expression vector (a) which comprises the gene fragment comprising a DNA encoding a protein of interest and also comprises the pair of transposon sequences at both terminals of the gene fragment and an expression vector (b) which comprises a DNA encoding a transposase (transferase) capable of recognizing the transposon sequences and having the activity to transfer the gene fragment inserted between the pair of transposon sequences to the chromosome.

19. The mammalian cell described in the above item 18, wherein the at least one of expression vector (a) which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment is an expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and a selectable marker gene and also

comprises a pair of transposon sequences at both terminals of the gene fragment.

20. The mammalian cell described in the above item 18 or 19, which is a cell prepared by further introducing an expression vector (c) which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment in addition to the expression vectors (a) and (b).

21. The mammalian cell described in any one of the above items 18 to 20, wherein the DNA encoding the protein of interest is a DNA which encodes an antibody.

22. The mammalian cell described in the above item 21, wherein the DNA which encodes an antibody is at least one of a DNA encoding a H chain of an antibody and a DNA encoding a L chain of an antibody.

23. The mammalian cell described in any one of the above items 18 to 22, into which an expression vector selected from the following (a) to (d) is introduced:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding an L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.

24. The mammalian cell described in any one of the above item 18 to 23, wherein the cell is a cell capable of surviving and proliferating in a serum-free medium;

25. The mammalian cell described in any one of the above items 18 to 24, wherein the cell is any one suspension mammalian cell selected from a suspension CHO cell in which a CHO cell is adapted to suspension culture, a PER.C6 cell, a rat myeloma cell YB2/3HL.P2.G11.16Ag.20 (or also called YB2/0) and a suspension mouse myeloma cell NS0 adapted to suspension culture;

26. The mammalian cell described in the above item 25, wherein the CHO cell is any one selected from CHO-K1, CHO-K1SV, DUKXB11, CHO/DG44, Pro-3 and CHO-S;

27. The mammalian cell described in any one of the above items 19 to 26, wherein the selectable marker gene is a cycloheximide resistance gene;

28. The mammalian cell described in the above item 27, wherein the cycloheximide resistance gene is a gene encoding a mutant of human ribosomal protein L36a;

29. The mammalian cell described in any one of the above items 19 to 28, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of DNA-type transposons which function in a mammalian cell;

30. The mammalian cell described in the above item 29, wherein the nucleotide sequences derived from a pair of the DNA-type transposons are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons;

31. The mammalian cell described in the above item 30, wherein the nucleotide sequences derived from a pair of the Tol2 transposons are the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3;

32. The mammalian cell described in the above item 30, wherein the nucleotide sequences derived from a pair of the Tol1 transposons are the nucleotide sequence shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15;

33. An expression vector, which comprises a gene fragment comprising a DNA encoding a protein of interest, and also comprises a pair of transposon sequences at both terminals of the gene fragment;

34. The expression vector described in the above item 33, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons.

35. The protein expression vector described in the above item 34, wherein the nucleotide sequences derived from a pair of the Tol2 transposons are the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3; and

36. The expression vector described in the above item 34, wherein the nucleotide sequences derived from a pair of the Tol1 transposons are the nucleotide sequence shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15.

Effect of Invention

[0028]

According to the protein production method of the invention, a protein of interest can be efficiently produced by using a suspension mammalian cell. In addition, the cell of the present invention can be used as a production cell for producing a recombinant protein or a recombinant polypeptide with a high efficiency.

Brief Description of the Drawings

[0029]

[Fig. 1] Fig. 1 shows a schematic illustration of a transposon vector for expressing an anti-human influenza M2 antibody. Tol2-L represents a left end Tol2 transposon (SEQ ID NO:2), Tol2-R represents a right end Tol2 transposon (SEQ ID NO:3), CMV represents a CMV promoter, poly A represents a polyadenylation site, Hc represents a human antibody H chain cDNA, Lc represents a human antibody L chain cDNA, and CHX-r represents a cycloheximide resistance gene.

[Fig. 2] Fig. 2 shows a schematic illustration of an anti-human influenza M2 antibody expression vector. CMV represents a CMV promoter, poly A represents a polyadenylation site, Hc represents a human antibody H chain cDNA, Lc represents a human antibody L chain cDNA and CHX-r represents a cycloheximide resistance gene.

[Fig. 3] Fig. 3 shows a schematic illustration of a Tol2 transposase expression vector. CAGGS represents a CAGGS promoter, poly A represents a polyadenylation site, and TPase cDNA represents a Tol2 transposase cDNA.

[Fig. 4] Fig. 4 shows a result of examining expression level of an anti-human influenza M2 antibody in a suspension CHO-K1 cell and an adhesive CHO-K1 cell when a Tol2 transposon vector for expressing an anti-human influenza M2 antibody was used. Fig. 4A represents a result of a suspension CHO-K1 cell and Fig. 4B represents a result of an adhesive CHO-K1 cell. In the both figures, the ordinate shows the amount of antibody production ($\mu\text{g/ml}$), and the abscissa shows the number of transgenic clones of each cell.

[Fig. 5] Fig. 5 shows a schematic illustration of a Tol1 transposon vector for expressing an anti-human influenza M2 antibody. Tol1-L represents a left end Tol1 transposon (SEQ ID NO:14), Tol1-R represents a right end Tol1 transposon (SEQ ID

NO:15), CMV represents a CMV promoter, poly A represents a polyadenylation site, Hc represents a human antibody H chain cDNA, Lc represents a human antibody L chain cDNA, and CHX-r represents a cycloheximide resistance gene.

[Fig. 6] Fig. 6 shows a schematic illustration of a Tol1 transposase expression vector. CAGGS represents a CAGGS promoter, poly A represents a polyadenylation site, and TPase cDNA represents a Tol1 transposase cDNA.

[Fig. 7] Fig. 7 shows a result of examining expression level of an anti-human influenza M2 antibody in a suspension CHO-K1 cell when a Tol1 transposon vector for expressing an anti-human influenza M2 antibody was used. The ordinate shows the amount of antibody production ($\mu\text{g/ml}$), and the abscissa shows the number of transgenic clones of each cell.

[Fig. 8] Fig. 8 shows a schematic illustration of a transposon vector for expressing an anti-human CD98 antibody heavy chain. Tol2-L represents a left end Tol2 transposon (SEQ ID NO:2), Tol2-R represents a right end Tol2 transposon (SEQ ID NO:3), Pmo represents a Moloney Murine Leukemia Virus promoter, poly A represents a polyadenylation site, and Hc represents an anti-human CD98 antibody heavy chain cDNA (SEQ ID NO:18).

[Fig. 9] Fig. 9 shows a schematic illustration of a transposon vector for expressing anti-human CD98 antibody light chain. Tol2-L represents a left end Tol2 transposon (SEQ ID NO:2), Tol2-R represents a right end Tol2 transposon (SEQ ID NO:3), CMV represents a CMV promoter, poly A represents a polyadenylation site, and Lc represents an anti-human CD98 antibody light chain cDNA (SEQ ID NO:21).

[Fig. 10] Fig. 10 shows a schematic illustration of a transposon vector for expressing a cycloheximide resistant gene. Tol2-L represents a left end Tol2 transposon (SEQ ID NO:2), Tol2-R represents a right end Tol2 transposon (SEQ ID NO:3), CMV represents a CMV promoter, poly A represents a polyadenylation site, and CHX-r represents a cycloheximide resistant gene (SEQ ID NO:7).

[Fig. 11] Fig. 11 shows production amount of anti-human $\text{TNF}\alpha$ antibody when $\text{TNF}\alpha$ -CHX tandem vector or $\text{TNF}\alpha$ H-CHX vector and $\text{TNF}\alpha$ L vector were gene-introduced into a CHO-K1 cell. The ordinate shows the concentration of the antibody ($\mu\text{g/ml}$) which is produced in the medium, the control plot is shown by Control, and the test plot is shown by Exp.

[Fig. 12] Fig. 12 shows production amount of anti-human CD20 antibody when CD20-CHX tandem vector or CD20H-CHX vector and CD20L vector were gene-introduced into a CHO-K1 cell. The ordinate shows the concentration of the antibody ($\mu\text{g/ml}$) which is produced in the medium, the control plot is shown by Control, and the test plot is shown by Exp.

[Fig. 13] Fig. 13 shows structure of the antibody expression vector A. In Fig. 13, Tol2-L represents a DNA fragment comprising the Tol2-L sequence (SEQ ID NO:2), and Tol2-R represents a DNA fragment comprising the Tol2-R sequence (SEQ ID NO:3), CMV represents a CMV promoter, poly A represents a polyadenylation site, Hc represents a heavy chain gene of CD98 antibody, Lc represents an anti-human CD98 antibody light chain gene, SO represents an SV40 promoter, SV represents an SV40 polyadenylation site, and Neo-r represents a neomycin resistance gene.

Embodiments for Carrying Out the Invention

[0030]

This invention relates to a method for producing a protein of interest, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair (two) of the transposon sequences, into a chromosome of the mammalian cell to obtain a suspension mammalian cell which expresses said protein of interest; and suspension-culturing the mammalian cell.

[0031]

Examples of the method for producing a protein of interest in the present invention (hereinafter referred to as the method of the present invention) comprise a method for producing a protein of interest, which comprises the following steps (A) to (C).

(A) a step of simultaneously introducing the following expression vectors (a) and (b) into a suspension mammalian cell:

(a) at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises transposon sequences at both terminals of the gene fragment,

(b) a vector which comprises a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome,

(B) a step of expressing transiently the transposase from the expression vector (b) which is introduced into the suspension mammalian cell in the step (A) to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome of the mammalian cell to obtain a suspension mammalian cell which expresses the protein of interest, and

(C) a step of suspension-culturing the suspension mammalian cell which expresses the protein of interest obtained in the step (B) to produce the protein of interest.

[0032]

In addition, the present invention relates to a suspension mammalian cell, into which at least one of expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector is introduced to integrate the gene fragment inserted between the pair of transposon sequences into chromosome, and which produces the protein of interest.

[0033]

In the present invention, the protein of interest is a protein comprised of one or more polypeptides, and according to the method of the invention, it can carry out any of the expression of at least one of the protein of interest and/or expression of at least one polypeptide.

[0034]

The at least one of expression vectors which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment means one or two or more species of the expression vector. Particularly, in order to express a protein of interest comprised of two or more polypeptides, it is necessary to use two or more expression vectors which comprise a gene fragment including a DNA encoding respective polypeptides and also comprise a pair of transposon sequences at both terminals of the gene fragment.

[0035]

More particularly, for example, when the above-mentioned protein of interest comprised of two or more polypeptides is an antibody, a H chain and a L chain of an antibody may be expressed using one expression vector or may be expressed using two expression vectors of a vector which expresses the H chain and a vector which expresses the L chain, respectively.

[0036]

According to the method of the present invention, it can produce a protein of interest using a suspension mammalian cell which produces the protein of interest, in which a gene fragment inserted between a pair of transposon sequences is integrated into chromosome, by introducing the expression vector which comprises a gene fragment including a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment.

[0037]

The selectable marker gene to be used as an index of gene insertion may be integrated into the same vector as the expression vector which comprises the DNA

encoding the protein of interest or may be integrated into a different vector.

[0038]

That is, at least one of the expression vectors which comprise a gene fragment including a DNA encoding a the protein of interest and also comprise a pair of
5 transposon sequences at both terminals of the gene fragment may be used as the expression vector which comprises a gene fragment including a DNA encoding a protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.

[0039]

Also, in addition to the expression vector which comprises a gene fragment including a DNA encoding a the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment including a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment may be further
15 introduced into a mammalian cell.

[0040]

Specifically, examples of the method for producing a protein of interest of the present invention include a method, comprising the following steps (A) to (C):

(A) a step of simultaneously introducing the following expression vectors (a) and
20 (b) into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(b) a vector which comprises a DNA encoding a transposase which recognizes
25 the transposon sequences and has activity of transferring the gene fragment inserted between a pair of the transposon sequences into a chromosome,

(B) a step of expressing the transposase transiently from the expression vector (b) which is introduced into the suspension mammalian cell in the step (A) to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome
30 of the mammalian cell and obtaining a suspension mammalian cell which expresses the protein of interest, and

(C) a step of suspension-culturing the suspension mammalian cell which expresses the protein of interest obtained in the step (B) to produce the protein of interest.

[0041]

In addition, examples of the method for producing a protein of interest of the present invention include a method, comprising the following steps (A) to (C):

(A) a step of simultaneously introducing the following expression vectors (a), (b)

and (c) into a suspension mammalian cell:

(a) at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(b) an expression vector which comprises a selectable marker and a pair of transposon sequences at both terminals of the selectable marker,

(c) a vector which comprises a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring the gene fragment inserted between a pair of the transposon sequences into a chromosome,

(B) a step of expressing transiently the transposase transiently from the expression vector (c) which is introduced into the suspension mammalian cell in the step (A) to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome of the mammalian cell and obtaining a suspension mammalian cell which expresses the protein of interest, and

(C) a step of suspension-culturing the suspension mammalian cell which expresses the protein of interest obtained in the step (B) to produce the protein of interest.

[0042]

The present invention relates to a suspension mammalian cell, into which at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a selectable marker and a pair of transposon sequences at both terminals of the selectable marker are introduced to integrate the gene fragment and the selectable marker inserted between a pair of the transposon sequences into a chromosome, and which produces a protein of interest.

[0043]

In addition, the present invention relates to a suspension mammalian cell into which a protein expression vector which comprises a gene fragment which comprising a DNA encoding a protein of interest and a selectable marker, and also comprises a pair of transposon sequences at both terminals of the gene fragment is introduced, to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome, and which produces a protein of interest.

[0044]

Furthermore, examples of the suspension mammalian cell which produces a protein of interest of the present invention include a suspension mammalian cell into which an expression vector (a) comprising a gene fragment comprising a DNA encoding a protein of interest and a selectable marker gene and also comprising

transposon sequences at both terminals of the gene fragment, and a vector (b) comprising a DNA encoding a transposase (a transferase) which recognizes the transposon sequences and has activity of transferring the gene fragment inserted between a pair of the transposon sequences into a chromosome to integrate the gene fragment inserted between a pair of the transposon sequences into the chromosome are simultaneously introduced and which produces the protein of interest.

[0045]

According to the present invention, the number of expression vectors which comprise a gene fragment including a DNA encoding the protein of interest and also comprise a pair of transposon sequences at both terminals of the gene fragment, to be introduced into a suspension mammalian cell, is not particularly limited as long as expression and production of the protein of interest can be carried out by the mammalian cell, and examples include preferably 1 to 20 species of expression vectors, more preferably 2 to 10 species of expression vectors, can be mentioned, and for example, 3 to 8 species of expression vectors, 4 to 7 species of expression vectors, 1 to 6 species of expression vectors, 1 to 5 species of expression vectors, 1 to 4 species of expression vectors and 1 to 3 species of expression vectors are preferable.

[0046]

In addition, examples of the embodiment of the present invention include a method for increasing integration of a gene fragment inserted between a pair of transposon sequences into chromosome of the mammalian cell, by simultaneously introducing into the suspension mammalian cell (a) at least one of expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment and (b) a vector which comprises a DNA encoding transposase capable of recognizing the transposon sequences and having the activity to introduce the gene fragment inserted between the pair of transposon sequences to chromosome, a method for integrating a DNA encoding a protein of interest into chromosome of the mammalian cell at a high frequency and a suspension mammalian cell which is obtained by the methods and can produce a protein of interest.

[0047]

The term "transposon" in the present specification is a transposable genetic element and means a gene unit which moves on a chromosome or from a chromosome to another chromosome (transposition) while keeping a certain structure.

[0048]

The transposon comprises a repeating transposon sequences (also called inverted repeat sequence (IR sequence) or terminal inverted repeat sequence (TIR

sequence)) which positions in the same direction or the reverse direction at both terminals of a gene unit and a nucleotide sequence encoding a transposase which recognizes the transposon sequence to introduce a gene existing between the transposon sequences.

5 [0049]

The transposase translated from the transposon can introduce a DNA by recognizing transposon sequences of both terminals of the transposon, cleaving out the DNA fragment inserted between a pair of the transposon sequences and inserting the fragment into the site to be introduced.

10 [0050]

The term “transposon sequence” in the present specification means the nucleotide sequence of a transposon recognized by a transposase and has the same meaning as the IR sequence or TIR sequence. A DNA comprising the nucleotide sequence may comprise an imperfect repeating moiety as long as it can be introduced (inserted into other position in the genome) by the activity of a transposase, and there is a transposon sequence specific to a transposase.

[0051]

As the transposon sequence to be used in the invention, a nucleotide sequence derived from a DNA-type transposon is preferable, and a nucleotide sequence derived from a pair of natural or artificial DNA-type transposons, which can be recognized by a transposase and be transposed in mammalian cells, is more preferable.

[0052]

Examples of the nucleotide sequence derived from a DNA-type transposon include the nucleotide sequences derived from the medaka fish-derived Tol1 transposon and Tol2 transposon, the Sleeping Beauty reconstructed from a non-autonomous transposon existed in an *Onchorhynchus* fish genome, the frog-derived artificial transposon Frog Prince and the insect-derived transposon PiggyBac.

[0053]

Particularly, among them, the nucleotide sequences derived from the medaka fish-derived Tol2 transposon comprising the nucleotide sequence shown in SEQ ID NO:6 and the medaka fish-derived Tol2 transposon comprising the nucleotide sequence shown in SEQ ID NO:13 are preferable.

[0054]

Examples of the nucleotide sequence derived from a pair of Tol2 transposons include the nucleotide sequence at positions 1 to 2229 and the nucleotide sequence at positions 4148 to 4682 in the Tol2 transposon nucleotide sequence shown in SEQ ID NO:6 of Sequence Listing.

[0055]

As the nucleotide sequence derived from a pair of Tol2 transposons, the nucleotide sequence at positions 1 to 200 (SEQ ID NO:2) (hereinafter referred to as “Tol2-L sequence”) and the nucleotide sequence at positions 2285 to 2788 (SEQ ID NO:3) (hereinafter referred to as “Tol2-R sequence”) in the Tol2 transposon nucleotide sequence shown in SEQ ID NO:1 of Sequence Listing are more preferable.

[0056]

As the transposon sequence derived from a pair of Tol1 transposons, example include the nucleotide sequence comprising a nucleotide sequence at positions 1 to 157 and the nucleotide sequence at positions the 1748 to 1855 in the Tol1 transposon nucleotide sequence shown in SEQ ID NO:13 of Sequence Listing.

[0057]

As the transposon sequence derived from a pair of Tol1 transposons, the nucleotide sequence at positions 1 to 200 (SEQ ID NO:14) (hereinafter referred to as “Tol1-L sequence”) and the nucleotide sequence at positions 1351 to 1855 (SEQ ID NO:15) (hereinafter referred to as “Tol1-R sequence”) in the Tol1 transposon nucleotide sequence shown in SEQ ID NO:13 of Sequence Listing are more preferable.

[0058]

Examples of the transposon sequence to be used in the invention include transposon sequences of which transposition reactions are controlled by using a partial sequence of a transposon sequence derived from the above-mentioned transposon, by adjusting the length of the nucleotide sequence and by modifying the nucleotide sequence due to addition, deletion or substitution.

[0059]

As the method for producing the protein of the interest of the present invention, examples also include a method in which at least one of the protein of interest is produced using at least two of transposon sequence and at least two of transposase.

[0060]

Specifically, examples include a protein production method which comprises the steps of introducing a vector comprising a DNA encoding a first protein of interest inserted into two Tol1 transposon sequences, a vector comprising a DNA encoding a second protein of interest inserted into two Tol2 transposon sequences, a Tol1 transposase expression vector and a Tol2 transposon expression vector, simultaneously or in order into chromosome of the mammalian cell and thereby obtaining a mammalian cell which produces the two proteins of interest.

[0061]

In addition, the first protein of interest and the second protein of interest may

be the same, and productivity of the protein of interest can also be improved by increasing the number of copies of the gene to be introduced into the cell.

[0062]

Regarding the control of the transposition reaction of a transposon, the transposition reaction can be accelerated or suppressed by accelerating or suppressing recognition of the transposon sequence by a transposase, respectively. In addition, with regard to the transposition reaction of transposon, the transposition reaction can be enhanced by shortening the length of the nucleotide sequence inserted between a pair (two) of the transposon sequences and the transposition reaction can be lowered by elongating the length. Therefore, when a protein of interest comprising plural proteins is expressed and prepared, the proteins of interest can be prepared by inserting DNA encoding each protein into a different expression vector, integrating the DNA in its chromosome of a host cell and can preparing a suspension mammalian cell which is able to prepare the protein of interest to produce the protein of interest by using the cell.

[0063]

The term “transposase” in the present specification means an enzyme which recognizes nucleotide sequences having transposon sequences and transfers a gene fragment existing between the nucleotide sequences on a chromosome or from the chromosome to another chromosome.

[0064]

Examples of the transposase include enzymes derived from Tol1 and Tol2 which are derived from medaka fish, the Sleeping Beauty (SB) reconstructed from a non-autonomous transposon existed in an *Onchorhynchus* fish genome, Sleeping Beauty 11 (SB11), the artificial transposon Frog prince (FP) which is derived from frog and the transposon PiggyBac (PB) which is derived from insect.

[0065]

As the transposase, a native enzyme may be used, and any transposase in which a part of its amino acids are substituted, deleted, inserted and/or added may be used as long as the same transposition activity as the transposase is maintained. By controlling the enzyme activity of the transposase, the transposition reaction of the DNA existing between the transposon sequences can be controlled.

[0066]

In order to analyze whether or not it possesses a transposition activity similar to that of transposase, it can be measured by the 2-components analyzing system disclosed in Japanese Published Unexamined Patent Application No.235575/2003.

[0067]

Particularly, whether or not a non-autonomous Tol2 element can be transferred and inserted into a mammalian cell chromosome by the activity of a transposase can be analyzed by separately using a plasmid comprising a Tol2 transposase-deleted Tol2 transposon (Tol2-derived non-autonomous transposon) and a plasmid comprising Tol2 transposase.

[0068]

The term “non-autonomous transposon” in the present specification means a transposon which is lost a transposase existed inside the transposon and can not therefore perform its autonomous transposition. The non-autonomous transposon can transfer the DNA inserted between transposon sequences of the non-autonomous transposon into the host cell chromosome, by allowing a transposase protein, an mRNA encoding the transposase protein or a DNA encoding the transposase protein to simultaneously present in the cell.

[0069]

The transposase gene means a gene encoding a transposase. In order to improve its expression efficiency in a mammalian cell, a sequence which adjusts a space between the Kozak’s consensus sequence (Kozak M., *Nucleic Acids Res.*, 12, 857 - 872 (1984)) or a ribosome binding sequence, Shine-Dalgarno sequence and the initiation codon, to an appropriate distance (e.g., from 6 to 18 bases) may be connected to an upstream site of the translation initiation codon ATG of the gene.

[0070]

According to the method of the invention, in order to integrate a gene fragment comprising a DNA encoding the protein of interest in at least one expression vector into the chromosome of a host cell, an expression vector which comprises the gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment is introduced into the host cell, and a transposase is allowed to act upon the transposon sequences comprised in the expression vector which is introduced into the cell.

[0071]

In order to allow a transposase to act upon the transposon sequences comprised in the expression vector which is introduced into the cell, the transposase may be injected into the cell, or an expression vector comprising a DNA encoding at least one protein of interest or a DNA encoding a protein of interest may be introduced into the host cell together with an expression vector comprising a DNA encoding the protein of interest and a selectable marker gene. In addition, by introducing an RNA encoding a transposase gene into the host cell, the transposase may be expressed in the cell.

[0072]

The expression vector is not particularly limited. Any expression vector can be used by optionally selecting from the expression vectors known to those skilled in the art, depending on a host cell into which an expression vector comprising a transposase gene is introduced; the use; and the like.

[0073]

In the case where a protein of interest comprised of two or more polypeptides or two or more proteins of interest is produced by the method of the invention, a protein producing cell in which a DNA encoding each protein is integrated in to a chromosome of a host cell can be prepared by inserting the DNA encoding each of protein on the same expression vector or inserting the DNA into respective different expression vector and introducing the expression vector into a host cell.

[0074]

The transposase may be inserted into an expression vector to express together with the protein of interest or may be inserted into a vector different from the expression vector. The transposase may be allowed to act transiently or may be allowed to act continuously, but it is preferably to allow the transposase to act transiently in order to prepare a cell for stable production.

[0075]

As the method for allowing the transposase to act transiently, examples include a method comprising preparing an expression vector which comprises a DNA encoding the transposase and an expression vector comprising a DNA encoding a protein of interest and then introducing both of the expression plasmids simultaneously into a host cell.

[0076]

The term “expression vector” in the present specification means an expression vector to be used for introducing a mammalian cell and expressing a protein of interest. The expression vector used in the invention has a structure in which at least a pair of transposon sequences is present at both sides of an expression cassette.

[0077]

The term “expression cassette” in the present specification means a nucleotide sequence which has a gene expression controlling region necessary for expressing a protein of interest and a sequence encoding the protein of interest. Examples of the gene expression controlling region include an enhancer, a promoter, and a terminator. The expression cassette may include a selectable marker gene.

[0078]

Any promoter can be used, so long as it can function in an animal cell. Examples include a promoter of IE (immediate early) gene of cytomegalovirus (CMV),

SV40 early promoter, a promoter of retrovirus, a metallothionein promoter, a heat shock promoter, SR α promoter, moloney murine leukemia virus, an enhancer and the like. Also, the enhancer of the IE gene of human CMV can be used together with the promoter.

5 [0079]

The “selectable marker gene” means an optional other marker gene which can be used for distinguishing a cell to which a plasmid vector is introduced from a cell lacking of the vector.

[0080]

10 Examples of the selectable marker gene include a drug resistance gene (a neomycin resistance gene, a dihydrofolate reductase (DHFR) gene, a puromycin resistance gene, a blasticidin resistance gene, a zeocin resistance gene, a hygromycin resistance gene, and a cycloheximide resistance gene (Japanese Published Unexamined Patent Application No.262879/2002)), fluorescence and bio-luminescence marker genes
15 (such as green fluorescent protein GFP) and the like.

[0081]

In the invention, the preferable selectable marker is a drug resistance gene and particularly preferable selectable marker is a cycloheximide resistance gene. Further, drug resistance property and luminescence property of the selectable marker protein can
20 also be changed by preparing an amino acid modified variant by genetically modifying the selectable marker gene or by controlling transcription or translation of the selectable marker gene (e.g., modification of a promoter, modification of an amino acid codon and the like). In addition, a selectable marker gene introduced cells having different drug resistance strengths can also be selected by adjusting the drug concentration.

25 [0082]

For controlling drug resistance property and luminescence property of the selectable marker protein, it is preferable to use an as the attenuated selectable marker gene. The attenuated selectable marker gene is a selectable marker gene which is modified in such a manner that activity of the protein encoded by the selectable marker
30 gene inside the cell is lowered.

[0083]

Examples of the selectable marker gene which is modified in such a manner that the activity in the cell becomes low include (A) an selectable marker gene in which an amino acid sequence of a protein encoded by a selectable marker gene is modified so
35 that activity of the protein in the cell is lowered and (B) an selectable marker gene in which a nucleotide sequence which controls expression of a selectable marker gene is modified or a nucleotide sequence inside of ORF (open reading frame) is modified so

that the expression of the selectable marker gene is lowered.

[0084]

Examples of the selectable marker gene in which an amino acid sequence of a protein encoded by a selectable marker gene is modified so that activity of the protein in the cell is lowered include the neomycin resistance gene described by Sauter et al. [5] *Biotech. Bioeng.*, 89, 530 - 538 (2005)] or Chen et al. [*Journal of Immunological Methods*, 295, 49 - 56 (2004)].

[0085]

Examples of the method for lowering expression level of a protein in the cell by modifying a nucleotide sequence which controls expression of the selectable marker gene include a method for modifying the sequence of promoter sequence, terminator sequence, enhancer sequence, kozak's consensus sequence or Shine-Dalgarno sequence, which controls expression of the selectable marker gene. More specifically, examples include a method in which a promoter sequence which controls expression of a selectable marker gene is replaced by a weaker promoter sequence. [10] [15]

[0086]

Examples of the method for lowering expression level of the protein in the cell by modifying a nucleotide sequence in the ORF of a selectable marker gene include a method in which a codon in the ORF is replaced by a synonymous codon having further lower frequency of codon usage in the cell. [20]

[0087]

Examples of the attenuated selectable marker gene of the invention include a selectable marker in which the above codon in the ORF of the gene is replaced by a synonymous codon having further lower frequency of codon usage in the cell. [25]

[0088]

In the cells of various biological species, the synonymous codon having further lower frequency of usage among each synonymous codon can be selected based on known literatures, data bases and the like.

[0089]

As such a replacement by a synonymous codon having lower frequency of usage, specifically in the case of CHO cell, examples include replacement of the codon of leucine with TTA, replacement of the codon of arginine with CGA or CGT, replacement of the codon of alanine with GCG, replacement of the codon of valine with GTA, replacement of the codon of serine with TCG, replacement of the codon of isoleucine with ATA, replacement of the codon of threonine with ACG, replacement of the codon of proline with CCG, replacement of the codon of glutamic acid with GAA, replacement of the codon of tyrosine with TAT, replacement of the codon of lysine with [30] [35]

AAA, replacement of the codon of phenylalanine with TTT, replacement of the codon of histidine with CAT, replacement of the codon of glutamine with CAA, replacement of the codon of asparagine with AAT, replacement of the codon of aspartic acid with GAT, replacement of the codon of cysteine with TGT and replacement of the codon of glycine with GGT.

[0090]

In an attenuated selectable marker gene, the number of codons to be placed compared to the selectable marker gene before the modification is not particularly limited as long as a protein producing cell can be efficiently obtained, but it is preferable to replace codons corresponding to 20 or more amino acid residues.

[0091]

In an attenuated selectable marker gene, the number of bases to be modified compared to the selectable marker gene before modification is not particularly limited, but it is preferable to modify 10% or more of the nucleotide sequence encoding the selectable marker gene.

[0092]

In addition, in an attenuated selectable marker gene, the amino acid residues encoded by the codons to be replaced is not particularly limited, but preferable examples include leucine, alanine, serine and valine.

[0093]

In the case of an attenuated selectable marker gene, in the case where the codons corresponding to leucine are replaced not particularly limited, but it is preferable to replace the codons corresponding to 70% or more of leucine residues among the codons corresponding to the total of the leucine residues contained in the selectable marker gene.

[0094]

Also, in the case of an attenuated selectable marker gene, when the codons corresponding to alanine are replaced not particularly limited, but it is preferable to replace the codons corresponding to 70% or more of alanine residues among the codons corresponding to the total of the alanine residues contained in the selectable marker gene.

[0095]

Specific examples of the attenuated selectable marker gene obtained by such as a modification in which codons are replaced with synonymous codons having lower frequency of usage include a neomycin resistance gene comprising the nucleotide sequence represented by SEQ ID NO:37, 38 or 39, a puromycin resistance gene comprising the nucleotide sequence represented by SEQ ID NO:41, 43 or 44, a Zeocin

resistance gene consisting of the nucleotide sequence represented by SEQ ID NO:45 or 46 and a hygromycin resistance gene comprising the nucleotide sequence represented by SEQ ID NO:47 or 48.

[0096]

In addition, it is possible to attenuate a selectable marker gene also by considerably increasing concentration of a drug in comparison with the conventionally used concentration when a drug-resistant cell is selected in preparing an antibody producing cell or by carrying out additional administration before the drug resistance gene metabolizes and degrades the drug.

[0097]

Cycloheximide (hereinafter, referred sometimes to as CHX) is a protein synthesis inhibitor, and examples of using a CHX resistance gene as the selectable marker gene include known cases of yeast [Kondo K., *J. Bacteriol.*, 177, 24, 7171 - 7177 (1995)] and animal cells (JP-A-2002-262879).

[0098]

In the case of animal cells, it has been revealed that a transformant expressing a protein encoded by the nucleotide sequence represented by SEQ ID NO:7 of SEQUENCE LISTING in which the 54-position proline of a human ribosomal protein subunit L36a encoded by the nucleotide sequence represented by SEQ ID NO:5 of SEQUENCE LISTING is replaced by glutamine provides resistance to cycloheximide. In addition, examples of the cycloheximide resistance marker include a mutant human ribosomal protein subunit L44 in which proline at position 54 of a human ribosomal protein subunit L44 is replaced by glutamine.

[0099]

The method for introducing the above-mentioned protein expression vector comprising a transposon sequence, a plasmid vector for expressing a transposase or RNA is not particularly limited. Examples include calcium phosphate transfection, electroporation, a liposome method, a gene gun method, lipofection and the like.

[0100]

Examples of the method for directly introducing a transposase in the form of a protein include a microinjection technique or supply into a cell by endocytosis. The gene introduction can be carried out by the method described in *Shin Idenshi Kogaku Handbook* (New Genetic Engineering Handbook), edited by Masami Muramatsu and Tadashi Yamamoto, published by Yodo-sha, ISBN 9784897063737.

[0101]

The host cell may be any mammalian cell as long as it can be subcultured and stably express a protein of interest. Examples of the host cell include PER.C6 cell,

human leukemia cell Namalwa cell, monkey cell COS cell, rat myeloma cell YB2/3HL.P2.G11.16Ag.20 (also referred to as YB2/0), mouse myeloma cell NS0, mouse myeloma cell SP2/0-Ag14, Syrian hamster cell BHK, HBT5637 (Japanese Unexamined Patent Application Publication No. 1998-000299), Chinese hamster ovarian cell CHO cell (*Journal of Experimental Medicine*, 108, 945 (1958); *Proc. Natl. Acad. Sci. USA.*, 601275 (1968); *Genetics*, 55, 513 (1968); *Chromosoma*, 41, 129 (1973); *Methods in Cell Science*, 18, 115 (1996); *Radiation Research*, 148, 260 (1997); *Proc. Natl. Acad. Sci. USA.*, 77, 4216 (1980); *Proc. Natl. Acad. Sci.*, 60, 1275 (1968); *Cell*, 6, 121 (1975); *Molecular Cell Genetics, Appendix I,II* (pp. 883-900)), CHO/DG44, CHO-K1 (ATCC CCL-61), DUKXB11 (ATCC CCL-9096), Pro-5 (ATCC CCL-1781), CHO-S (Life Technologies, Cat #11619), Pro-3 and subclonal cell line of CHO cell.

[0102]

In addition, the above-mentioned host cell can also be used in the protein production method of the invention by modifying the cell so as to be suitable for the protein production, due to modification of chromosomal DNA, introduction of an exogenous gene, and the like.

[0103]

Further, in order to control the sugar chain structure bound to a protein of interest to be produced, Lec13 which acquired lectin resistance [*Somatic Cell and Molecular Genetics*, 12, 55 (1986)] and a CHO cell from which α 1,6-fucosyltransferase gene is deleted (WO2005/35586, WO2002/31140), a cell deficient in GDP-mannose 4,6-dehydratase (GMD) and a cell deficient in Fx protein can also be used as the host cell.

[0104]

In the present invention, the protein of interest also includes any one of a protein consisting of at least one polypeptide and a complex protein consisting of two or more polypeptides of protein. In addition, a protein and a polypeptide are synonymous in the invention, but a protein molecule having a relatively low molecular weight or a protein constituting a complex protein may be defined sometimes as a polypeptide.

[0105]

The protein of interest in the invention may be any protein or polypeptide as long as it can be expressed by the method of the invention. Particularly, examples of the protein of interest include a human serum protein, an albumin binding protein, a peptide hormone, a growth factor, a cytokine, a blood coagulation factor, a fibrinolytic protein, an antibody, a selectable marker protein, a membrane protein, partial fragments of various proteins and the like. Particularly, examples of the protein of interest include human vein immunoglobulin (IVIG), erythropoietin (EPO), albumin, growth

hormone (GH), follicle-stimulating hormone (FSH), hepatocyte growth factor (HGF), insulin, insulin-like growth factor-I (IGF-I), interferon (INF), Fas ligand, blood coagulation factors (II, VII, VIII, IX, X), prothrombin, fibrinogen, protein C, protein S, antithrombin III (ATIII), the tissue plasminogen activator (tPA), a monoclonal antibody,
5 a polyclonal antibody and the like.

[0106]

The antibody is a molecule comprising of an antibody heavy chain (H chain) polypeptide and two antibody light chain (L chain) polypeptides, and as a subclass, IgA, IgD, IgE, IgG and IgM subclasses are known. Further, the IgG is classified into IgG1,
10 IgG2, IgG3 and IgG4.

[0107]

The IgG antibody is a heterotetrameric molecule consisting of two H chain polypeptides and two L chain polypeptides. Each of the H chain and L chain consists of a variable region (V) which relates to the antigen binding and a constant region (C) and each of them is called VH, CH, VL or CL, respectively. The CH region is further
15 classified into CH1, CH2 and CH3 regions, and the CH2 and CH3 regions are called in combination as Fc region or simply as Fc.

[0108]

The antibody includes a monoclonal antibody which reacts with a single
20 epitope, a polyclonal antibody which reacts with two or more epitopes and a recombinant antibody.

[0109]

The monoclonal antibody is an antibody which is secreted by a single clonal antibody producing cell and recognizes only one epitope (also called an antigenic
25 determinant), and the amino acid sequence (primary structure) constituting a monoclonal antibody is uniform.

[0110]

The polyclonal antibody is a mixture of monoclonal antibodies and can react with two or more epitopes.

30 [0111]

Examples of the recombinant antibody include a chimeric antibody, a humanized antibody, a human antibody, a Fc fusion protein, Fc amino acid modified antibody, and a multivalent antibody and a partial fragment thereof. An amino acid modified antibody may have an amino acid modification in either a variable region or a
35 constant region and antibody activity is controlled.

[0112]

The multivalent antibody includes a multivalent antibody which reacts with

two or more different epitopes on one antigen, a multivalent antibody which react with two or more different antigens and the like, but it may include any multivalent antibody. In addition, the multivalent antibody may be any multivalent antibody having any structure as long as it retains the binding activity to the antigen (WO2001/77342, US
5 Patent No. 7,612,181 and WO2009/131239).

[0113]

According to the producing method of the present invention, any of the above protein of interest and/or the peptide of interest can be expressed and produced.

[0114]

10 Examples of the cell into which a DNA encoding at least one protein of interest of the present invention include an antibody producing cell prepared by the following steps (A) and (B).

Step (A) a step of simultaneously introducing both of one combination of expression vector selected from the following (a) to (c) or expression vector (d) and
15 expression vector (e) into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
20 vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
25 vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
30 vector which comprises a gene fragment comprising a DNA encoding a H chain antibody of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA
35 encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment;

(e) a vector comprising a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome; and

Step (B) a step of selecting a suspension mammalian cell which expresses an antibody in which the genes of the above H chain, L chain and selectable marker which are inserted between a pair of the transposon sequence are integrated into a chromosome of the above mammalian cell by transiently expressing the transposase from the expression vector (e) which is introduced into the suspension mammalian cell in the step (A).

[0115]

Examples of the method for producing an antibody of the present invention include a method for producing a protein of interest comprising the following steps (A) to (C).

Step (A) a step of simultaneously introducing one combination of expression vector selected from the following (a) to (c) or expression vector (d), and expression vector (e) into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also

comprises a pair of transposon sequences at both terminals of the gene fragment;

(e) a vector comprising a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome;

Step (B) a step of obtaining a suspension mammalian cell which expresses an antibody in which the genes of the above H chain, L chain and selectable marker which are inserted between a pair of the transposon sequence are integrated into a chromosome of the above mammalian cell by transiently expressing the transposase from the expression vector (e) which is introduced into the suspension mammalian cell in the step (A); and

Step (C) a step of producing the antibody by suspension-culturing a suspension mammalian cell obtained in the step (B) which expresses an antibody.

[0116]

In addition, the present invention includes a method for producing a cell line which has a high antibody productivity and a method for screening the cell line comprising the following steps (A) and (B).

Step (A) a step of simultaneously introducing one combination of expression vector selected from the following (a) to (c) or expression vector (d), and expression vector (e) into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the

gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment;

(e) a vector comprising a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome; and

Step (B) a step of selecting a suspension mammalian cell which highly expresses an antibody in which the genes of the above H chain, L chain and selectable marker which are inserted between a pair of the transposon sequence are integrated into a chromosome of the above mammalian cell by transiently express the transposase from the expression vector (e) which is introduced into the suspension mammalian cell in the step (A).

[0117]

In addition, the present invention includes a method for producing an antibody comprising the following steps (A) , (B) and (C).

Step (A) a step of simultaneously introducing one combination of expression vector selected from the following (a) to (c) or expression vector (d) and expression vector (e) into a suspension mammalian cell:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the

gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment;

(e) a vector comprising a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome;

Step (B) a step of obtaining a suspension mammalian cell which expresses an antibody in which the genes of the above H chain, L chain and selectable marker which are inserted between a pair of the transposon sequence are integrated into a chromosome of the above mammalian cell by transiently expressing the transposase from the expression vector (e) which is introduced into the suspension mammalian cell in the step (A); and

Step (C) a step of producing the antibody by suspension-culturing a suspension mammalian cell obtained in the step (B) which expresses an antibody.

[0118]

Examples of the mammalian cell into which a DNA encoding at least one protein of interest of the present invention include a polyclonal antibody producing cell into which several different antibody genes are introduced, a complex molecule producing cell and the like.

[0119]

Examples of a polyclonal antibody producing cell include a cell into which at least two or more different monoclonal antibody genes are introduced, a cell into which genes of several monoclonal antibodies against several antigens are introduced, a cell which is immunized by an antigen and into which a gene library of a non-human antibody is introduced, a cell into which a gene library of antibody derived from a patient is introduced and the like.

[0120]

The complex molecule producing cell may be any cell as long as DNAs encoding respective proteins which are co-expressed in a cell to form a complex molecule is introduced. Specific examples include a cell into which Fc γ RIII (CD16) and common γ chain are co-transfected, a cell into which neonatal Fc receptor (FcRn) and β 2 macroglobulin are co-expressed, a cell into which CD98 and LAT1 are co-transfected (WO2007/114496) and the like

[0121]

The antibody which is produced by the antibody production method of the present invention can be any antibody and examples include an antibody which

recognize a tumor-related antigen, an antibody which recognizes an allergy- or inflammation-related antigen, an antibody which recognizes an cardiovascular disease-related antigen, an antibody which recognizes an antigen which relating to autoimmune diseases, an antibody which recognizes virus- or bacterial infection-related antigen and the like.

[0122]

Examples of the tumor-related antigen includes CD1a, CD2, CD3, CD4, CD5, CD6, CD7, CD9, CD10, CD13, CD19, CD20, CD21, CD22, CD25, CD28, CD30, CD32, CD33, CD38, CD40, CD40 ligand (CD40L), CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD55, CD59, CD63, CD64, CD66b, CD69, CD70, CD74, CD80, CD89, CD95, CD98, CD105, CD134, CD137, CD138, CD147, CD158, CD160, CD162, CD164, CD200, CD227, adrenomedullin, angiopoietin related protein 4 (ARP4), aurora, B7-H1, B7-DC, integrin, bone marrow stromal antigen 2 (BST2), CA125, CA19.9, carbonic anhydrase 9 (CA9), cadherin, cc-chemokine receptor (CCR) 4, CCR7, carcinoembryonic antigen (CEA), cysteine-rich fibroblast growth factor receptor-1 (CFR-1), c-Met, c-Myc, collagen, CTA, connective tissue growth factor (CTGF), CTLA-4, cytokeratin-18, DF3, E-catherin, epidermal growth factor receptor (EGFR), EGFRvIII, EGFR2 (HER2), EGFR3 (HER3), EGFR4 (HER4), endoglin, epithelial cell adhesion molecule (EpCAM), endothelial protein C receptor (EPCR), ephrin, ephrin receptor (Eph), EphA2, endotheliase-2 (ET2), FAM3D, fibroblast activating protein (FAP), Fc receptor homolog 1 (FcRH1), ferritin, fibroblast growth factor-8 (FGF-8), FGF8 receptor, basic FGF (bFGF), bFGF receptor, FGF receptor (FGFR) 3, FGFR4, FLT1, FLT3, folate receptor, Frizzled homologue 10 (FZD10), frizzled receptor 4 (FZD-4), G250, G-CSF receptor, ganglioside (such as GD2, GD3, GM2 and GM3), globo H, gp75, gp88, GPR-9-6, heparanase I, hepatocyte growth factor (HGF), HGF receptor, HLA antigen (such as HLA-DR), HM1.24, human milk fat globule (HMFG), hRS7, heat shock protein 90 (hsp90), idiotype epitope, insulin-like growth factor (IGF), IGF receptor (IGFR), interleukin (such as IL-6 and IL-15), interleukin receptor (such as IL-6R and IL-15R), integrin, immune receptor translocation associated-4 (IRTA-4), kallikrein 1, KDR, KIR2DL1, KIR2DL2/3, KS1/4, lamp-1, lamp-2, laminin-5, Lewis y, sialyl Lewis x, lymphotoxin-beta receptor (LTBR), LUNX, melanoma-associated chondroitin sulfate proteoglycan (MCSP), mesothelin, MICA, Mullerian inhibiting substance type II receptor (MISIIR), mucin, neural cell adhesion molecule (NCAM), Necl-5, Notch1, osteopontin, platelet-derived growth factor (PDGF), PDGF receptor, platelet factor-4 (PF-4), phosphatidylserine, Prostate Specific Antigen (PSA), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), Parathyroid hormone related protein/peptide (PTHrP), receptor activator of NF-kappaB ligand

(RANKL), receptor for hyaluronic acid mediated motility (RHAMM), ROBO1, SART3, semaphorin 4B (SEMA4B), secretory leukocyte protease inhibitor (SLPI), SM5-1, sphingosine-1-phosphate, tumor-associated glycoprotein-72 (TAG-72), transferrin receptor (TfR), TGF-beta, Thy-1, Tie-1, Tie2 receptor, T cell immunoglobulin domain and mucin domain 1 (TIM-1), human tissue factor (hTF), Tn antigen, tumor necrosis factor (TNF), Thomsen-Friedenreich antigen (TF antigen), TNF receptor, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor (such as DR4 and DR5), system ASC amino acid transporter 2 (ASCT2), trkC, TROP-2, TWEAK receptor Fn14, type IV collagenase, urokinase receptor, vascular endothelial growth factor (VEGF), VEGF receptor (such as VEGFR1, VEGFR2 and VEGFR3), vimentin, VLA-4 and the like, and antibodies against the above antigens.

[0123]

Further, examples of the antibody which recognizes a tumor-related antigen include [*AntiCancer Res.*, 13, 331 (1993)], anti-GD3 antibody [*Cancer Immunol. Immunother.*, 36, 260 (1993)], anti-GM2 antibody [*Cancer Res.*, 54, 1511 (1994)], anti-CD52 antibody [*Proc. Natl. Acad. Sci. USA*, 89, 4285 (1992)], anti-MAGE antibody [*British J. Cancer*, 83, 493 (2000)], anti-HM1.24 antibody [*Molecular Immunol.*, 36, 387 (1999)], anti-parathyroid hormone related protein (PTHrP) antibody [*Cancer*, 88, 2909 (2000)], anti-bFGF antibody, anti-FGF-8 antibody [*Proc. Natl. Acad. Sci. USA*, 86, 9911 (1989)], anti-bFGFR antibody, anti-FGFR1 antibody (WO2005/037235), anti-FGF-8R antibody [*J. Biol. Chem.*, 265, 16455 (1990)], anti-IGF antibody [*J. Neurosci. Res.*, 40, 647 (1995)], anti-IGF-IR antibody [*J. Neurosci. Res.*, 40, 647 (1995)], anti-PSMA antibody [*J. Urology*, 160, 2396 (1998)], anti-VEGF antibody [*Cancer Res*, 57, 4593 (1997), Avastin (R)], anti-VEGFR antibody [*Oncogene*, 19, 2138 (2000), WO96/30046], anti-CD20 antibody [*Curr. Opin. Oncol.*, 10, 548 (1998), US5, 736, 137, Rituxan (R), Ocrelizumab, Ofatumumab], anti-EGFR antibody (Erbix (R), Vectivix (R)), anti-HER2 antibody [*Proc. Natl. Acad. Sci. USA*, 89, 4285 (1992), US5, 725, 856, Herceptin (R), Pertuzumab), anti-HER3 antibody (US2008/0124345), c-Met antibody (US6, 468, 529), anti-CD10 antibody, anti-EGFR antibody (WO96/402010), anti-Apo-2R antibody (WO98/51793), anti-ASCT2 antibody (WO2010/008075), anti-CEA antibody [*Cancer Res.*, 55 (23 suppl): 5935s-5945s, (1995)], anti-CD38 antibody, anti-CD33 antibody, anti-CD22 antibody, anti-CD20 amino acid modified antibody (*Immunology*, 115, 4393, 2010.), anti-EpCAM antibody, anti-A33 antibody, anti-folate receptor antibody (MRAb-003) and the like.

[0124]

Examples of the antibody which recognizes an allergy- or inflammation-related antigen include anti-interleukin 6 antibody [*Immunol. Rev.*, 127, 5 (1992)],

anti-interleukin 6 receptor antibody [*Molecular Immunol.*, 31, 371 (1994)],
anti-interleukin 5 antibody [*Immunol. Rev.*, 127, 5 (1992)], anti-interleukin 5 receptor
antibody, anti-interleukin 4 antibody [*Cytokine*, 3, 562 (1991)], anti-interleukin 4
receptor antibody [*J. Immunol. Meth.*, 217, 41 (1998)], anti-tumor necrosis factor
antibody [*Hybridoma*, 13, 183 (1994)], anti-tumor necrosis factor receptor antibody
[*Molecular Pharmacol.*, 58, 237 (2000)], anti-CCR4 antibody [*Nature*, 400, 776 (1999)],
anti-chemokine antibody [Peri *et al.*, *J. Immuno. Meth.*, 174, 249-257 (1994)],
anti-chemokine receptor antibody [*J. Exp. Med.*, 186, 1373 (1997)] and the like.

Examples of the antibody which recognizes a cardiovascular disease-related antigen
include anti-GpIIb/IIIa antibody [*J. Immunol.*, 152, 2968 (1994)], anti-platelet-derived
growth factor antibody [*Science*, 253, 1129 (1991)], anti-platelet-derived growth factor
receptor antibody [*J. Biol. Chem.*, 272, 17400 (1997)], anti-blood coagulation factor
antibody [*Circulation*, 101, 1158 (2000)], anti-IgE antibody, anti- α V β 3 antibody,
anti- α 4 β 7 antibody, and the like.

[0125]

Examples of the antibody which recognizes virus- or bacterial infection-related
antigen includes anti-gp120 antibody [*Structure*, 8, 385 (2000)], anti-CD4 antibody [*J.
Rheumatology*, 25, 2065 (1998)], anti-CCR5 antibody, anti-verotoxin antibody [*J. Clin.
Microbiol.*, 37, 396 (1999)], anti-M2 antibody (JP2003-235575) and the like.

[0126]

The effector activity of a monoclonal antibody produced by the method of the
present invention can be controlled by various methods. Examples of the known
methods include a method for controlling an amount of fucose (hereinafter, referred to
also as “core fucose”) which is bound N-acetylglucosamine (GlcNAc) through α -1,6
bond in a reducing end of a complex type N-linked sugar chain which is bound to
asparagine (Asn) at position 297 of an Fc region of an antibody (WO2005/035586,
WO2002/31140, and WO00/61739), a method for controlling an effector activity by
modifying amino acid residue(s) of an Fc region of the antibody, and the like. The
effector activity of the monoclonal antibody produced by the method of the present
invention can be controlled by using any of the methods.

[0127]

The “effector activity” means an antibody-dependent activity which is induced
via an Fc region of an antibody. As the effector activity, an antibody-dependent
cellular cytotoxicity (ADCC activity), a complement-dependent cytotoxicity (CDC
activity), an antibody-dependent phagocytosis (ADP activity) by phagocytic cells such
as macrophages or dendritic cells, and the like are known.

[0126]

In addition, by controlling a content of core fucose of a complex type N-linked sugar chain of Fc region of a monoclonal antibody which is produce by the method of the present invention, an effector activity of the antibody can be increased or decreased.

[0128]

5 As a method for lowering a content of fucose which is bound to a complex type N-linked sugar chain bound to Fc region of the antibody, an antibody to which fucose is not bound can be obtained by the expression of an antibody using a CHO cell which is deficient in a gene encoding α 1,6-fucosyltransferase. The antibody to which fucose is not bound has a high ADCC activity.

10 [0129]

On the other hand, as a method for increasing a content of fucose which is bound to a complex type N-linked sugar chain bound to Fc of an antibody, an antibody to which fucose is bound can be obtained by the expression of an antibody using a host cell into which a gene encoding α 1,6-fucosyltransferase is introduced. The antibody to which fucose is bound has a lower ADCC activity than the antibody to which fucose is not bound.

[0130]

Further, by modifying amino acid residue(s) in an Fc region of an antibody, the ADCC activity or CDC activity can be increased or decreased. For example, the CDC activity of an antibody can be increased by using the amino acid sequence of the Fc region of the antibody described in US2007/0148165.

[0131]

Further, the ADCC activity or CDC activity of an antibody can be increased or decreased by carrying out amino acid modification described in US Patent Nos.

25 6,737,056, or 7,297,775 or 7,317,091.

[0133]

30 The term "suspension mammalian cell" in the present invention means a cell which does not adhere to a cell culture anchorage coated for facilitating adhesion of culture cells, such as microbeads, a culture container for tissue culture (also referred to as a tissue culture or adhesion culture container and the like) and the like, and can survive and grow while suspending in the culture solution.

[0134]

As long as the cell does not adhere to the cell culture anchorage, the cell may survive and grow in a state of a single cell in the culture solution or survive and grow in a state of a mass of cells formed by the agglutination of two or more cells.

35 [0135]

In addition, as the suspension mammalian cell to be used in the present invention, a cell which can survive and grow in a serum-free medium that does not contain fetal calf serum (hereinafter referred to as FCS) and the like, while suspending in the culture solution without adhering to the cell culture anchorage, is preferable, and a mammalian cell which can survive and grow while suspending in a protein-free medium that does not contain protein is more preferable.

[0136]

The culture container for tissue culture may be any one such as a flask, a Petri dish and the like as long as it is coated for adhesion culture is applied thereto.

Particularly, for example, whether or not it is a suspension mammalian cell can be confirmed using commercially available tissue culture flask (manufactured by Greiner), adhesion culture flask (manufactured by Sumitomo Bakelite) and the like.

[0137]

As the suspension mammalian cell to be used in the present invention, it may be either a cell prepared by further adapting a cell originally having a suspension property to suspension culture or a suspension mammalian cell prepared by adapting an adhesive mammalian cell to suspension culture conditions.

[0138]

Examples of the cell originally having a suspension property include PER.C6 cell, a rat myeloma cell YB2/3HL.P2.G11.16Ag.20 (or also called YB2/0), CHO-S cell (manufactured by Invitrogen) and the like.

[0139]

The above “suspension mammalian cell prepared by adapting an adhesive mammalian cell to suspension culture conditions” can be prepared by the method described in *Mol. Biotechnol.*, 2000, 15(3), 249 - 57 or by the method shown in the following, and can be prepared by establishing a cell which shows proliferation property and surviving property similar to those before adapting the suspension culture or superior to those before adapting to suspension culture (*J. Biotechnol.*, 2007, 130(3), 282 - 90).

[0140]

The term “similar to those before the suspension culture adaptation” means that survival ratio, proliferation rate (doubling time) and the like of the cell adapted to the suspension culture are substantially the same as those of the cell before adapting suspension culture.

[0141]

In the present invention, examples of the method for adapting an adhesive mammalian cell to suspension culture conditions include the following method. The

serum content of a serum-containing medium is reduced to 1/10 and sub-culturing is repeated at relatively high concentration of cell. When the mammalian cell comes to be able to survive and proliferate, the serum content is further reduced and the sub-culturing is repeated. By this method, a suspension mammalian cell which can survive and proliferate under serum-free conditions can be prepared.

[0142]

In addition, a suspension mammalian cell can also be prepared by a method comprising culturing with the addition of an appropriate nonionic surfactant such as Pluronic-F68 or the like in the culture solution.

[0143]

Examples of the adhesive mammalian cell which acquires suspension property by adapting to a suspension culture condition include a mouse myeloma cell NS0, a CHO cell and the like.

[0144]

In the present invention, as a property possessed by the suspension mammalian cell, suspension culturing is carried out under the condition of 2×10^5 cells/ml, and then the cell concentration after culturing for 3 or 4 days is preferably 5×10^5 cells/ml or more, more preferably 8×10^5 cells/ml or more, particularly preferably 1×10^6 cells/ml or more, most preferably 1.5×10^6 cells/ml or more.

[0145]

In addition, doubling time of the suspension mammalian cell of the present invention is preferably 48 hours or less, more preferably 24 hours or less, particularly preferably 18 hours or less, most preferably 11 hours or less.

[0146]

Examples of the medium for suspension culturing include commercially available medium, such as CD-CHO medium (Invitrogen), EX-CELL 325-PF medium (SAFC Biosciences), SFM4CHO medium (HyClone) and the like. In addition, it can also be obtained by mixing saccharides, amino acids and the like which are necessary for the culturing of mammalian cells.

[0147]

The suspension mammalian cell can be cultured using a culture container which can be used for suspension culturing under a culture condition capable of suspension culturing. Examples of the culture container include a 96-well plate for suspension cell culture (manufactured by Corning), a T-flask (manufactured by Becton Dickinson), a conical flask (manufactured by Corning) and the like.

[0148]

Regarding the culture conditions, for example, it can be statically cultured in an atmosphere of 5% CO₂ at a culture temperature of 37°C. A shaking culture equipment, such as culturing equipment for suspension culture exclusive use, e.g., Wave Bioreactor (manufactured by GE Healthcare Bioscience), can be also used.

[0149]

Regarding the suspension culture conditions for a suspension mammalian cell using the Wave Bioreactor equipment, the cell can be cultured by the method described on the GE Healthcare Bioscience homepage

http://www.gelifesciences.co.jp/tech_support/manual/pdf/cellcult/wave_03_16.pdf.

[0150]

In addition to the shaking culture, culturing by a rotation agitation equipment such as a bioreactor, can also be used. Culturing using a bioreactor can be carried out by the method described in *Cytotechnology*, (2006) 52: 199 - 207, and the like.

[0151]

In the present invention, when a cell line other than the suspension mammalian cells is used, any cell line can be used so long as it is a mammalian cell line adapted to the suspension culture by the above-mentioned method and is a cell line which can be used in the protein production method of the present invention.

[0152]

Purification of the protein of interest produced by the suspension mammalian cell is carried out by separating the protein of interest from impurities other than the protein of interest in a culture solution or cell homogenate containing the protein of interest. Examples of the separation method include centrifugation, dialysis, ammonium sulfate precipitation, column chromatography, a filtering and the like. The separation can be carried out based on the difference in physicochemical properties of the protein of interest and impurities or the difference in their avidity for the column carrier itself.

[0153]

As the method for purifying the protein of interest, the purification is carried out by the method described in *Protein Experimentation Note* (the first volume) - *Extraction, Separation and Expression of Recombinant Protein* (translation of a textbook written in Japanese) (edited by Masato Okada and Kaori Miyazaki, published by Yodo-sha, ISBN 9784897069180) and the like.

[0154]

The entire contents of the references, such as the scientific documents, patents, patent applications cited herein are incorporated herein by reference to the same degree of those illustratively described, respectively.

[0155]

The present invention has been described in the above by showing preferred embodiments thereof for the sake of easy understanding. Hereinafter, the present invention is further described specifically based on examples, but the above-mentioned explanations and the following examples are provided merely for the purpose of exemplifications and not provided for the purpose of limiting the invention. Accordingly, the scope of the invention is not limited to the embodiments and examples which are specifically described in the present specification, but is limited by the claims alone.

[0156]

Various experimental techniques relating to recombination described in the followings, such as the cloning and the like were carried out in accordance with the genetic engineering techniques described in *Molecular Cloning 2nd* edition edited by J. Sambrook, E. F. Frisch and T. Maniatis, *Current Protocols in Molecular Biology* edited by Frederick M. Ausubel *et al*, published by Current Protocols, and the like.

EXAMPLES

[0157]

[Example 1]

Preparation of transposon vector for expressing anti-human influenza M2 antibody

A plasmid which comprises a gene expression cassette for mammalian cells comprising an arbitrary human antibody gene and a drug resistance marker gene inserted between a pair of Tol2 transposon sequences was used as a plasmid vector for protein expression.

[0158]

Each DNA of the used genes was chemically and artificially synthesized based on a known nucleotide sequence or obtained by preparing primers for its both terminal sequences and then carrying out PCR using an appropriate DNA source as a template. In order to carry out the gene manipulation later, a restriction site for a restriction enzyme was added to the terminal of the primer.

[0159]

In the nucleotide sequence (SEQ ID NO:1) of the non-autonomous Tol2 transposon disclosed by Japanese Published Unexamined Patent Application No.235575/2003, the nucleotide sequence at position 1 to 200 (Tol2-L sequence) (SEQ ID NO:2) and the nucleotide sequence at positions 2285 to 2788 (Tol2-R sequence) (SEQ ID NO:3) were used as the transposon sequences.

[0160]

Each synthetic DNA fragments comprising a pair of transposon sequences (manufactured by TAKARA BIO INC.) was prepared by the following method. A DNA fragment comprising a nucleotide sequence in which a recognition sequence of a restriction enzyme *NruI* was attached to both of the 5'-terminal and 3'-terminal of the Tol2-R sequence was prepared. Then, a DNA fragment comprising a nucleotide sequence in which a recognition sequence of a restriction enzyme *FseI* was attached to the 5'-terminal of the Tol2-L sequence and a restriction enzyme *AscI* was attached to the 3'-terminal thereof was prepared.

[0161]

Next, the thus prepared DNA fragments comprising Tol2-R sequence and Tol2-L sequence were inserted into an expression vector N5LG1_M2_Z3 vector (WO2006/061723) comprising a nucleotide sequence encoding an amino acid sequence of anti-human influenza M2 antibody Z3G1.

[0162]

The N5LG1_M2_Z3 vector (WO2006/061723) into which a nucleotide sequence (SEQ ID NO:9) encoding the H chain (SEQ ID NO:10) and a nucleotide sequence (SEQ ID NO:11) encoding the L chain (SEQ ID NO:12) of the anti-human influenza M2 antibody Z3G1 (ATCC Deposit No. PTA-5968: deposited March 13, 2004, American Type Culture Collection, Manassas, VA, USA) were inserted under the control of the CMV enhancer/promoter control was used as an antibody gene expression cassette.

[0163]

The DNA fragment comprising the Tol2-R sequence was inserted into the restriction enzyme *NruI* site positioned at the 5'-terminal side of a gene fragment comprising the antibody gene expression cassette and a selectable marker gene on the N5LG1_M2_Z3 vector. Then, the DNA fragment comprising the Tol2-L sequence was inserted into the restriction enzyme *FseI* and *AscI* sites positioned at the 3'-terminal side.

[0164]

In addition, a transposon vector for expressing an anti-human influenza M2 antibody was constructed (Fig. 1) by inserting a cycloheximide resistance gene expression cassette in which a nucleotide sequence (SEQ ID NO:5) encoding a resistance gene for cycloheximide (a gene in which proline at position 54 of the human ribosomal protein L36a was substituted with glutamine) is connected under the control of the CMV enhancer/promoter into the *FseI* recognition site of the N5LG1_M2_Z3 vector connected with the Tol2 transposon sequence.

[0165]

On the other hand, a vector comprising no transposon sequences was named anti-human influenza M2 antibody expression vector and used as the control vector (Fig. 2).

[0166]

5 [Example 2]

Preparation of transposase expression vector

The transposase was expressed using an expression vector independent of the expression vector of the antibody of interest. That is, a gene which is encoding a medaka fish-derived Tol2 transposase (SEQ ID NO:4) was inserted into a downstream
10 of the CAGGS promoter of a pCAGGS vector (*Gene*, 108, 193 - 200, 1991) to prepare a Tol2 transposase expression vector (hereinafter referred to as Tol2 vector) (Fig. 3).

[0167]

[Example 3]

Preparation of transformant using mammal animal cell

15 (1) Preparation of suspension CHO cell

An adhesive CHO cell which had been cultured using α -MEM medium (Invitrogen) containing 10% serum (FCS) was peeled off by a trypsin treatment and then recovered, followed by shaking culture at 37°C in a 5% CO₂ incubator using the fresh the α -MEM medium containing 10% FCS. Several days thereafter, growth of
20 these cells was confirmed and then shaking culture was carried out by inoculating them into a α -MEM medium containing 5% FCS at a concentration of 2×10^5 cells/ml followed by shaking culture.

[0168]

Further several days thereafter, the inoculation was similarly carried out using
25 the α -MEM medium containing 5% FCS. Finally, a cell adapted to the suspension culture was prepared by repeating the sub-culture and shaking culture using the serum-free α -MEM medium and confirming that the cells have the same growing ability as the case of their culturing in the presence of serum.

[0169]

30 (2) Preparation of CHO cell which produces antibody

As the expression vector, the transposon vector for expressing the anti-human influenza M2 antibody prepared in Example 1 and Example 2 (hereinafter referred to as a transposon vector) and Tol2 vector pCAGGS-T2TP (Fig. 3, Kawakami K. & Noda T., *Genetics*, 166, 895 - 899 (2004)) were used. In addition, the anti-human influenza M2
35 antibody expression vector having no transposon sequences was used as the control.

[0170]

By introducing the above expression vectors into the suspension culture-adapted CHO-K1 cell (American Type Culture Collection Cat. No. CCL-61) or HEK293 cell (Invitrogen, FreeStyle 293F cell), the frequencies of obtaining cycloheximide-resistant clones were compared.

[0171]

Each cells (4×10^6 cells) was suspended in 400 μ l of PBS, and the transposon vector for expressing the anti-human influenza M2 antibody (10 μ g) and Tol2 vector (25 μ g) were co-transfected directly in the form of circular DNA by electroporation. In this connection, in order to express the Tol2 transposase transiently, the Tol2 vector was directly introduced in the form of circular DNA for the purpose of preventing from integrating into the host chromosome.

[0172]

In addition, as the control, the anti-human influenza M2 antibody expression vector (10 μ g) was linearized by a restriction enzyme and then introduced into each cells, in accordance with the standard gene introduction method by electroporation.

[0173]

The electroporation was carried out using a cuvette of 4 mm in gap width (manufactured by Bio-Rad), using an electroporator (Gene Pulser Xcell System (manufactured by Bio-Rad)) under conditions of 300 V in voltage, 500 μ F in electrostatic capacity and room temperature.

[0174]

After the gene introduction by electroporation, each cell was seeded into three 96-well plates and cultured in a CO₂ incubator for 3 days using the EX-CELL 325-PF medium manufactured by SAFC Biosciences for the CHO cell, and the FreeStyle-293 medium (manufactured by Invitrogen) for the HEK293 cell.

[0175]

Next, from the day of medium exchange on the 4th day of the gene introduction, 3 μ g/ml of cycloheximide was added to the medium so that the cells were cultured in the presence of cycloheximide, followed by culturing for 3 weeks while carrying out the medium exchange in every week.

[0176]

After culturing for 3 weeks, the number of wells in which cycloheximide-resistant colonies were found was counted. The results are shown in Table 1 and Table 2.

[0177]

[Table 1]

Table 1 Comparison of the numbers of cycloheximide-resistant cells (CHO cell)

	Transposon vector	Conventional vector
Test 1	155 / 288	0 / 288
Test 2	100 / 288	0 / 288
Test 3	94 / 288	0 / 288

[0178]

[Table 2]

Table 2 Comparison of the numbers of cycloheximide-resistant cells (HEK293 cell)

	Transposon vector	Conventional vector
Test 1	0 / 288	0 / 288
Test 2	0 / 288	0 / 288
Test 3	0 / 288	0 / 288

5

[0179]

As shown in Table 1, each the anti-human influenza M2 antibody expression transposon vector or anti-human influenza M2 antibody expression vector was introduced into the suspension CHO-K1 cell. As a result, cycloheximide-resistant transformants were not obtained from the cells into which the anti-human influenza M2 antibody expression vector was introduced as in the other cell lines, but cycloheximide-resistant transformants were obtained from the cell into which the transposon vector for expressing anti-human influenza M2 antibody was introduced with a high frequency.

10

15

[0180]

On the other hand, as shown in Table 2, cycloheximide-resistant transformants were not obtained when either of the transposon vector for expressing anti-human influenza M2 antibody and anti-human influenza M2 antibody expression vector was introduced into the HEK293 cells.

20

[0181]

Based on these results, it was found that the gene encoding a protein of interest and cycloheximide resistance gene which were inserted between a pair of transposon sequences were efficiently introduced into the chromosome of the host cell in the suspension mammalian cell.

25

[0182]

(3) Examination on the antibody production in suspension CHO cell and adhesive CHO cell

In order to examine antibody production efficiency in a suspension CHO cell or an adhesive CHO cell, the amounts of antibodies produced by each cell line were

examined. As the suspension CHO cell, a suspension CHO-K1 cell adapted to suspension culture was used. In addition, as the adhesive CHO cell, an adhesive CHO-K1 cell before adaptation to suspension culture was used.

[0183]

5 The anti-human influenza M2 antibody expression transposon vector (10 µg) and Tol2 vector (25 µg) were introduced into the suspension CHO-K1 cell and the adhesive CHO-K1 cell by electroporation, respectively. Thereafter, the suspension CHO-K1 cell and the adhesive CHO-K1 cell were inoculated into three 96-well plates for each cell.

10 [0184]

A medium for suspension cells (EX-CELL 325-PF, manufactured by SAFC Biosciences) was used for the suspension CHO-K1 cell, and the α-MEM medium containing 10% serum was used for the adhesive CHO-K1 cell. Each cell was cultured in a CO₂ incubator for 3 days. From the day of medium exchange of the 4th day of the electroporation, 3 µg/ml of cycloheximide was added to the medium so that the cells were cultured in the presence of cycloheximide and the cells were further cultured for 3 weeks. In this case, the medium exchange was carried out every week.

[0185]

20 For the suspension CHO-K1 cell, 1×10^6 of the cells were seeded into a 6-well plate, followed by shaking-culture in a CO₂ incubator for 3 days, and the amount of the antibody protein was measured by HPLC using the culture supernatant.

[0186]

25 For the adhesive CHO-K1 cell, medium exchange was carried out when the cell reached confluent on a 6-well plate (2×10^6 cells), and after static culturing for 3 days, the amount of the antibody protein was measured by HPLC using the culture supernatant.

[0187]

30 The antibody concentration in the culture supernatant was measured in accordance with the method described in *Yeast Res.*, 7 (2007), 1307 - 1316. The results are shown in Fig. 4.

[0188]

35 As shown in Fig. 4A, a large number of cells showing a markedly high antibody expression level were obtained when the CHO-K1 cell adapted to suspension culture was used. On the other hand, as shown in Fig. 4B, only the cells showing an expression level of the HPLC detection limit (5 µg/ml) or less were obtained when the adhesive CHO-K1 cell was used.

[0189]

Based on these results, it was found that, in order to express a protein of interest using a transposon vector, the protein of interest could be expressed at a high level when a suspension mammalian cell is used.

[0190]

In addition, it was found from the results of Examples 1 to 3 that the method of the invention could be used as a novel method for producing a protein of interest, by efficiently preparing a production cell which can highly express an exogenous gene using a suspension mammalian cell adapted to suspension culture.

[0191]

[Example 4]

Preparation of antibody expression cell using Tol1 transposon and antibody preparation (1)

Preparation of Tol1 transposon vector for expressing anti-human influenza M2 antibody

In the same manner as in Example 1, a plasmid which comprised a gene expression cassette for mammalian cells, comprising an arbitrary human antibody gene and a drug resistance marker gene inserted between a pair of Tol1 transposon sequences, was used as a protein expression plasmid vector.

[0192]

Each DNA of the used genes was chemically synthesized in the artificial way based on the known sequence information or obtained by preparing primers of its both terminal sequences and carrying out PCR using an appropriate DNA source as the template. For the gene manipulation to be carried out later, a restriction enzyme digestion site was added to the end of the primer.

[0193]

In the nucleotide sequence of the non-autonomous Tol1 transposon represented by SEQ ID NO:13 in Sequence Listing (WO2008/072540), the nucleotide sequence at positions 1 to 200 (Tol1-L sequence) (SEQ ID NO:14) and the nucleotide sequence at positions 1351 to 1855 (Tol1-R sequence) (SEQ ID NO:15) were used as the transposon sequences.

[0194]

Each of the synthetic DNA fragments comprising each a pair of transposon sequences was prepared by the following method. A DNA fragment comprising a nucleotide sequence in which a recognition sequence of a restriction enzyme *NruI* was connected to both of the 5'-terminal and 3'-terminal of the Tol1-R sequence. Then, a DNA fragment comprising a nucleotide sequence in which a recognition sequence of a restriction enzyme *FseI* was connected to the 5'-terminal of the Tol1-L sequence and a restriction enzyme *AscI* was connected to the 3'-terminal thereof.

[0195]

Next, the thus prepared DNA fragments comprising Toll1-R sequence and Toll1-L sequence were inserted into the expression vector N5LG1_M2_Z3 vector. The DNA fragment comprising the Toll1-R sequence was inserted into the restriction enzyme *Nru*I site, existing on the 5'-terminal side of a gene fragment comprising the antibody gene expression cassette and a selectable marker gene on the N5LG1_M2_Z3 vector, and the DNA fragment comprising the Toll1-L sequence was inserted into the restriction enzyme *Fse*I and *Asc*I sites existing on the 3'-terminal side.

[0196]

In addition, Toll1 transposon vector for expressing an anti-human influenza M2 antibody was constructed (Fig. 5) by inserting a cycloheximide resistance gene expression cassette in which a resistance gene for cycloheximide (a gene in which proline at position 54 in the human ribosomal protein L36a was mutated to glutamine) is connected under the control of the CMV enhancer/promoter into the *Fse*I recognition site of the N5LG1_M2_Z3 vector connected with the Toll1 transposon sequence.

[0197]

(2) Preparation of Toll1 transposase expression vector

The transposase was expressed using an expression vector independent from the expression vector of the antibody of interest. That is, a Toll1 transposase gene expression cassette in which a DNA fragment encoding a medaka fish-derived Toll1 transposase (SEQ ID NO:17) comprised of the nucleotide sequence represented by SEQ ID NO:16 was connected under the CMV enhancer/promoter control was inserted into pBluescriptII SK (+) (manufactured by Stratagene) and used as the Toll1 transposase expression vector pTollase (Fig. 6).

[0198]

(3) Preparation of CHO cell which produces antibody

Using the expression vectors prepared in the above (1) to (3), the introduction efficiency of the expression vector by Toll1 transposon was examined in the same manner as Example 3. The result was shown in Table 3.

[0199]

[Table 3]

Toll1 transposon vector	
Tests 1	133 / 192
Tests 2	67 / 192
Tests 3	122 / 192

[0199]

As shown in Table 3, when the Tol1 transposon vector for expressing the anti-human influenza M2 antibody was introduced into the suspension CHO-K1 cell, cycloheximide-resistant transformants were obtained at a high frequency as in the case with Example 3 in which the Tol2 transposon vector for expressing the anti-human influenza M2 antibody was introduced.

[0200]

It was found based on these results that the antibody gene and cycloheximide resistance gene inserted between a pair of transposon sequences are efficiently transduced into the chromosome of the host cell, namely the suspension mammalian cell, in the case of using the Tol1 transposon, too.

[0201]

(4) Examination on antibody production by suspension CHO cell

Antibody production efficiency of the suspension CHO cell was examined using the Tol1 transposon in the same manner as Example 3(3).

[0202]

The antibody concentration in culture supernatant was measured in accordance with the method described in *FEMS Yeast Res.*, 7 (2007), 1307 - 1316. The results are shown in Fig. 7.

[0203]

As shown in Fig. 7, a large number of cells showing a markedly high antibody expression level were also obtained in the case using the Tol1 transposon. From this result, it was found that similar to the case using the nucleotide sequence derived from Tol2 transposon, a suspension mammalian cell capable of highly expressing the protein of interest could also be obtained when a nucleotide sequence derived from Tol1 transposon is used as the transposon sequence.

[0204]

[Example 5] Preparation of anti-human CD98 antibody

(1) Preparation of anti-human CD98 antibody heavy chain expression transposon vector and anti-human CD98 antibody light chain expression transposon vector

In order to prepare an anti-human CD98 antibody having the variable region H chain and L chain represented by the amino acid sequences of SEQ ID NOs:20 and 23, respectively, amino acid sequences of the H chain and L chain were prepared by connecting amino acid sequence of human IgG1 antibody constant region to each antibody variable region.

[0205]

Using the sequences integrated into a vector (N5KG1-Val C2IgG1NS/I117L)

disclosed in Japanese Patent No. 4324637 as the gene sequences (SEQ ID Nos:18 and 21, respectively) of the anti-human CD98 antibody heavy chain variable region and light chain variable region to which a signal sequence had been connected, and using the transposon sequence, and promoter similar to those used in Example 1, an anti-human CD98 antibody heavy chain expression transposon vector (hereinafter, referred to as CD98H vector) and an anti-human CD98 antibody light chain expression transposon vector (hereinafter, referred to as CD98L vector) were respectively constructed (Figs. 8 and 9).

[0206]

The DNA fragment to be used was chemically synthesized in the artificial way based on the conventionally known sequence or obtained by preparing primers of its both terminal sequences and carrying out PCR using an appropriate DNA source as the template. A restriction enzyme digestion site was attached to a terminal of each primer for the sake of the later gene recombination operations.

[0207]

(2) Preparation of cycloheximide resistance gene expression transposon vector

A cycloheximide resistance gene expression transposon vector (hereinafter, referred CHX vector) was constructed by connecting the sequence encoding a cycloheximide resistance gene (SEQ ID NO:7) under control of the CMV enhancer/promoter described in Example 1 and inserting a pair of transposon sequences (Tol-2L, Tol2-R) into both terminals of the cycloheximide resistance gene expression cassette (Fig. 10).

[0208]

The DNA fragment to be used was artificially chemically synthesized based on the conventionally known sequence or obtained by preparing primers of its both terminal sequences and then carrying out PCR using an appropriate DNA source as the template. A restriction enzyme digestion site was attached to a terminal of each primer for the sake of the later gene recombination operations.

[0209]

(3) Preparation of CHO cell which produces anti-human CD98 antibody

The CD98H vector (Fig. 8), CD98L vector (Fig. 9) and CHX vector (Fig. 10) prepared in the above-mentioned (1) and (2) and the Tol2 vector (Fig. 3) prepared in Example 2 were introduced into CHO-K1 cell which was adapted to suspension culture, and the number of appeared cells capable of highly expressing the antibody was compared.

[0210]

In the test plot, 4×10^6 cells of the CHO-K1 cell were suspended in 400 μ l of

PBS, and CD98H vector (10 µg), CD98L vector (10 µg), CHX vector (10 µg) and Tol2 vector (10 µg) were directly co-transfected in a form of circular DNA by electroporation. In order to express Tol2 transposase transiently and to prevent integration into the host chromosome, the Tol2 vector was introduced directly in the form of circular DNA.

The electroporation was carried out using an electroporator (Gene Pulser Xcell system, manufactured by Bio-Rad) under conditions of voltage of 300 V, electrostatic capacity of 500 µF and room temperature and using a cuvette of 4 mm in gap width (manufactured by Bio-Rad).

[0211]

Also, in the control plot, each of CD98H vector (10 µg), CD98L vector (10 µg) and CHX vector (10 µg) was linearized using a restriction enzyme *PciI* (Takara Bio Inc.) and then electroporation was carried out in the same manner as the above.

[0212]

After the gene introduction by electroporation, the cells in each cuvette were suspended in a CD OptiCHO medium supplemented with 0.5% soybean hydrolyzate (hereinafter, referred to as 0.5CD medium), inoculated onto one 96-well plate and cultured for 4 days in a CO₂ incubator. Next, from the medium exchange after 5 days of the gene introduction, culturing was carried out in the presence of cycloheximide using the 0.5CD medium supplemented with 3 µg/ml of cycloheximide (C4859, Sigma-Aldrich) followed by culturing for 4 weeks while carrying out the medium exchange at intervals of one week.

[0213]

After 4 weeks of the culturing, expression of the antibody was determined by a sandwich method (LENCETM, Perkin-Elmer Corp) using FRET (fluorescence resonance energy transfer). Regarding the antibody high expression cells, clones expressing the antibody at a concentration in culture supernatant of 5.0 µg/ml or more were counted as the antibody-expressing cells, with the results shown in Table 4.

[0214]

[Table 4]

	Control plot	Test plot
	The number of wells where the antibody is expressed	
Plate 1	10/96	29/96
Plate 1	20/96	49/96

[0215]

As shown in Table 4, large number of anti-human CD98 antibody expression cells were found in the test plot in which Tol2 vector was co-transfected into the suspension CHO-K1 cell together with anti-human CD98 heavy chain expression

transposon vector, anti-human CD98 light chain expression transposon vector and cycloheximide resistance gene vector, but the anti-human CD98 antibody expression cells were not found in the control plot in which Tol2 vector was not co-transfected in spite of making the vectors into linear chains.

5 [0216]

[Example 6] Production of anti-human CD98 antibody

(1) Preparation of expression transposon vector comprising anti-human CD98 antibody heavy chain gene fragment, anti-human CD98 antibody light chain gene fragment and cycloheximide resistance gene

10 An expression transposon vector containing anti-human CD98 antibody heavy chain gene fragment, anti-human CD98 antibody light chain gene fragment and cycloheximide resistance gene (hereinafter, referred to as CD98-CHX tandem vector) was constructed using a synthetic DNA and a PCR method in the same manner as in the above by connecting the anti-human CD98 antibody heavy chain expression transposon
15 vector prepared in Example 5(1) with the anti-human CD98 antibody light chain expression gene cassette prepared in Example 5(1) and the cycloheximide resistance gene cassette prepared in Example 5(2).

[0217]

(2) Preparation of expression transposon vector comprising anti-human CD98 antibody
20 heavy chain gene fragment and cycloheximide resistance gene

An expression transposon vector comprising anti-human CD98 antibody heavy chain gene fragment and cycloheximide resistance gene (hereinafter, referred to as CD98H-CHX expression transposon vector) was constructed using a synthetic DNA and a PCR method in the same manner as in the above by connecting the anti-human
25 CD98 antibody heavy chain expression transposon vector prepared in Example 5(1) with the cycloheximide resistance gene cassette prepared in Example 5(2).

[0218]

(3) Preparation of CHO cell producing anti-human CD98 antibody

Using the expression transposon vectors prepared in the above Example 5(1)
30 and (2) and the above Example 6(1) and (2), the incidence of cells capable of highly expressing anti-CD98 antibody were compared on the case of gene-transferring H chain and L chain of anti-human CD98 antibody using the same expression vector (control plot), on the case of gene-transferring H chain or L chain of anti-human CD98 antibody or cycloheximide resistance gene respectively using different expression vectors (test
35 plot 1) and on the case of gene-transferring H chain or L chain using different expression vectors (test plot 2).

[0219]

In the test plot 1, 4×10^6 cells of the CHO-K1 cell were suspended in 400 μ l of PBS, and CD98H vector (10 μ g), CD98L vector (10 μ g), CHX vector (10 μ g) and Tol2 vector (10 μ g) were directly co-transfected as circular DNA by electroporation.

[0220]

In the test plot 2, 4×10^6 cells of the CHO-K1 cell were suspended in 400 μ l of PBS, and CD98H-CHX vector (10 μ g), CD98L vector (10 μ g) and Tol2 vector (10 μ g) were directly co-transfected as circular DNA by electroporation.

[0221]

In the control plot, 4×10^6 cells of the CHO-K1 cell were suspended in 400 μ l of PBS, and CD98-CHX tandem vector (10 μ g) and Tol2 vector (20 μ g) were directly co-transfected as circular DNA by electroporation. Also, in all of the tests, in order to express Tol2 transposase transiently and to prevent integration into the host chromosome, the Tol2 vector was introduced directly in the form of circular DNA.

[0222]

In the following method, the incidence of antibody producing cells was confirmed in the same manner as Example 5(3). Regarding the antibody producing cells, the clones in which the antibody concentration in culture supernatant was 3.0 μ g/ml or more were counted as the antibody-expressing cells. The results are shown in Table 5.

[0223]

[Table 5]

	Control plot	Test plot 1	Test plot 2
	The number of wells where the antibody is expressed		
Plate 1	18/96	82/96	95/96
Plate 2	21/96	85/96	96/96
Total	39/192	167/192	191/192

[0224]

In the test plot 1 in which CD98H vector, CD98L vector and CHX vector were introduced and the test plot 2 in which CD98H vector and CD98L vector were introduced, the incidence of the cells capable of highly expressing the anti-human CD98 antibody was markedly increased.

[0225]

The above results show that cells having a high antibody productivity can be easily obtained and produced when different expression vectors in which the antibody heavy chain gene and antibody light chain gene are respectively inserted between transposon sequences are co-transfected into the suspension CHO cell, in comparison with a case in which an expression vector prepared by integrating the antibody heavy

chain gene and antibody light chain gene into the same expression vector is introduced to the suspension CHO cell. In addition, it was revealed from the results of test plot 1 and test plot 2 that even when the vector to be introduced is two or more, at least one drug resistance gene (selectable marker gene) is enough. Further, it was revealed that the drug resistance gene may be present on an expression vector into which the antibody heavy chain gene is integrated or on a different independent vector.

[0226]

The above results show that a transposon vector is effective as a means for efficiently introducing genes arranged on two or more vectors into a suspension of mammalian cells, which was conventionally difficult to achieve. Further, it is shown that for the purpose of achieving high productivity of a protein comprising more than one polypeptides or of more than one proteins, it is effective to introduce polypeptides and proteins using different transposon vectors.

[0227]

(4) Culturing of CHO cell which produces anti-human CD98 antibody

The top three cell lines having high antibody productivity were selected from each of the cells into which the CD98-CHX tandem vector obtained in the above-mentioned Example 6(3) was introduced and the cells into which the CD98H-CHX vector and CD98L vector were introduced, and their antibody expression levels were compared. Details of the tests are shown below.

[0228]

The CHO-K1 cell obtained in Example 6(3) which was selected based on the cycloheximide resistance and also expresses the anti-CD98 antibody, was expansion-cultured using a 96-well plate, a 24-well plate and a 6-well plate (Corning Glassworks) in that order. After the expansion culturing, antibody concentration in each culture supernatant was measured, and the top three cell lines CHO cells having high level of anti-CD98 antibody expression were selected. Next, each of the thus selected three cell lines were suspended in 3 ml of 0.5% CD medium (Invitrogen), namely 0.5 CD medium, to a density of 2×10^5 cells/ml, and cultured on a shaker for 5 days in an atmosphere of 37°C and 5% CO₂ using a 6-well plate. The amount of the antibody in the medium after 5 days of culturing was determined by HPLC (Waters Associates, Inc.). The results are shown in Table 6.

[0229]

[Table 6]

	Cells derived from control plot			Cells derived from test plot 2		
Expression level of antibody	70	67	41	196	87	67

(mg/L)

[0230]

As shown in Table 6, the CHO-K1 cell into which CD98H vector and CD98L vector were co-transfected has a high antibody production level in comparison with the CHO-K1 cell into which CD98-CHX tandem vector was introduced.

[0231]

The above results show that not only an antibody high producer cell line can be obtained and produced easily, but also the thus obtained cell has a high antibody productivity, when different expression vectors in which the antibody heavy chain gene and antibody light chain gene are respectively inserted between a pair of transposon sequences are co-transfected into the suspension CHO cell.

[0232]

[Example 7] Production of anti-human tumor necrosis factor-alpha (TNF α) antibody

(1) Preparation of expression transposon vector containing a TNF α antibody heavy chain gene fragment, a TNF α antibody light chain gene fragment and cycloheximide resistance gene

In order to prepare anti-human TNF α antibody having the amino acid sequence of SEQ ID NO:26 and SEQ ID NO:29, an anti-human TNF α antibody heavy chain gene fragment, an anti-human TNF α antibody light chain gene fragment and a cycloheximide resistance gene expression transposon vector (hereinafter, referred to as TNF α -CHX tandem vector) were constructed by replacing VH and VL gene fragments of the expression transposon vector comprising the anti-human CD98 heavy chain gene fragment and light chain gene fragment and cycloheximide resistance gene prepared in Example 6(1) (CD98-CHX tandem vector) by the anti-human TNF α antibody-derived VH and VL, respectively.

[0233]

The sequences of anti-human TNF α antibody heavy chain gene and light chain gene were prepared using a synthetic DNA, by preparing amino acid sequences (SEQ ID NOs:26 and 29) in which a signal sequence was connected to the amino acid sequences (SEQ ID NOs:25 and 28) of the heavy chain variable region subunit or light chain variable region subunit of Adalimumab (recombinant) described in Fig. 1 and Fig.2, respectively, of HUMIRA(R) subcutaneous injection 40 mg inspection report (Pharmaceutical and Medical Devices Agency, February 14, 2008) and determining the nucleotide sequences in such a manner that the amino acid sequences did not change (SEQ ID NOs:24 and 27) . For the sake of the latter gene manipulations, a restriction enzyme digestion site was added to the terminal of the artificial sequences.

[0234]

(2) Preparation of expression transposon vector comprising anti-human TNF α antibody heavy chain fragment and cycloheximide resistance gene

An expression transposon vector containing anti-human TNF α antibody heavy chain fragment and cycloheximide resistance gene (hereinafter, referred to as TNF α H-CHX vector) was constructed by modifying a VH gene fragment region of the expression transposon vector containing anti-human CD98 antibody heavy chain fragment and cycloheximide resistance gene (CD98H-CHX vector) prepared in Example 6(2) to an anti-human TNF α antibody VH gene fragment. As the anti-human TNF α antibody heavy chain gene, a sequence of the same sequence shown in this item (1) was used.

[0235]

(3) Preparation of anti-human TNF α antibody light chain gene expression transposon vector

An anti-human TNF α antibody light chain gene expression transposon vector (hereinafter, referred to as CD98L vector) was constructed by modifying the light chain gene region of the anti-human CD98 antibody light chain gene expression transposon vector prepared in Example 6(1) to anti-human TNF α antibody light chain. As the anti-human TNF α antibody VL gene, the same sequence as the sequence shown in this item (1) was used.

[0236]

(4) Preparation of CHO cell which produces anti-human TNF α antibody

In order to prepare CHO-K1 cell which produced anti-human TNF α antibody, the TNF α -CHX tandem vector (20 μ g) prepared in the above-mentioned (1) and the Tol2 transposase expression vector (Tol2 vector) (10 μ g) prepared in Example 2 were introduced into CHO-K1 cell adapted to suspension culturing prepared in Example 3 (control plot).

[0237]

In the same manner, the TNF α H-CHX vector (10 μ g), TNF α L vector (10 μ g) and Tol2 vector (10 μ g) prepared in the above-mentioned (2) and (3) were directly co-transfected in the form of circular DNA (test plot). The incidences of cells capable of highly expressing the antibody were compared by carrying out the gene introduction, cell culturing and the like in the same manner as in Example 6 except that culturing of the gene-introduced cells was carried out on five plates of the 96-well plate. Regarding the cell having a high antibody productivity, the clones in which the antibody concentration in culture supernatant was 3.0 μ g/ml or more were counted as the antibody-expressing cells. The results are shown in Table 7.

[0238]

[Table 7]

	Control plot	Test plot
	The number of wells where the antibody is expressed	
Plate 1	20/96	83/96
Plate 2	22/96	76/96
Plate 3	21/96	82/96
Plate 4	20/96	79/96
Plate 5	27/96	81/96
Total	110/480	401/480

[0239]

As shown in Table 7, as in the case of the anti-human CD98 antibody producing cell prepared in Example 6, the CHO-K1 cell into which TNF α H-CHX vector and TNF α L vector were co-transfected showed about 4 times higher incidence of cells in which the anti-human TNF α antibody was highly expressed, in comparison with the CHO-K1 cell into which TNF α -CHX tandem vector was introduced.

[0240]

This result shows that, regarding any case of the antibody, a cell line having a high antibody productivity can be easily obtained and produced by co-transfecting the antibody heavy chain gene and the antibody light chain gene which are respectively inserted between a pair of transposon sequences introduced into different expression vectors, in the suspension CHO cell.

[0241]

(5) Culturing of CHO cell which produces anti-human TNF α antibody

The cells which are selected based on the cycloheximide resistance from the TNF α -CHX tandem vector-introduced cells obtained in the above-mentioned (4) and the cells into which the TNF α H-CHX vector and TNF α L vector were co-transfected, and also expressing the anti-human TNF α antibody, were selected and expansion-cultured using 96-well plate, 24-well plate and 6-well plate in that order. Regarding 4 cell lines of the TNF α -CHX tandem vector-introduced cells succeeded in the expansion culturing and 52 cell lines into which the TNF α H-CHX vector and TNF α L vector were co-transfected, these cells were cultured in the same manner as in Example 6(4) except that the culturing period was 7 days, and the expression levels of the antibodies were measured. The results are shown in Fig. 11.

[0242]

As a result, the CHO-K1 cell into which the TNF α H-CHX vector and TNF α L vector were co-transfected showed about 2.4 times higher antibody productivity than that of the CHO-K1 cell into which the TNF α -CHX tandem vector was introduced.

[0243]

This result shows that, as in the case of Example 6(4), not only a cell having a high antibody productivity can be obtained and produced, but also the thus obtained cell has a high antibody productivity, when different expression vectors in which each of the antibody heavy chain gene and the antibody light chain gene are respectively inserted between a pair of transposon sequences are co-transfected into the suspension CHO cell.

[0244]

[Example 8] Production of anti-human CD20 antibody

(1) Preparation of expression transposon vector comprising anti-human CD20 antibody heavy chain gene fragment, anti-human CD20 antibody light chain gene fragment and cycloheximide resistance gene

In order to prepare an anti-human CD20 antibody comprising VH and VL represented by the amino acid sequences of SEQ ID NOs:32 and 35, respectively, an expression transposon vector comprising an anti-human CD20 antibody heavy chain gene fragment, an anti-human CD20 antibody light chain gene fragment and a cycloheximide resistance gene (hereinafter, referred to as CD98-CHX tandem vector) was constructed by replacing antibody VH and VL gene regions of the CD98-CHX tandem vector prepared in Example 6(1) by the anti-human CD20 antibody-derived VH and VL, respectively.

[0245]

The gene sequences of anti-human CD20 antibody VH region and VL region were prepared using a synthetic DNA, by preparing the nucleotide sequence described in GenBank accession No. AR000013 and amino acid sequences (SEQ ID NOs:31 and 34, respectively) in which a signal sequence was connected to the amino acid sequences (SEQ ID NOs:32 and 35, respectively) of the VH and VL of rituximab described in accompanying sheet of Rituxan(R) for injection 10 mg/ml inspection report (reported by National Institute of Health Sciences, No. 3395, August 28, 2003) and determining the nucleotide sequences in such a manner that the amino acid sequences did not change (SEQ ID NOs:30 and 33). For the sake of the latter gene manipulations, a restriction enzyme digestion site was added to the terminal of the artificial sequences.

[0246]

(2) Preparation of expression transposon vector comprising anti-human CD20 antibody heavy chain gene fragment and cycloheximide resistance gene

An expression transposon vector comprising anti-human CD20 antibody heavy chain gene fragment and cycloheximide resistance gene (hereinafter, referred to as CD20H-CHX vector) was constructed by modifying the antibody VH gene region of the CD98H-CHX vector prepared in Example 6(2) to an anti-human CD20

antibody-derived VH. As the anti-human CD20 antibody heavy chain gene, the same sequence as a sequence shown in the above-mentioned (1) was used.

[0247]

(3) Preparation of anti-human CD20 antibody light chain gene expression transposon vector

An anti-human CD20 antibody light chain gene expression transposon vector (hereinafter, referred to as CD20L vector) was constructed by modifying the VL gene regions of the anti-human CD98 antibody prepared in Example 6(1) to the anti-human CD20 antibody-derived VL. As the anti-human CD20 antibody heavy and light genes, the same sequences as a sequence shown in the above-mentioned (1) were used.

[0248]

(4) Preparation of CHO cell which produces anti-human CD20 antibody

In order to prepare CHO-K1 cell which produces anti-human CD20 antibody, the CD20-CHX tandem vector prepared in the above-mentioned (1) and the Tol2 transposase expression vector (Tol2 vector) prepared in Example 2 were introduced into CHO-K1 cell adapted to suspension culturing prepared in Example 3(1) (control plot).

[0249]

In the same manner, the CD20H-CHX vector (10 μ g) and CD20L vector (10 μ g) prepared in the above-mentioned (2) and (3) were co-transfected into CHO-K1 cell together with Tol2 vector (10 μ g) (test plot). The incidences of cells capable of highly expressing the antibody were compared by carrying out the gene introduction, cell culturing and the like in the same manner as Example 6 except that culturing of the gene-introduced cells was carried out on five plates of the 96-well plate. Also, antibody concentrations of 3.0 μ g/ml or more were counted as the antibody-expressing wells. The results are shown in Table 8.

[0250]

[Table 8]

	Control plot	Test plot
	The number of wells where the antibody is expressed	
Plate 1	2/96	4/96
Plate 2	2/96	9/96
Plate 3	4/96	4/96
Plate 4	1/96	8/96
Plate 5	2/96	5/96
Total	11/480	30/480

[0251]

As a result, the CHO-K1 cell into which the CD20H-CHX vector and CD20L

vector were co-transfected showed about 3 times higher incidence of cells which highly expresses the anti-human CD20 antibody in comparison with the CHO-K1 cell into which the CD20-CHX tandem vector was introduced.

[0252]

5 This result is similar to the result of the case of anti-human CD98 antibody and anti-human TNF α antibody carried out in Example 6(3) or Example 7(3) and shows that an antibody high level producer cell line can be easily obtained and produced regarding each case of the antibodies when different expression vectors in which each of the antibody heavy chain gene and the antibody light chain gene are respectively integrated
10 between transposon sequences are co-transfected into the suspension CHO cell.

[0253]

(5) Culturing of CHO cell which produces anti-human CD20 antibody

The cells which are selected based on the cycloheximide resistance from the CD20-CHX tandem vector-introduced cells obtained in the above-mentioned (3) and the
15 cells into which the CD20H-CHX vector and CD20L vector were co-transfected, and also expressing the anti-human CD20 antibody, were selected and expansion-cultured using 96-well plate, 24-well plate and 6-well plate in that order. Regarding 4 cell lines of the control plot cells succeeded in the expansion culturing and 50 cell lines of test plot cells, these cells were cultured in the same manner as in Example 6(4) except that
20 the culturing period was 7 days, and their antibody expression levels were measured. The results are shown in Fig. 12.

[0254]

As shown in Fig. 12, it was revealed that the CHO-K1 cell into which the CD20H-CHX vector and CD20L vector were co-transfected had about 1.6 times higher
25 antibody productivity than the CHO-K1 cell into which the CD20-CHX tandem vector was introduced.

[0255]

This result is similar to the result of the case of anti-human CD98 antibody and anti-human TNF α antibody carried out in Example 6(4) or Example 7(5) and shows that
30 not only a cell line having a high antibody productivity can be easily obtained and produced when different expression vectors in which the antibody heavy chain gene and antibody light chain gene are respectively integrated between transposon sequences are co-transfected into the suspension CHO cell, but also the thus obtained cell has a high antibody productivity.

[0256]

35 [Example 9] Preparation of a transposon vector which expresses neomycin resistance gene and anti-human CD98 antibody

(1) Preparation of a transposon vector which expresses wild type neomycin resistance gene and anti-human CD98 antibody

A plasmid which comprised a gene expression cassette for mammalian cell use comprising an arbitrary human antibody gene and a drug resistance marker gene inserted between a pair of Tol2-derived nucleotide sequences was used as the plasmid vector for protein expression.

[0257]

The DNA of the gene to be used was obtained by carrying out chemical synthesis in the artificial way based on a conventionally known nucleotide sequence or by preparing primers of its both terminal sequences and thereby carrying out PCR using an appropriate DNA source. For the sake of the latter gene manipulations, a restriction enzyme digestion site was added to the primer terminal.

[0258]

In the non-autonomous Tol2 transposon nucleotide sequence (SEQ ID NO:1) disclosed by JP-A-2003-235575, a nucleotide sequence at positions 1 to 200 (Tol2-L sequence) (SEQ ID NO:2) and a nucleotide sequence at positions 2285 to 2788 (Tol2-R sequence) (SEQ ID NO:3) were used as the transposon sequences.

[0259]

A DNA fragment comprising either of the Tol2-R sequence and Tol2-L sequence was synthesized.

[0260]

A DNA fragment including a nucleotide sequence (SEQ ID NO:18) which encodes antibody H chain under control of CMV promoter, amplified based on the anti-human CD98 antibody N5KG1-Val C2IgG1NS/I117L vector (Japanese Patent No. 4324637), was prepared as the antibody heavy chain gene cassette, and a DNA fragment comprising a nucleotide sequence (SEQ ID NO:21) which encoded antibody light chain under control of SV40 promoter, amplified based on the anti-human CD98 antibody N5KG1-Val C2IgG1NS/I117L vector, as the antibody light chain gene cassette.

[0261]

As the neomycin resistance gene cassette, a DNA fragment comprising a DNA which comprises a nucleotide sequence encoding a neomycin resistance gene under control of SV40 promoter (a DNA which encodes a neomycin phosphotransferase consisting of the nucleotide sequence represented by SEQ ID NO:36 and GenBank Accession No. U47120.2) was prepared.

[0262]

An anti-CD98 antibody expression vector A was prepared by connecting the above-mentioned antibody heavy chain gene expression cassette, antibody light chain

gene expression cassette and neomycin resistance gene expression cassette and further connecting its both terminals with a DNA fragment comprising a Tol2-R sequence and a DNA fragment comprising a Tol2-L sequence (Fig. 13).

[0263]

- 5 (2) Preparation of anti-human CD98 antibody expression transposon vector comprising a modified type neomycin resistance gene 1

An anti-human CD98 antibody expression transposon vector B in which the neomycin resistance gene of the anti-human CD98 antibody expression transposon vector A obtained in (1) which comprises a wild type neomycin resistance gene was
10 replaced by a modified type neomycin resistance gene 1 comprising the nucleotide sequence represented by SEQ ID NO:37 was prepared.

[0264]

The modified type neomycin resistance gene 1 encodes an amino acid sequence identical to that of the wild type neomycin resistance gene and was modified
15 to have a nucleotide sequence in which 167 bases corresponding to 22% of the entire were modified. Specifically, among the total of 32 leucine residues, codons corresponding to 25 leucine residues were modified so as to be TAA.

[0265]

- 20 (3) Preparation of anti-human CD98 antibody expression transposon vector comprising a modified type neomycin resistance gene 2

An anti-human CD98 antibody expression transposon vector C in which the neomycin resistance gene of the anti-human CD98 antibody expression transposon vector A obtained in (1) which comprises a wild type neomycin resistance gene was
25 replaced by a modified type neomycin resistance gene 2 comprising the nucleotide sequence represented by SEQ ID NO:38 was prepared.

[0266]

The modified type neomycin resistance gene 2 encoded the amino acid sequence identical to that of the wild type neomycin resistance gene and had a
30 nucleotide sequence in which the 180 bases corresponding to 23% of the entire were modified. Specifically, among the total of 32 leucine residues, codons corresponding to 28 leucine residues were modified so as to be TAA.

[0267]

- (4) Preparation of anti-human CD98 antibody expression transposon vector having a modified type neomycin resistance gene 3

35 An anti-human CD98 antibody expression transposon vector D in which the neomycin resistance gene of the anti-human CD98 antibody expression transposon vector A obtained in (1) which comprises a wild type neomycin resistance gene was

replaced by a modified type neomycin resistance gene 3 comprising the nucleotide sequence represented by SEQ ID NO:39 was prepared.

[0268]

The modified type neomycin resistance gene 3 encoded the amino acid sequence identical to that of the wild type neomycin resistance gene and had a nucleotide sequence in which 203 bases corresponding to 26% of the entire were modified. Specifically, among the total of 32 leucine residues, codons corresponding to 30 leucine residues were modified so as to be TAA.

[0269]

[Example 10] Antibody production by antibody producer CHO cells which expresses modified type neomycin resistance gene

Antibody producing cells A to D were prepared by introducing each of the anti-human CD98 expression transposon vectors A to D prepared in Example 9(1) to (4) into the suspension CHO-K1 cell together with a vector pCAGGS-T2TP which expresses a Tol2 transposase comprising the amino acid sequence represented by SEQ ID NO:40 [Kwakami K. & Noda T., *Genetics*, 166, 895 - 899 (2004)].

[0270]

Introduction of vectors into the suspension CHO cell was carried out by suspending the CHO cell (4×10^6 cells) in 400 μ l of PBS buffer and co-transfecting the anti-human CD98 antibody expression transposon vector (10 μ g) and Tol2 transposase expression vector pCAGGS-T2TP (20 μ g) directly in the form of circular DNA by electroporation.

[0271]

In this case, the Tol2 transposase expression vector was also introduced directly as circular DNA in order to transiently express Tol2 transposase.

[0272]

In addition, as a control which did not use Tol2 transposase, the anti-human CD98 antibody expression transposon vector D (10 μ g) of Example 19(4) was linearized using a restriction enzyme *Pci*I (TARA BIO INC.) and then introduced into suspension CHO-K1 cell by electroporation.

[0273]

The electroporation was carried out using an electroporator [Gene Pulser Xcell system (manufactured by Bio-Rad)] under conditions of voltage of 300 V, electrostatic capacity of 500 μ F and room temperature and using a cuvette of 4 mm in gap width (manufactured by Bio-Rad).

[0274]

After the gene introduction by electroporation, the cells in each cuvette were

inoculated onto one 96-well plate and cultured for 3 days in a CO₂ incubator using a CD OptiCHO medium (Invitrogen) supplemented with 5% soybean hydrolyzate.

[0275]

Next, from the medium exchange after 4 days of the gene introduction, culturing was carried out in the presence of G418 (Geneticin(R), Invitrogen) by adding the G418 to give a final concentration of 500 µg/ml, and the culturing was carried out for 3 weeks while changing the medium at intervals of one week.

[0276]

After the culturing, expression of the antibody was determined using LANCE(R) assay (Perkin-Elmer Corp) by a sandwich method to which FRET (fluorescence resonance energy introduction) was applied. The results are shown in Table 9.

[0277]

[Table 9]

	Antibody producing cells				
	A (Wild Type)	B (Modified Type 1)	C (Modified Type 2)	D (Modified Type 3)	Control cell
Antibody expression level (mg/L) of cells showing maximum expression	0.5	2.0	1.6	5.1	-
Average antibody expression level (mg/L) of top 10 cells	0.5	0.7	0.7	1.7	-

[0278]

As shown in Table 9, expression levels of anti-human CD98 antibody of the cells B to D expressing the modified type neomycin resistance genes were higher than that of the cell A which expressed the wild type neomycin resistance gene.

[0279]

Particularly, in the case of the anti-human CD98 antibody producing cell D which expresses the modified type neomycin resistance gene 3, the cell line showing the 10 times higher expression level than that of the anti-human CD98 antibody producing cell A which expresses the wild type neomycin resistance gene was obtained.

[0280]

In addition, even when the modified type neomycin resistance gene 3 was used, it was not able to obtain a cell which expresses the anti-human CD98 antibody by the control cell into which the Tol2 transposase expression vector was not co-transfected in spite of making the vector into linear form.

5 [0281]

[Example 11] Preparation of transposon vector expressing puromycin resistance gene and anti-human CD98 antibody

(1) Preparation of anti-human CD98 antibody expression transposon vector comprising modified type puromycin resistance gene 1

10 An anti-human CD98 antibody expression transposon vector E in which the neomycin resistance gene of the anti-human CD98 antibody expression transposon vector A obtained in Example 9(1) which comprised wild type neomycin resistance gene, was replaced by a modified type puromycin resistance gene 1 consisting of the nucleotide sequence represented by SEQ ID NO:41 was prepared.

15 [0282]

The modified type puromycin resistance gene 1 encoded an amino acid sequence identical to that of the wild type puromycin resistance gene consisting of the nucleotide sequence represented by SEQ ID NO:42 (a puromycin-N-acetyltransferase gene, consists of the nucleotide sequence disclosed in GenBank Accession No.

20 U07648.1) and had a nucleotide sequence in which 17 bases corresponding to the 3% of the entire bases are modified. Specifically, among the total of 28 alanine residues contained in the puromycin resistance gene, codons corresponding to 17 alanine residues were changed to GCG by the modification and, together with the codons which were already GCG in the wild type, the codons which correspond to all of the alanine
25 residues were changed to GCG.

[0283]

(2) Preparation of anti-human CD98 antibody expression transposon vector comprising modified type puromycin resistance gene 2

30 An anti-human CD98 antibody expression transposon vector F in which the neomycin resistance gene of the anti-human CD98 antibody expression transposon vector A obtained in Example 9(1) which comprises wild type neomycin resistance gene was replaced by a modified type puromycin resistance gene 2 comprising the nucleotide sequence represented by SEQ ID NO:43 was prepared. The modified type puromycin resistance gene 2 encodes an amino acid sequence identical to that of the wild type
35 puromycin resistance gene and had a nucleotide sequence in which 79 bases corresponding to the 14% of the entire bases are modified. Specifically, in addition to the modification of codons which correspond to the alanine residues of the modified

type puromycin resistance gene 1, the codons corresponding to leucine residues were changed so as to be TAA, and the codons corresponding to valine residues were changed so as to be GTA and the codon of serine were changed so as to be TCG.

[0284]

- 5 [Example 12] Antibody production by antibody producing CHO cell which expresses modified type puromycin resistance gene 1

Antibody producing cells E and F were prepared by introducing the anti-human CD98 antibody expression transposon vector E of Example 11(1) comprising the modified type puromycin resistance gene 1, the anti-human CD98 antibody expression
10 transposon vector F of Example 11(2) comprising the modified type puromycin resistance gene 2 and the Tol2 transposase expression vector pCAGGS-T2TP into the suspension CHO-K1 cell.

[0285]

- 15 Introduction of the vectors into suspension cell was carried out by suspending the suspension CHO cell (4×10^6 cells) in 400 μ l of PBS buffer and co-transfecting the anti-human CD98 antibody expression transposon vector comprising the modified type puromycin resistance gene in the form of circular DNA (10 μ g) and the pCAGGS-T2TP (20 μ g) directly by electroporation.

[0286]

- 20 In this case, the Tol2 transposase expression vector pCAGGS-T2TP was also introduced directly in the form of circular DNA in order to transiently express Tol2 transposase.

[0287]

- 25 The electroporation was carried out using an electroporator [Gene Pulser Xcell system (manufactured by Bio-Rad)] under conditions of voltage of 300 V, electrostatic capacity of 500 μ F and room temperature and using a cuvette of 4 mm in gap width (manufactured by Bio-Rad).

[0288]

- 30 After the gene introduction by electroporation, the cells in each cuvette were inoculated onto one 96-well plate and cultured for 3 days in a CO₂ incubator using a CD OptiCHO medium (Invitrogen) supplemented with 5% soybean hydrolyzate.

[0289]

- 35 Next, from the medium exchange after 2 days of the gene introduction, culturing was carried out for 4 weeks while adding puromycin (P9620, Sigma-Aldrich) to give a final concentration of 5 μ g/ml and carrying out the medium exchange to the puromycin-containing medium at intervals of one week.

[0290]

After the culturing, expression level of the antibody was determined using LANCE(R) assay (Perkin-Elmer Corp) by a sandwich method to which FRET (fluorescence resonance energy transfer) was applied. The results are shown in Table 2.

[0291]

[Table 10]

	Antibody producing cells	
	E (Modification 1)	F (Modification 2)
Antibody expression level (mg/L) of cells showing maximum expression	1.0	2.2
Average antibody expression level (mg/L) of top 10 cells	0.7	1.6

[0292]

As shown in Table 10, the antibody producing cell F which expresses the modified type puromycin resistance gene 2 showed two times or more antibody productivity of the antibody producing cell E which expresses the modified type puromycin resistance gene 1.

[0293]

[Example 13] Antibody production by antibody producing CHO cell which expresses modified type puromycin resistance gene 2

The antibody producing cell F obtained in Example 12 which expresses the modified type puromycin resistance gene 2 was cultured using a conical flask to produce anti-human CD98 antibody.

[0294]

Specifically, the antibody producing cell F was expansion-cultured using 96-well plate, 24-well plate and 6-well plate in that order. Two cell lines of the antibody producing cell F in which the number of cell was sufficiently increased (cell line 1 and cell line 2) were selected, and respectively suspended in 35 ml of the CD OptiCHO medium (Invitrogen) supplemented with 5% soybean hydrolyzate so as to give a cell density of 2×10^5 cells/ml and cultured for 1 week on a shaker using a 125 ml capacity of conical flask (with a bent cap, Corning Glassworks) in an atmosphere of 37°C and 5% CO₂, thereby producing the anti-human CD98 antibody.

[0295]

Amount of the antibody in the medium after culturing was determined by HPLC (Waters Associates, Inc.). The results are shown in Table 11.

[0296]

[Table 11]

	Cell line 1	Cell line 2
Antibody expression level (mg/l)	15.6	14.8

[0297]

The above results show that in the suspension CHO cell, the antibody gene inserted between a pair of transposon sequences and the modified type drug resistance gene are introduced efficiently into the host chromosome and also are effective for the selection of a high expression cell. In addition, it was found that the thus obtained cell can be expansion-cultured and production of the protein of interest under a suspension culturing condition is possible.

[0298]

By the method for producing the protein of the present invention, a protein of interest can be efficiently produced using a suspension mammalian cell. The cell of the present invention can be used as a protein producing cell for producing a recombinant protein.

[Sequence Listing]

[0299]

SEQ ID NO:1 - Description of Artificial sequence; Nucleotide Sequence of Non-autonomous Tol2 Transposon

SEQ ID NO:2 - Description of Artificial sequence; Tol2-L sequence

SEQ ID NO:3 - Description of Artificial sequence; Tol2-R sequence

SEQ ID NO:7 - Description of Artificial sequence; Nucleotide Sequence of Cycloheximide Resistance Gene

SEQ ID NO:8 - Description of Artificial sequence; Amino Acid Sequence of Protein encoding Cycloheximide Resistance Gene

SEQ ID NO:9 - Description of Artificial sequence; Nucleotide Sequence encoding M2Z3 Antibody H chain

SEQ ID NO:10 - Description of Artificial sequence; Amino Acid Sequence of M2Z3 Antibody H chain

SEQ ID NO:11 - Description of Artificial sequence; Nucleotide Sequence encoding M2Z3 Antibody L chain

SEQ ID NO:12 - Description of Artificial sequence; Amino Acid Sequence of M2Z3 Antibody L chain

SEQ ID NO:13 - Description of Artificial sequence; Nucleotide Sequence of Non-autonomous Tol1

SEQ ID NO:14 - Description of Artificial sequence; Tol1-L sequence

- SEQ ID NO:15 - Description of Artificial sequence; Toll-R sequence
- SEQ ID NO:18 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-CD98 Antibody Heavy Chain Variable Region
- SEQ ID NO:19 - Description of Artificial sequence; Amino Acid Sequence of Anti-CD98 Antibody Heavy Chain Variable Region
- 5 SEQ ID NO:20 - Description of Artificial sequence; Amino Acid Sequence of Anti-CD98 Antibody Heavy Chain Variable Region
- SEQ ID NO:21 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-CD98 Antibody Light Chain Variable Region
- 10 SEQ ID NO:22 - Description of Artificial sequence; Amino Acid Sequence of Anti-CD98 Antibody Light Chain Variable Region
- SEQ ID NO:23 - Description of Artificial sequence; Amino Acid Sequence of Anti-CD98 Antibody Light Chain Variable Region
- SEQ ID NO:24 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-human TNF α Antibody Heavy Chain Variable Region
- 15 SEQ ID NO:25 - Description of Artificial sequence; Amino Acid Sequence of Anti-human TNF α Antibody Heavy Chain Variable Region
- SEQ ID NO:26 - Description of Artificial sequence; Amino Acid Sequence of Anti-human TNF α Antibody Heavy Chain Variable Region
- 20 SEQ ID NO:27 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-human TNF α Antibody Light Chain Variable Region
- SEQ ID NO:28 - Description of Artificial sequence; Amino Acid Sequence of Anti-human TNF α Antibody Light Chain Variable Region
- SEQ ID NO:29 - Description of Artificial sequence; Amino Acid Sequence of Anti-human TNF α Antibody Light Chain Variable Region
- 25 SEQ ID NO:30 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-human CD20 Antibody Heavy Chain Variable Region
- SEQ ID NO:31 - Description of Artificial sequence; Amino Acid Sequence of Anti-human CD20 Antibody Heavy Chain Variable Region
- 30 SEQ ID NO:32 - Description of Artificial sequence; Amino Acid Sequence of Anti-human CD20 Antibody Heavy Chain Variable Region
- SEQ ID NO:33 - Description of Artificial sequence; Nucleotide Sequence encoding Anti-human CD20 Antibody Light Chain Variable Region
- SEQ ID NO:34 - Description of Artificial sequence; Amino Acid Sequence of Anti-human CD20 Antibody Light Chain Variable Region
- 35 SEQ ID NO:35 - Description of Artificial sequence; Amino Acid Sequence of Anti-human CD20 Antibody Light Chain Variable Region

- SEQ ID NO:36 - Description of Artificial sequence; Nucleotide Sequence of Wild Type of Neomycin Resistance Gene
- SEQ ID NO:37 - Description of Artificial sequence; Nucleotide Sequence of Modified Type of Neomycin Resistance Gene
- 5 SEQ ID NO:38 - Description of Artificial sequence; Nucleotide Sequence of Modified Type of Neomycin Resistance Gene
- SEQ ID NO:39 - Description of Artificial sequence; Nucleotide Sequence of Modified Type of Neomycin Resistance Gene
- SEQ ID NO:41 - Description of Artificial sequence; Nucleotide Sequence of Modified
- 10 Type of Puromycin Resistance Gene
- SEQ ID NO:42 - Description of Artificial sequence; Nucleotide Sequence of Wild Type of Puromycin Resistance Gene
- SEQ ID NO:43 - Description of Artificial sequence; Nucleotide Sequence of Modified Type of Puromycin Resistance Gene
- 15 SEQ ID NO:44 - Description of Artificial sequence; Nucleotide Sequence of Modified Type of Puromycin Resistance Gene
- SEQ ID NO:45 - Description of Artificial sequence; Nucleotide Sequence of Modified type of Zeocin resistance gene
- SEQ ID NO:46 - Description of Artificial sequence; Nucleotide Sequence of Modified
- 20 type of Zeocin resistance gene
- SEQ ID NO:47 - Description of Artificial sequence; Nucleotide Sequence of Modified type of Hygromycin resistance gene
- SEQ ID NO:48 - Description of Artificial sequence; Nucleotide Sequence of Modified type of Hygromycin resistance gene
- 25

Claims

[Claim 1]

A method for producing a protein of interest, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment comprising the DNA encoding the protein of interest inserted between a pair of the transposon sequences into a chromosome of the mammalian cell to obtain a mammalian cell which expresses the protein of interest; and suspension-culturing the mammalian cell.

[Claim 2]

A method for producing a protein of interest, comprising the following steps (A) to (C):

(A) a step of simultaneously introducing the following expression vectors (a) and (b) into a suspension mammalian cell:

(a) at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(b) an expression vector which comprises a DNA encoding a transposase which recognizes the transposon sequences and has activity of transferring a gene fragment inserted between a pair of the transposon sequences into a chromosome,

(B) a step of obtaining a suspension mammalian cell which expresses the protein of interest by expressing transiently the transposase from the expression vector which is introduced into the suspension mammalian cell in the step (A) to integrate the gene fragment inserted between a pair of the transposon sequences into a chromosome of the mammalian cell, and

(C) a step of suspension-culturing the suspension mammalian cell which expresses the protein of interest obtained in the step (B) to produce the protein of interest.

[Claim 3]

A method for obtaining a suspension mammalian cell which expresses a protein of interest, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises transposon sequences at both terminals of the gene fragment into a suspension mammalian cell, and integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell.

[Claim 4]

The method according to any one of claims 1 to 3, wherein at least one of the expression vectors which comprises a gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment is an expression vector which comprises a gene fragment
5 comprising a DNA encoding the protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.
[Claim 5]

The method according to any one of claims 1 to 4, comprising introducing an expression vector which comprises a gene fragment comprising a selectable marker and
10 comprises a pair of transposon sequences at both terminals of the gene fragment into a mammalian cell in addition to the expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment.
[Claim 6]

15 The method according to any one of claims 1 to 5, wherein the DNA encoding the protein of interest is a DNA encoding an antibody.
[Claim 7]

The method according to any one of claim 6, wherein the DNA encoding an antibody is at least one of a DNA encoding a H chain of the antibody and a DNA
20 encoding a L chain of the antibody.
[Claim 8]

The method according to any one of claims 4 to 7, wherein an expression vector selected from the following (a) to (d) is introduced into a suspension mammalian cell:

25 (a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
30 vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression
35 vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.

[Claim 9]

The method according to any one of claims 1 to 8, wherein the suspension mammalian cell is a cell capable of surviving and proliferating in a serum-free medium.

[Claim 10]

The method according to any one of claims 1 to 9, wherein the suspension mammalian cell is at least one selected from a suspension CHO cell in which a CHO cell is adapted to suspension culture, a PER.C6 cell, a rat myeloma cell YB2/3HL.P2.G11.16Ag.20 (or also called YB2/0) and a suspension mouse myeloma cell NS0 adapted to suspension culture.

[Claim 11]

The method according to claim 10, wherein the CHO cell is at least one selected from CHO-K1, CHO-K1SV, DUKXB11, CHO/DG44, Pro-3 and CHO-S.

[Claim 12]

The method according to any one of claims 4 to 11, wherein the selectable marker gene is a cycloheximide resistance gene.

[Claim 13]

The method according to any one of claim 12, wherein the cycloheximide resistance gene is a ribosome protein.

[Claim 14]

The method according to any one of claims 1 to 13, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of DNA-type transposons which function in a mammalian cell.

[Claim 15]

The method according to claim 14, wherein the nucleotide sequences derived from a pair of DNA type transposons are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons.

[Claim 16]

The method according to claim 15, wherein the nucleotide sequences derived from a pair of Tol2 transposons are a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3.
[Claim 17]

5 The method according to claim 15, wherein the nucleotide sequences derived from a pair of Tol1 transposons are the nucleotide sequences shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15.
[Claim 18]

10 A suspension mammalian cell, which has a chromosome into which a gene fragment inserted between a pair of the transposons is integrated and which produces a protein of interest obtainable by simultaneously introducing at least one of expression vector (a) which comprises the gene fragment comprising a DNA encoding a protein of interest and also comprises the pair of transposon sequences at both terminals of the gene fragment and an expression vector (b) which comprises a DNA encoding a
15 transposase (transferase) capable of recognizing the transposon sequences and having the activity to transfer the gene fragment inserted between the pair of transposon sequences to the chromosome.

[Claim 19]

20 The mammalian cell according to claim 18, wherein the at least one of expression vector (a) which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment is an expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.

25 [Claim 20]

 The mammalian cell according to claim 18 or 19, which is a cell prepared by further introducing an expression vector (c) which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment in addition to the expression vectors (a) and (b).

30 [Claim 21]

 The mammalian cell according to any one of claims 18 to 20, wherein the DNA encoding the protein of interest is a DNA which encodes an antibody.

[Claim 22]

35 The mammalian cell according to claim 21, wherein the DNA which encodes an antibody is at least one of a DNA encoding a H chain of an antibody and a DNA encoding a L chain of an antibody.

[Claim 23]

The mammalian cell according to any one of claims 18 to 22, into which an expression vector selected from the following (a) to (d) is introduced:

(a) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment

(b) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment,

(c) an expression vector which comprises a gene fragment comprising a DNA encoding a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment and an expression vector which comprises a gene fragment comprising a DNA encoding a H chain of an antibody and also comprises a pair of transposon sequences at both terminals of the gene fragment, and

(d) an expression vector which comprises a gene fragment comprising a DNA encoding a H chain and a L chain of an antibody and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment.

[Claim 24]

The mammalian cell according to any one of claim 18 to 23, wherein the cell is a cell capable of surviving and proliferating in a serum-free medium.

[Claim 25]

The mammalian cell according to any one of claims 18 to 24, wherein the cell is any one suspension mammalian cell selected from a suspension CHO cell in which a CHO cell is adapted to suspension culture, a PER.C6 cell, a rat myeloma cell YB2/3HL.P2.G11.16Ag.20 (or also called YB2/0) and a suspension mouse myeloma cell NS0 adapted to suspension culture.

[Claim 26]

The mammalian cell according to claim 25, wherein the CHO cell is any one selected from CHO-K1, CHO-K1SV, DUKXB11, CHO/DG44, Pro-3 and CHO-S.

[Claim 27]

The mammalian cell according to any one of claims 19 to 26, wherein the selectable marker gene is a cycloheximide resistance gene.

[Claim 28]

5 The mammalian cell according to claim 27, wherein the cycloheximide resistance gene is a gene encoding a mutant of human ribosomal protein L36a.

[Claim 29]

10 The mammalian cell according to any one of claims 19 to 28, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of DNA-type transposons which function in a mammalian cell.

[Claim 30]

15 The mammalian cell according to claim 29, wherein the nucleotide sequences derived from a pair of the DNA-type transposons are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons.

[Claim 31]

The mammalian cell according to claim 30, wherein the nucleotide sequences derived from a pair of the Tol2 transposons are the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3.

20 [Claim 32]

The mammalian cell according to claim 30, wherein the nucleotide sequences derived from a pair of the Tol1 transposons are the nucleotide sequence shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15.

[Claim 33]

25 An expression vector, which comprises a gene fragment comprising a DNA encoding a protein of interest, and also comprises a pair of transposon sequences at both terminals of the gene fragment.

[Claim 34]

30 The expression vector according to claim 33, wherein a pair of the transposon sequences are nucleotide sequences derived from a pair of Tol1 transposons or nucleotide sequences derived from a pair of Tol2 transposons.

[Claim 35]

35 The protein expression vector according to claim 34, wherein the nucleotide sequences derived from a pair of the Tol2 transposons are the nucleotide sequence shown in SEQ ID NO:2 and the nucleotide sequence shown in SEQ ID NO:3.

[Claim 36]

The expression vector according to claim 34, wherein the nucleotide sequences derived from a pair of the Toll transposons are the nucleotide sequence shown in SEQ ID NO:14 and the nucleotide sequence shown in SEQ ID NO:15.

SEQUENCE LISTING

<110> Kyowa Hakko Kirin Co., Ltd.
Research Organization of Information and Systems

<120> Protein production method

<130> W503694

<150> JP2010-279849

<151> 2010-12-15

<160> 48

<170> PatentIn version 3.3

<210> 1

<211> 2788

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: nonautologous Tol2 transposon

<400> 1

cagagggtgta aagtacttga gtaattttac ttgattactg tacttaagta ttatTTTTTgg	60
ggattttttac ttactttgag tacaattaaa aatcaatact tttactttta ctttaattaca	120
tttttttaga aaaaaaagta ctttttactc cttacaattt tatttacagt caaaaagtac	180
ttatTTTTTg gagatcactt cattctatTT tcccttgcta ttaccaaacc aattgaattg	240
cgctgatgcc cagtttaatt taaatgttat ttattctgcc tatgaaaatc gttttcacat	300
tatatgaaat tggtcagaca gtgtcattgg tcctttggaa gtgacgtcat gtcacatcta	360
ttaccacaat gcacagcacc ttgacctgga aattagggaa attataacag tcaatcagtg	420
gaagaaaatg gaggaagtat gtgattcatc agcagctgcg agcagcacag tccaaaatca	480
gccacaggat caagagcacc cgtggccgta tcttcgcgaa ttcttttctt taagtgggtg	540
aaataaagat tcattcaaga tgaaatgtgt cctctgtctc ccgcttaata aagaaatato	600
ggccttcaaa agttcgccat caaacctaag gaagcatatt gaggtaagta cattaagtat	660
tttgtttttac tgatagtttt tttttttttt tttttttttt tttttgggtg tgcattgttt	720
gacgttgatg gcgcgccttt tatatgtgta gtaggcctat tttcactaat gcatgctgatt	780
gacaatataa ggctcacgta ataaatgct aaaatgcatt tgtaattggg aacgttaggt	840
ccacgggaaa tttggcgctt attgcagctt tgaataatca ttatcattcc gtgctctcat	900
tgtgtttgaa ttcattgcaaa acacaagaaa accaagcgag aaattttttt ccaaactatgt	960
tgtattgtca aaacggtaac actttacaat gaggttgatt agttcatgta ttaactaaca	1020
ttaaataacc atgagcaata catttgttac tgtatctggt aatctttgtt aacgttaggt	1080
aatagaaata cagatgttca ttgtttgttc atgttagttc acagtgcatt aactaatgtt	1140
aacaagatat aaagtattag taaatgttga aattaacatg tatacgtgca gttcattatt	1200
agttcatgtt aactaatgta gtttaactaac gaaccttatt gtaaaagtgt taccatcaaa	1260
actaatgtaa tgaatcaaat tcacctgtc atgtcagcct tacagtcctg tgtttttgtc	1320
aatataatca gaaataaaat taatgtttga ttgtcactaa atgctactgt atttctaaaa	1380
tcaacaagta ttttaacatta taaagtgtgc aattggctgc aaatgtcagt tttattaaag	1440
ggttagttca cccaaaaatg aaaataatgt cattaatgac tcgccctcat gtcgttccaa	1500

```

gcccgtaaga cctccgttca tottcagaac acagttaaag atattttaga tttagtccga 1560
gagctttctg tgccctcatt gagaatgtat gtacggtata ctgtccatgt ccagaaaggt 1620
aataaaaaa tcaaagtagt ccatgtgaca tcagtgggtt agttagaatt ttttgaagca 1680
tcgaatacat tttggtccaa aaataacaaa acctacgact ttattoggca ttgtattctc 1740
ttccgggtct gttgtcaatc cgcgttcacg acttcgcagt gacgctacaa tgctgaataa 1800
agtcgtaggt tttgttattt ttggacaaaa atgtattttc gatgcttcaa ataattctac 1860
ctaaccact gatgtacat ggactacttt gatgttttta ttacctttct ggacatggac 1920
agtataccgt acatacattt tcagtggagg gacagaaagc tctcggacta aatctaaaaat 1980
atcttaaaact gtgttccgaa gatgaacgga ggtgttacgg gcttggaaacg acatgagggt 2040
gagtcattaa tgacatcttt tcatttttgg gtgaactaac cctttaatgc tgtaatcaga 2100
gagtgtatgt gtaattgtta catttattgc atacaatata aatatttatt tgttgttttt 2160
acagagaatg caccctaaat acctcaaaaa ctactctaaa ttgacagcac agaagagaaa 2220
gatcgggaca gatctcatat gctcggggc ccatctggcc tgtgtttcag acaccagga 2280
gtctctgctc acgtttctg ctatttgcag cctctctatc aagactaata cacctcttcc 2340
cgcatcggtc gcctgtgaga ggcttttcag cactgcagga ttgcttttca gccccaaaag 2400
agctaggctt gacactaaca attttgagaa tcagcttcta ctgaagttaa atctgagggt 2460
ttacaacttt gagtagcgtg tactggcatt agattgtctg tcttatagtt tgataattaa 2520
atacaaacag ttctaaagca ggataaaacc ttgtatgcat ttcatttaat gttttttgag 2580
attaaaagct taaacaagaa tctctagttt tcttcttgc ttttactttt acttccttaa 2640
tactcaagta caattttaat ggagtacttt tttactttta ctcaagtaag attctagcca 2700
gatactttta cttttaattg agtaaaattt tccctaagta cttgtacttt cacttgagta 2760
aaatttttga gtacttttta cacctctg 2788

```

```

<210> 2
<211> 200
<212> DNA
<213> Artificial

```

```

<220>
<223> Description of artificial sequence: Tol2-L transposon sequence

```

```

<400> 2
cagagggtga aagtacttga gtaattttac ttgattactg tacttaagta ttatttttgg 60
ggatttttac tttacttgag tacaattaaa aatcaatact tttactttta cttaattaca 120
tttttttaga aaaaaaagta ctttttactc cttacaattt tatttacagt caaaaagtac 180
ttattttttg gagatcactt 200

```

```

<210> 3
<211> 504
<212> DNA
<213> Artificial

```

```

<220>
<223> Description of artificial sequence: Tol2-R transposon sequence

```

```

<400> 3
ctgctcacgt ttctgtctat ttgcagctc tctatcaaga ctaatacacc tottcccgca 60
tcggctgcct gtgagaggct tttcagcact gcaggattgc tttcagccc caaaagagct 120

```

```

aggcttgaca ctaacaattt tgagaatcag cttctactga agttaaatct gaggttttac 180
aactttgagt agcgtgtact ggcattagat tgtctgtctt atagtttgat aattaaatac 240
aaacagttct aaagcaggat aaaaccttgt atgcatttca tttaatgttt tttgagatta 300
aaagcttaaa caagaatctc tagttttctt tcttgctttt acttttactt ccttaatact 360
caagtacaat tttaatggag tactttttta cttttactca agtaagattc tagccagata 420
cttttacttt taattgagta aaattttccc taagtacttg tacttttact tgagtaaaat 480
ttttgagtac tttttacacc tctg 504

```

```

<210> 4
<211> 2156
<212> DNA
<213> Oryzias latipes

```

```

<220>
<221> CDS
<222> (85).. (2034)

```

```

<400> 4
acgtcatgtc acatctatta ccacaatgca cagcaccttg acctggaaat tagggaaatt 60
ataacagtca atcagtggaa gaaa atg gag gaa gta tgt gat tca tca gca 111
                        Met Glu Glu Val Cys Asp Ser Ser Ala
                        1                    5

gct gcg agc agc aca gtc caa aat cag cca cag gat caa gag cac ccg 159
Ala Ala Ser Ser Thr Val Gln Asn Gln Pro Gln Asp Gln Glu His Pro
10                    15                    20                    25

tgg ccg tat ctt cgc gaa ttc ttt tct tta agt ggt gta aat aaa gat 207
Trp Pro Tyr Leu Arg Glu Phe Phe Ser Leu Ser Gly Val Asn Lys Asp
30                    35                    40

tca ttc aag atg aaa tgt gtc ctc tgt ctc ccg ctt aat aaa gaa ata 255
Ser Phe Lys Met Lys Cys Val Leu Cys Leu Pro Leu Asn Lys Glu Ile
45                    50                    55

tcg gcc ttc aaa agt tcg cca tca aac cta agg aag cat att gag aga 303
Ser Ala Phe Lys Ser Ser Pro Ser Asn Leu Arg Lys His Ile Glu Arg
60                    65                    70

atg cac cca aat tac ctc aaa aac tac tct aaa ttg aca gca cag aag 351
Met His Pro Asn Tyr Leu Lys Asn Tyr Ser Lys Leu Thr Ala Gln Lys
75                    80                    85

aga aag atc ggg acc tcc acc cat gct tcc agc agt aag caa ctg aaa 399
Arg Lys Ile Gly Thr Ser Thr His Ala Ser Ser Ser Lys Gln Leu Lys
90                    95                    100                    105

gtt gac tca gtt ttc cca gtc aaa cat gtg tct cca gtc act gtg aac 447
Val Asp Ser Val Phe Pro Val Lys His Val Ser Pro Val Thr Val Asn
110                    115                    120

aaa gct ata tta agg tac atc att caa gga ctt cat cct ttc agc act 495
Lys Ala Ile Leu Arg Tyr Ile Ile Gln Gly Leu His Pro Phe Ser Thr
125                    130                    135

gtt gat ctg cca tca ttt aaa gag ctg att agt aca ctg cag cct ggc 543
Val Asp Leu Pro Ser Phe Lys Glu Leu Ile Ser Thr Leu Gln Pro Gly
140                    145                    150

att tct gtc att aca agg cct act tta cgc tcc aag ata gct gaa gct 591
Ile Ser Val Ile Thr Arg Pro Thr Leu Arg Ser Lys Ile Ala Glu Ala
155                    160                    165

gct ctg atc atg aaa cag aaa gtg act gct gcc atg agt gaa gtt gaa 639
Ala Leu Ile Met Lys Gln Lys Val Thr Ala Ala Met Ser Glu Val Glu
170                    175                    180                    185

```

tgg att gca acc aca acg gat tgt tgg act gca cgt aga aag tca ttc Trp Ile Ala Thr 190 Thr Asp Cys Trp Thr 195 Ala Arg Arg Lys Ser Phe 200	687
att ggt gta act gct cac tgg atc aac cct gga agt ctt gaa aga cat Ile Gly Val 205 Ala His Trp Ile Asn Pro Gly Ser Leu Glu Arg His 215	735
tcc gct gca ctt gcc tgc aaa aga tta atg ggc tct cat act ttt gag Ser Ala Ala Leu Ala Cys Lys Arg Leu Met Gly Ser His Thr Phe Glu 220 225 230	783
gta ctg gcc agt gcc atg aat gat atc cac tca gag tat gaa ata cgt Val Leu Ala Ser Ala Met Asn Asp Ile His Ser Glu Tyr Glu Ile Arg 235 240 245	831
gac aag gtt gtt tgc aca acc aca gac agt ggt tcc aac ttt atg aag Asp Lys Val Val Cys Thr Thr Thr Asp Ser Gly Ser Asn Phe Met Lys 250 255 260 265	879
gct ttc aga gtt ttt ggt gtg gaa aac aat gat atc gag act gag gca Ala Phe Arg Val Phe Gly Val Glu Asn Asn Asp Ile Glu Thr Glu Ala 270 275 280	927
aga agg tgt gaa agt gat gac act gat tct gaa ggc tgt ggt gag gga Arg Arg Cys Glu Ser Asp Asp Thr Asp Ser Glu Gly Cys Gly Glu Gly 285 290 295	975
agt gat ggt gtg gaa ttc caa gat gcc tca cga gtc ctg gac caa gac Ser Asp Gly Val Glu Phe Gln Asp Ala Ser Arg Val Leu Asp Gln Asp 300 305 310	1023
gat ggc ttc gaa ttc cag cta cca aaa cat caa aag tgt gcc tgt cac Asp Gly Phe Glu Phe Gln Leu Pro Lys His Gln Lys Cys Ala Cys His 315 320 325	1071
tta ctt aac cta gtc tca agc gtt gat gcc caa aaa gct ctc tca aat Leu Leu Asn Leu Val Ser Ser Val Asp Ala Gln Lys Ala Leu Ser Asn 330 335 340 345	1119
gaa cac tac aag aaa ctc tac aga tct gtc ttt ggc aaa tgc caa gct Glu His Tyr Lys Lys Leu Tyr Arg Ser Val Phe Gly Lys Cys Gln Ala 350 355 360	1167
tta tgg aat aaa agc agc cga tcg gct cta gca gct gaa gct gtt gaa Leu Trp Asn Lys Ser Ser Arg Ser Ala Leu Ala Ala Glu Ala Val Glu 365 370 375	1215
tca gaa agc cgg ctt cag ctt tta agg cca aac caa acg cgg tgg aat Ser Glu Ser Arg Leu Gln Leu Leu Arg Pro Asn Gln Thr Arg Trp Asn 380 385 390	1263
tca act ttt atg gct gtt gac aga att ctt caa att tgc aaa gaa gca Ser Thr Phe Met Ala Val Asp Arg Ile Leu Gln Ile Cys Lys Glu Ala 395 400 405	1311
gga gaa ggc gca ctt cgg aat ata tgc acc tct ctt gag gtt cca atg Gly Glu Gly Ala Leu Arg Asn Ile Cys Thr Ser Leu Glu Val Pro Met 410 415 420 425	1359
ttt aat cca gca gaa atg ctg ttc ttg aca gag tgg gcc aac aca atg Phe Asn Pro Ala Glu Met Leu Phe Leu Thr Glu Trp Ala Asn Thr Met 430 435 440	1407
cgt cca gtt gca aaa gta ctc gac atc ttg caa gcg gaa acg aat aca Arg Pro Val Ala Lys Val Leu Asp Ile Leu Gln Ala Glu Thr Asn Thr 445 450 455	1455
cag ctg ggg tgg ctg ctg cct agt gtc cat cag tta agc ttg aaa ctt Gln Leu Gly Trp Leu Leu Pro Ser Val His Gln Leu Ser Leu Lys Leu 460 465 470	1503
cag cga ctc cac cat tct ctc agg tac tgt gac cca ctt gtg gat gcc Gln Arg Leu His His Ser Leu Arg Tyr Cys Asp Pro Leu Val Asp Ala 475 480 485	1551

cta caa caa gga atc caa aca cga ttc aag cat atg ttt gaa gat cct 1599
 Leu Gln Gln Gly Ile Gln Thr Arg Phe Lys His Met Phe Glu Asp Pro 505
 490 495 500

gag atc ata gca gct gcc atc ctt ctc cct aaa ttt cgg acc tct tgg 1647
 Glu Ile Ile Ala Ala Ile Leu Leu Pro Lys Phe Arg Thr Ser Trp 520
 510 515

aca aat gat gaa acc atc ata aaa cga ggc atg gac tac atc aga gtg 1695
 Thr Asn Asp Glu Thr Ile Ile Lys Arg Gly Met Asp Tyr Ile Arg Val 535
 525 530

cat ctg gag cct ttg gac cac aag aag gaa ttg gcc aac agt tca tct 1743
 His Leu Glu Pro Leu Asp His Lys Lys Glu Leu Ala Asn Ser Ser Ser 550
 540 545

gat gat gaa gat ttt ttc gct tct ttg aaa ccg aca aca cat gaa gcc 1791
 Asp Asp Glu Asp Phe Phe Gly Tyr Leu Lys Pro Thr Thr His Glu Ala 565
 555 560

agc aaa gag ttg gat gga tat ctg gcc tgt gtt tca gac acc agg gag 1839
 Ser Lys Glu Leu Asp Gly Tyr Leu Ala Cys Val Ser Asp Thr Arg Glu 585
 570 575 580

tct ctg ctc acg ttt cct gct att tgc agc ctc tct atc aag act aat 1887
 Ser Leu Leu Thr Phe Pro Ala Ile Cys Ser Leu Ser Ile Lys Thr Asn 600
 590 595

aca cct ctt ccc gca tcg gct gcc tgt gag agg ctt ttc agc act gca 1935
 Thr Pro Leu Pro Ala Ser Ala Ala Cys Glu Arg Leu Phe Ser Thr Ala 615
 605 610

gga ttg ctt ttc agc ccc aaa aga gct agg ctt gac act aac aat ttt 1983
 Gly Leu Leu Phe Ser Pro Lys Arg Ala Arg Leu Asp Thr Asn Asn Phe 630
 620 625

gag aat cag ctt cta ctg aag tta aat ctg agg ttt tac aac ttt gag 2031
 Glu Asn Gln Leu Leu Leu Lys Leu Asn Leu Arg Phe Tyr Asn Phe Glu 645
 635 640

tag cgtgtactgg cattagattg tctgtcttat agtttgataa ttaaatacaa 2084

acagttctaa agcaggataa aacottgtat gcatttcatt taatgttttt tgagattaaa 2144

agcttaaaca ag 2156

<210> 5
 <211> 649
 <212> PRT
 <213> Oryzias latipes

<400> 5

Met Glu Glu Val Cys Asp Ser Ser Ala Ala Ala Ser Ser Thr Val Gln
 1 5 10 15

Asn Gln Pro Gln Asp Gln Glu His Pro Trp Pro Tyr Leu Arg Glu Phe
 20 25 30

Phe Ser Leu Ser Gly Val Asn Lys Asp Ser Phe Lys Met Lys Cys Val
 35 40 45

Leu Cys Leu Pro Leu Asn Lys Glu Ile Ser Ala Phe Lys Ser Ser Pro
 50 55 60

Ser Asn Leu Arg Lys His Ile Glu Arg Met His Pro Asn Tyr Leu Lys
 65 70 75 80

Asn Tyr Ser Lys Leu Thr Ala Gln Lys Arg Lys Ile Gly Thr Ser Thr

85	90	95
His Ala Ser Ser Ser Lys Gln Leu Lys Val Asp Ser Val Phe Pro Val		
100	105	110
Lys His Val Ser Pro Val Thr Val Asn Lys Ala Ile Leu Arg Tyr Ile		
115	120	125
Ile Gln Gly Leu His Pro Phe Ser Thr Val Asp Leu Pro Ser Phe Lys		
130	135	140
Glu Leu Ile Ser Thr Leu Gln Pro Gly Ile Ser Val Ile Thr Arg Pro		
145	150	155
Thr Leu Arg Ser Lys Ile Ala Glu Ala Ala Leu Ile Met Lys Gln Lys		
165	170	175
Val Thr Ala Ala Met Ser Glu Val Glu Trp Ile Ala Thr Thr Thr Asp		
180	185	190
Cys Trp Thr Ala Arg Arg Lys Ser Phe Ile Gly Val Thr Ala His Trp		
195	200	205
Ile Asn Pro Gly Ser Leu Glu Arg His Ser Ala Ala Leu Ala Cys Lys		
210	215	220
Arg Leu Met Gly Ser His Thr Phe Glu Val Leu Ala Ser Ala Met Asn		
225	230	235
Asp Ile His Ser Glu Tyr Glu Ile Arg Asp Lys Val Val Cys Thr Thr		
245	250	255
Thr Asp Ser Gly Ser Asn Phe Met Lys Ala Phe Arg Val Phe Gly Val		
260	265	270
Glu Asn Asn Asp Ile Glu Thr Glu Ala Arg Arg Cys Glu Ser Asp Asp		
275	280	285
Thr Asp Ser Glu Gly Cys Gly Glu Gly Ser Asp Gly Val Glu Phe Gln		
290	295	300
Asp Ala Ser Arg Val Leu Asp Gln Asp Asp Gly Phe Glu Phe Gln Leu		
305	310	315
Pro Lys His Gln Lys Cys Ala Cys His Leu Leu Asn Leu Val Ser Ser		
325	330	335
Val Asp Ala Gln Lys Ala Leu Ser Asn Glu His Tyr Lys Lys Leu Tyr		
340	345	350
Arg Ser Val Phe Gly Lys Cys Gln Ala Leu Trp Asn Lys Ser Ser Arg		
355	360	365
Ser Ala Leu Ala Ala Glu Ala Val Glu Ser Glu Ser Arg Leu Gln Leu		
370	375	380
Leu Arg Pro Asn Gln Thr Arg Trp Asn Ser Thr Phe Met Ala Val Asp		

385 390 395 400
 Arg Ile Leu Gln Ile Cys Lys Glu Ala Gly Glu Gly Ala Leu Arg Asn
 405 410 415
 Ile Cys Thr Ser Leu Glu Val Pro Met Phe Asn Pro Ala Glu Met Leu
 420 425 430
 Phe Leu Thr Glu Trp Ala Asn Thr Met Arg Pro Val Ala Lys Val Leu
 435 440 445
 Asp Ile Leu Gln Ala Glu Thr Asn Thr Gln Leu Gly Trp Leu Leu Pro
 450 455 460
 Ser Val His Gln Leu Ser Leu Lys Leu Gln Arg Leu His His Ser Leu
 465 470 475 480
 Arg Tyr Cys Asp Pro Leu Val Asp Ala Leu Gln Gln Gly Ile Gln Thr
 485 490 495
 Arg Phe Lys His Met Phe Glu Asp Pro Glu Ile Ile Ala Ala Ala Ile
 500 505 510
 Leu Leu Pro Lys Phe Arg Thr Ser Trp Thr Asn Asp Glu Thr Ile Ile
 515 520 525
 Lys Arg Gly Met Asp Tyr Ile Arg Val His Leu Glu Pro Leu Asp His
 530 535 540
 Lys Lys Glu Leu Ala Asn Ser Ser Ser Asp Asp Glu Asp Phe Phe Ala
 545 550 555 560
 Ser Leu Lys Pro Thr Thr His Glu Ala Ser Lys Glu Leu Asp Gly Tyr
 565 570 575
 Leu Ala Cys Val Ser Asp Thr Arg Glu Ser Leu Leu Thr Phe Pro Ala
 580 585 590
 Ile Cys Ser Leu Ser Ile Lys Thr Asn Thr Pro Leu Pro Ala Ser Ala
 595 600 605
 Ala Cys Glu Arg Leu Phe Ser Thr Ala Gly Leu Leu Phe Ser Pro Lys
 610 615 620
 Arg Ala Arg Leu Asp Thr Asn Asn Phe Glu Asn Gln Leu Leu Leu Lys
 625 630 635 640
 Leu Asn Leu Arg Phe Tyr Asn Phe Glu
 645

<210> 6
 <211> 4682
 <212> DNA
 <213> *Oryzias latipes*

<400> 6
 cagagggtgta aagtacttga gtaattttac ttgattactg tacttaagta ttatttttgg 60
 ggattttttac tttaacttgag tacaattaaa aatcaatact tttaactttta ottaattaca 120

tttttttaga aaaaaaagta ctttttactc cttacaatth tatttacagt caaaaagtac	180
ttattttttg gagatcactt cattctatth tcccttgcta ttaccaaacc aattgaattg	240
cgctgatgcc cagtttaatt taaatgttat ttattctgcc tatgaaaac gttttcacat	300
tatatgaaat tggctagaca tgttcattgg tcttttgaa gtgacgtcat gtcacatcta	360
ttaccacaat gcacagcacc ttgacctgga aattagggaa attataacag tcaatcagt	420
gaagaaaatg gaggaagtat gtgattcatc agcagctgcg agcagcacag tccaaaatca	480
gccacaggat caagagcacc cgtggccgta tcttcgcgaa ttcttttctt taagtgggt	540
aaataaagat tcattcaaga tgaaatgtgt cctctgtctc ccgcttaata aagaaatctc	600
ggccttcaaa agttcgccat caaacctaag gaagcatatt gaggtaagta cattaagtat	660
tttgttttac tgatagtttt tttttttttt tttttttttt tttttgggtg tgcattgttt	720
gacgttgatg gcgcgccttt tatatgtgta gtaggcctat tttactaat gcatgcgatt	780
gacaatataa ggctcacgta ataaaatgct aaaatgcatt tgtaattggt aacgttaggt	840
ccacgggaaa tttggcgctt attgcagctt tgaataatca ttatcattcc gtgctctcat	900
tgtgtttgaa ttcattgcaa acacaagaaa accaagcgag aaattttttt ccaaactgt	960
tgtattgtca aaacggtaac actttacaat gaggttgatt agttcatgta ttaactaaca	1020
ttaaataacc atgagcaata catttgttac tgtatctgtt aatctttgtt aacgttaggt	1080
aataagaaata cagatgttca ttgtttgttc atgttagttc acagtgcatt aactaatgtt	1140
aacaagatat aaagtattag taaatgttga aattaacatg tatacgtgca gttcattatt	1200
agttcatgtt aactaatgta gttactaac gaaccttatt gtaaaagtgt taccatcaaa	1260
actaatgtaa tgaaatcaat tcacctgtc atgtcagcct tacagtcctg tgtttttgtc	1320
aataataatca gaaataaaat taatgtttga ttgtactaa atgtactgt atttctaaaa	1380
tcaacaagta ttttaacatta taaagtgtgc aattggctgc aaatgtcagt tttattaaag	1440
ggttagttca cccaaaaatg aaaataatgt cattaatgac tgcacctcat gtgtttccaa	1500
gcccgttaaga cctccgttca tcttcagaac acagtttaag atattttaga tttagtccga	1560
gagctttctg tgctccatt gagaatgtat gtaaggata ctgtccatgt ccagaaaggt	1620
aataaaaaaca tcaaagtagt ccattgtgaca tcagtgggtt agttagaatt ttttgaagca	1680
tgaatacat tttgttccaa aaataacaaa acctacgact ttattggca ttgtattctc	1740
ttccgggtct gttgtcaatc cgcgttcacg acttcgcagt gacgtacaa tgctgaataa	1800
agtcgtaggt tttgtatttt ttggacaaa atgtattttc gatgcttcaa ataattctac	1860
ctaaccact gatgtccat ggactacttt gatgttttta ttacctttct ggacatggac	1920
agtataccgt acatacatth tcagtggagg gacagaaagc tctcggaata aatctaaaat	1980
atcttaaaact gtgttccgaa gatgaacgga ggtgttacgg gcttggaacg acatgagggt	2040
gagtcattaa tgacatcttt tcatttttgg gtgaactaac cctttaatgc tgtaatcaga	2100
gagtgtatgt gtaattgtta catttattgc atacaatata aatatttatt tgttgttttt	2160
acagagaatg cacccaaatt acctcaaaaa ctactctaaa ttgacagcac agaagagaaa	2220
gatcgggacc tccacctatg cttcagcag taagcaactg aaagttgact cagttttccc	2280
agtcaaaacat gtgtctccag tcaactgtgaa caaagctata ttaaggtaca tcattcaagg	2340
acttcatcct ttcagcactg ttgatctgcc atcatttaaa gagctgatta gtacactgca	2400

gcctggcatt tctgtcatta caaggcctac ttacgctcc aagatagctg aagctgctct 2460
gatcatgaaa cagaaagtga ctgctgccat gactgaagtt gaattggattg caaccacaac 2520
ggattgttgg actgcacgta gaaagtcatt catttggtgta actgctcact ggatcaaccc 2580
tggaagtctt gaaagacatt ccgctgcact tgctgcataa agattaatgg gctctcatac 2640
ttttgaggta ctggccagtg ccatgaatga tatccactca gactatgaaa tacgtgacaa 2700
ggttgtttgc acaaccacag acagtgggtc caactttatg aaggctttca gagtttttgg 2760
tgtggaaaac aatgatatcg agactgaggo aagaagggtgt gaaagtgatg acactgattc 2820
tgaaggctgt ggtgagggaa gtgatgggtt ggaattccaa gatgcctcac gactcctgga 2880
ccaagacgat ggcttcgaat tccagctacc aaaacatcaa aagtgtgcct gtcacttact 2940
taacctagtc tcaagcgttg atgccccaaa agctctctca aatgaacact acaagaaact 3000
ctacagatct gtctttggca aatgccaaag tttatggaat aaaagcagcc gatcggctct 3060
agcagctgaa gctgttgaat cagaaagccg gcttcagctt ttaaggccaa accaaacgcg 3120
gtggaattca acttttatgg ctgttgacag aattcttcaa atttgcaaag aagcaggaga 3180
aggcgcaatt cggaatatac gcacctctct tgaggttcca atgtaagtgt tttccctc 3240
tatcgatgta acaaatgtg ggttgttttt gtttaatact ctttgattat gctgatttct 3300
cctgtagggtt taatccagca gaaatgctgt tcttgacaga gtgggccaac acaatgcgtc 3360
cagttgcaaa agtactcgac atcttgcaag cggaaacgaa tacacagctg ggggtggctgc 3420
tgcctagtgt ccatcagtta agcttgaaac ttcagcgact ccaccattct ctcagggtact 3480
gtgacccact tgtggatgcc ctacaacaag gaatccaaac acgattcaag catatgtttg 3540
aagatcctga gatcatagca gctgccatcc ttctccctaa atttcggacc tcttgacaa 3600
atgatgaac catcataaaa cgaggtaaat gaatgcaagc aacatacact tgacgaattc 3660
taatctgggc aaccttgag ccataccaaa attattcttt tatttattta tttttgact 3720
ttttaggaat gttatatccc atctttggct gtgatctcaa tatgaatatt gatgtaaagt 3780
attcttgtag caggtttag ttatccctca gtgtttcttg aaacaaact catatgtatc 3840
atatgtggtt tggaatgca gttagatttt atgctaaaat aagggtttg catgatttta 3900
gatgtagatg actgcacgta aatgtagtta atgacaaaat ccataaaatt tgttcccagt 3960
cagaagcccc tcaaccaaac tttctttgt gtctgctcac tgtgcttga ggcatggact 4020
acatcagagt gcatctggag cctttggacc acaagaagga attggccaac agttcatctg 4080
atgatgaaga ttttttgcct tctttgaaac cgacaacaca tgaagccagc aaagagttgg 4140
atggatatct ggctgtgtt tcagacacca gggagtctct gctcacgttt cctgctattt 4200
gcagcctctc tatcaagact aatacacctc ttccgcacg ggtgcctgt gagaggcttt 4260
tcagcactgc aggattgctt ttcagcccca aaagagctag gcttgacact aacaattttg 4320
agaatcagct tctactgaag ttaaactcga ggttttcaa ctttgagtag cgtgtactgg 4380
cattagattg tctgtcttat agtttgataa ttaatacaa acagttctaa agcaggataa 4440
aaccttgtat gcatttcatt taatgttttt tgagattaaa agcttaaca agaattctta 4500
gttttcttct ttgcttttac tttacttcc ttaatactca agtacaattt taatggagta 4560
cttttttact tttactcaag taagattcta gccagatact tttactttta attgagtaaa 4620
attttcccta agtacttgta ctttcaactg agtaaaattt ttgagtactt tttacacctc 4680

tg

4682

<210> 7
 <211> 321
 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: Cycloheximide resistant gene

<220>
 <221> CDS
 <222> (1)..(321)

<400> 7
 atg gtc aac gta cct aaa acc cga aga acc ttc tgt aag aag tgt ggc 48
 Met Val Asn Val Pro Lys Thr Arg Arg Thr Phe Cys Lys Lys Cys Gly
 1 5 10 15
 aag cat cag cct cac aaa gtg aca cag tat aag aag ggc aag gat tct 96
 Lys His Gln Pro His Lys Val Thr Gln Tyr Lys Lys Gly Lys Asp Ser
 20 25 30
 ttg tat gcc cag gga agg agg cgc tat gat cgg aag cag agt ggc tat 144
 Leu Tyr Ala Gln Gly Arg Arg Arg Tyr Asp Arg Lys Gln Ser Gly Tyr
 35 40 45
 ggt ggg cag aca aag caa att ttc cgg aag aag gct aag acc aca aag 192
 Gly Gly Gln Thr Lys Gln Ile Phe Arg Lys Lys Ala Lys Thr Thr Lys
 50 55 60
 aag att gtg cta agg ctg gaa tgt gtt gag cct aac tgc aga tcc aag 240
 Lys Ile Val Leu Arg Leu Glu Cys Val Glu Pro Asn Cys Arg Ser Lys
 65 70 75 80
 agg atg ctg gcc att aag aga tgc aag cat ttt gaa ctg gga gga gat 288
 Arg Met Leu Ala Ile Lys Arg Cys Lys His Phe Glu Leu Gly Gly Asp
 85 90 95
 aag aag aga aag ggc caa gtg atc cag ttc taa 321
 Lys Lys Arg Lys Gly Gln Val Ile Gln Phe
 100 105

<210> 8
 <211> 106
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 8
 Met Val Asn Val Pro Lys Thr Arg Arg Thr Phe Cys Lys Lys Cys Gly
 1 5 10 15
 Lys His Gln Pro His Lys Val Thr Gln Tyr Lys Lys Gly Lys Asp Ser
 20 25 30
 Leu Tyr Ala Gln Gly Arg Arg Arg Tyr Asp Arg Lys Gln Ser Gly Tyr
 35 40 45
 Gly Gly Gln Thr Lys Gln Ile Phe Arg Lys Lys Ala Lys Thr Thr Lys
 50 55 60
 Lys Ile Val Leu Arg Leu Glu Cys Val Glu Pro Asn Cys Arg Ser Lys
 65 70 75 80

Arg Met Leu Ala Ile Lys Arg Cys Lys His Phe Glu Leu Gly Gly Asp
85 90 95

Lys Lys Arg Lys Gly Gln Val Ile Gln Phe
100 105

<210> 9
<211> 1404
<212> DNA
<213> Artificial

<220>
<223> M2Z3 Heavy chain

<220>
<221> CDS
<222> (1)..(1404)

<400> 9
atg gac tgg acc tgg agc atc ctt ttc ttg gtg gca gca gca aca ggt 48
Met Asp Trp Thr Trp Ser Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1 5 10 15
gcc cac tcc cag gtt cag ctg gtg cag tct gga gct gag gtg aag aag 96
Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30
cct ggg gcc tca gtg aag gtc tcc tgc aag gct tct ggt tac acc ttt 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45
acc agc tat ggt atc agc tgg gtg cga cag gcc cct gga caa ggg ctt 192
Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60
gag tgg atg gga tgg atc agc gct tac aat ggt aac aca aac tat gca 240
Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala
65 70 75 80
cag aag ctc cag ggc aga gtc acc atg acc aca gac aca tcc acg agc 288
Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser
85 90 95
aca gcc tac atg gag ctg agg agc ctg aga tct gac gac acg gcc gtg 336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110
tat tac tgt gcg agg gca gca gct ggc gga tac ttc cag cac tgg ggc 384
Tyr Tyr Cys Ala Arg Ala Ala Ala Gly Gly Tyr Phe Gln His Trp Gly
115 120 125
cag ggc acc ctg gtc acc gtc tcc tca gct agc acc aag ggc cca tcg 432
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140
gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg 480
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
145 150 155 160
gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg 528
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct 576
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg 624
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac 672

Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His		
210						215					220						
aag	ccc	agc	aac	acc	aag	gtg	gac	aag	aaa	gtt	gag	ccc	aaa	tct	tgt	720	
Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	225	
225					230					235					240		
gac	aaa	act	cac	aca	tgc	cca	ccg	tgc	cca	gca	cct	gaa	ctc	ctg	ggg	768	
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	245	
				245					250					255			
gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	816	
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	260	
			260				265						270				
atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	864	
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	275	
		275					280					285					
gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	912	
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	290	
290					295						300						
cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	960	
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	305	
305					310					315					320		
cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	1008	
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	325	
				325					330				335				
aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	1056	
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	335	
			340					345				350					
gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	1104	
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	355	
		355					360				365						
tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	1152	
Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	370	
		370				375				380							
ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	1200	
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	385	
				390					395					400			
tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	1248	
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	405	
				405				410					415				
gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	1296	
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	420	
			420				425						430				
gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	1344	
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	435	
			435			440					445						
cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	1392	
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	450	
					455						460						
ccg	ggt	aaa	tga													1404	
Pro	Gly	Lys														465	
465																	
<210>	10																
<211>	467																
<212>	PRT																
<213>	Artificial																
<220>																	
<223>	Synthetic Construct																

<400> 10

Met Asp Trp Thr Trp Ser Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1 5 10 15

Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala
65 70 75 80

Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Ala Ala Ala Gly Gly Tyr Phe Gln His Trp Gly
115 120 125

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
145 150 155 160

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
210 215 220

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
225 230 235 240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
245 250 255

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
260 265 270

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
275 280 285

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
290 295 300

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
305 310 315 320

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
325 330 335

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
340 345 350

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
355 360 365

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
370 375 380

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
385 390 395 400

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
405 410 415

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
420 425 430

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
435 440 445

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
450 455 460

Pro Gly Lys
465

<210> 11
<211> 708
<212> DNA
<213> Artificial

<220>
<223> M223 Light chain

<220>
<221> CDS
<222> (1).. (708)

<400> 11	
atg gcc agc ttc cct ctc ctc ctc acc ctc ctc act cac tgt gca ggg	48
Met Ala Ser Phe Pro Leu Leu Leu Thr Leu Leu Thr His Cys Ala Gly	
1 5 10 15	
tcc tgg gcc cag tot gtg ctg act cag cca ccc tca gcg tct ggg acc	96
Ser Trp Ala Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr	
20 25 30	
ccc ggg cag agg gtc acc atc tct tgt tct gga agc aac tcc aac atc	144
Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile	
35 40 45	
gga agt aaa act gta aac tgg tac cag cag ctc cca gga acg gcc ccc	192
Gly Ser Lys Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro	
50 55 60	

aaa ctc ctc atc tct agt aat aat cag cgg ccc tca ggg gtc cct gac 240
 Lys Leu Leu Ile Ser Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp
 65 70 75 80
 cga ttc tct ggc tcc aag tct ggc acc tca gcc tcc ctg gcc atc agt 288
 Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser
 85 90 95
 ggg ctc cag tct gag gat gag gct gat tat tac tgt gca gca tgg gat 336
 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp
 100 105 110
 gac agc ctg aat ggt gtg gta ttc ggc gga ggg acc aag ctg acc gtc 384
 Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val
 115 120 125
 cta ggt cag ccc aag gct gcc ccc tcg gtc act ctg ttc cca ccc tcc 432
 Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser
 130 135 140
 tct gag gag ctt caa gcc aac aag gcc aca ctg gtg tgt ctc ata agt 480
 Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser
 145 150 155 160
 gac ttc tac ccg gga gcc gtg aca gtg gcc tgg aag gca gat agc agc 528
 Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser
 165 170 175
 ccc gtc aag gcg gga gtg gag acc acc aca ccc tcc aaa caa agc aac 576
 Pro Val Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn
 180 185 190
 aac aag tac gcg gcc agc agc tac ctg agc ctg acg cct gag cag tgg 624
 Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp
 195 200 205
 aag tcc cac aaa agc tac agc tgc cag gtc acg cat gaa ggg agc acc 672
 Lys Ser His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr
 210 215 220
 gtg gag aag aca gtg gcc cct aca gaa tgt tca tag 708
 Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
 225 230 235

<210> 12
 <211> 235
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 12

Met Ala Ser Phe Pro Leu Leu Leu Thr Leu Leu Thr His Cys Ala Gly
1 5 10 15

Ser Trp Ala Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr
20 25 30

Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile
35 40 45

Gly Ser Lys Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro
50 55 60

Lys Leu Leu Ile Ser Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp
65 70 75 80

Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser

85 90 95
 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp
 100 105 110
 Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val
 115 120 125
 Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser
 130 135 140
 Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser
 145 150 155 160
 Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser
 165 170 175
 Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn
 180 185 190
 Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp
 195 200 205
 Lys Ser His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr
 210 215 220
 Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
 225 230 235

<210> 13
 <211> 1855
 <212> DNA
 <213> artificial

<220>
 <223> nonautologous Tol1 transposon

<400> 13
 cagtagcggt totagcacg gccggtccgg gcggtggcct gggcgggaaa actgaagggg 60
 ggcggcacgg gcggtcagc cctttgtaat atattaatat gcaccactat tggtttactt 120
 atgtcacagt ttgtaagttt gtaacagcct gaacctggcc gcgcgcgcgc cctcgccccg 180
 cagctgcgct ctctgtctt tgagaagtag acacaaatgt gtgtgaagaa ggagaaggga 240
 gggggcgcgg ggtgagcacg gagcgtcgcc gcgtttgcgc atgcgcacaaa cctggctggc 300
 tcatttttca ggggaggcga cggtcgcggg ctigtatgaaa aaaataaaag taaaaactgc 360
 gactgcgcgc tcattgtagc aatcagcgcc cctggctgta gctgcacgcg ctctgtctgg 420
 aaatgtgtga agaggggggg gggggggggg gotgcgggga atcagttcaa ttgtgggacg 480
 cttocaaatt aagtggctag gtggggacaa gggcgggggg ttgaatctac ttcataaaac 540
 ctttttatat tataagtcag tcataagtg acattotata acctacattt taataaaggt 600
 ataaaaaata tattctgctt tttttgggtt aattttgtgt gaaatgtcca aataaaaaaa 660
 atggcaacac aaaacaatgc tgtcactaag gtgacagttg gttcagtcga cggacttgat 720
 gccttcttgc tgacgtgagg acatttatgc caaacaacg ccaataaaca tctaaaatat 780
 ggaaaagaaa aggtcaaagc catctggtgc ccaatttaga aagaaaagaa aagaagaaga 840

ggagaaaaga gataaagaaa agggtaagtc ctcacagctt gatgcatgtt ttttctaaat 900
 tctaattgcta cctgccctac aacaacgttg ccgatgaaaa ctttatittg gtcgatgacc 960
 aacactgaat taggoccaaag tgttgcaaag agcgtcattt tttttttttt ttttagattt 1020
 tattcttaaa aatttgctct gccttaactt gtaacattag ttatgattca tgtgtctgtc 1080
 tgctctgctg taacacaaaag gttttgttgg gttttgctgt tgtatactag ctcataatgt 1140
 taaaaaagct gtgatggta cacagcatgc tgggtgctgc ataagatgct aatggggcaa 1200
 ataatttgag attggtcatt aatttaataa tcatttgtgg cagcctaaac gttttcacia 1260
 tgtttttttg acatttaact ggggatttag gggtaattt tgagcctgca tatgaagttt 1320
 attttttatt tgttttacia atgtgggatt atatttttag ccaatagaat ttccataaat 1380
 ctgtaggtag ttttaaaaat gaatatattac catttactgc aactctatgg ggacaaaaca 1440
 taatgtaaca ggtcataact aaaaatgtgc caatcaaagg attgaagacg gaaaacatga 1500
 gtttaatttt cttctctgaa gtagagatcg atatagaaca tgacaattta aatttccaat 1560
 tcataaatgt ttttaaaaata tttattttat attattttatt taacattgag ttgattcaa 1620
 tattttctta gctaactgta tttttgccat gcttatggtc tttttttttt tgtgttctga 1680
 taacttttat aatgcttttc agaattttga catcttttgt atccacttct taatttcaat 1740
 gacaataaaa catttcagtt gacgaagaca aacaaaagttc tgttgtagct atgggggggg 1800
 ggggcgcctg gggatggctc cgccggggga gtaattcagg gtagaaccgc cactg 1855

<210> 14
 <211> 200
 <212> DNA
 <213> artificial

<220>
 <223> Tol1-L transposon sequence

<400> 14
 cagtagcggg tctaggcacg ggccgtccgg gcggtggcct ggggcggaaa actgaagggg 60
 ggccggcacg gcggctcagc cctttgtaat atattaatat gcaccactat tggtttactt 120
 atgtcacagt ttgtaagttt gtaacagcct gaacctggcc gcgcgcgcgc cctcgccccg 180
 cagctgcgct ctctgtctt 200

<210> 15
 <211> 505
 <212> DNA
 <213> artificial

<220>
 <223> Tol1-R transposon sequence

<400> 15
 atatttttag ccaatagaat ttccataaat ctgtaggtag ttttaaaaat gaatatattac 60
 catttactgc aactctatgg ggacaaaaca taatgtaaca ggtcataact aaaaatgtgc 120
 caatcaaagg attgaagacg gaaaacatga gtttaatttt cttctctgaa gtagagatcg 180
 atatagaaca tgacaattta aatttccaat tcataaatgt ttttaaaaata tttattttat 240
 attattttatt taacattgag ttgattcaa tattttctta gctaactgta tttttgccat 300
 gcttatggtc tttttttttt tgtgttctga taacttttat aatgcttttc agaattttga 360
 catcttttgt atccacttct taatttcaat gacaataaaa catttcagtt gacgaagaca 420

aacaaagttc tgttgtgact atgggggggg ggggcgcctg gggatgggtct cgcccgggga 480
gtaattcagg gtagaacgc cactg 505

<210> 16
<211> 2745
<212> DNA
<213> Oryzias latipes

<220>
<221> CDS
<222> (30)..(2585)

<400> 16
gccaaacaaa cgccaaaaac atctaaaat atg gag aaa aaa agg tca aag cca 53
Met Glu Lys Lys Arg Ser Lys Pro
1 5

tct ggt gcc caa ttt aga aag aaa aga aaa gaa gaa gag gag aaa aga 101
Ser Gly Ala Gln Phe Arg Lys Lys Arg Lys Glu Glu Glu Glu Lys Arg
10 15 20

gat aaa gaa aag ggg gca ctt cta aga tat ttt gga tog tct acc act 149
Asp Lys Glu Lys Gly Ala Leu Leu Arg Tyr Phe Gly Ser Ser Thr Thr
25 30 35 40

gct caa gat gag aca tct acc tcc ctg cca gct atc tca tca gcc aca 197
Ala Gln Asp Glu Thr Ser Thr Ser Leu Pro Ala Ile Ser Ser Ala Thr
45 50 55

gtc aca gtc tca ccc cct cag gat gag cta cca tct aca tcc tct gct 245
Val Thr Val Ser Pro Pro Gln Asp Glu Leu Pro Ser Thr Ser Ser Ala
60 65 70

act cat gta gtt cca cag ttg tta cct gag caa agt ttt gat agt gag 293
Thr His Val Val Pro Gln Leu Leu Pro Glu Gln Ser Phe Asp Ser Glu
75 80 85

gct gaa gac gtt gtt cca tct acg tct acc cag ctt gag act tca gaa 341
Ala Glu Asp Val Val Pro Ser Thr Ser Thr Gln Leu Glu Thr Ser Glu
90 95 100

atg cct ggt gat gaa acc cca ctg acc ccg act gct gag gac cag cct 389
Met Pro Gly Asp Glu Thr Pro Leu Thr Pro Thr Ala Glu Asp Gln Pro
105 110 115 120

cta cca act gac cct gca aag tgg ccc tca cct ctg act gac agg ata 437
Leu Pro Thr Asp Pro Ala Lys Trp Pro Ser Pro Leu Thr Asp Arg Ile
125 130 135

cgg atg gag ctg gtt cga aga gga cca agt agc ata cca cct gac ttt 485
Arg Met Glu Leu Val Arg Arg Gly Pro Ser Ser Ile Pro Pro Asp Phe
140 145 150

gtt ttc cca aga aat gac agt gat ggg aga agt tgt cat cac cac tat 533
Val Phe Pro Arg Asn Asp Ser Asp Gly Arg Ser Cys His His His Tyr
155 160 165

ttc agg aag aca cta gta agt ggt gaa aaa ata gca aga act tgg ttg 581
Phe Arg Lys Thr Leu Val Ser Gly Glu Lys Ile Ala Arg Thr Trp Leu
170 175 180

atg tat tca aaa gtg aag aac agc ctc ttt tgc ttt tgt tgc aaa ttg 629
Met Tyr Ser Lys Val Lys Asn Ser Leu Phe Cys Phe Cys Cys Lys Leu
185 190 195 200

ttt tcc aac aaa aac att aat tta aca act tct ggt aca gca aac tgg 677
Phe Ser Asn Lys Asn Ile Asn Leu Thr Thr Ser Gly Thr Ala Asn Trp
205 210 215

aaa cat gca agc aca tac ctc aca gca cac gaa aaa agc cca gaa cac 725
Lys His Ala Ser Thr Tyr Leu Thr Ala His Glu Lys Ser Pro Glu His
220 225 230

ctc aat tgt atg aaa gca tgg aag gaa ctg tca ggg agg atc aga agt Leu Asn Cys Met Lys Ala Trp Lys Glu Leu Ser Gly Arg Ile Arg Ser 235 240 245	773
ggg aaa aca att gat aag cag gag atg gca ctt ctg gaa gag gag cgg Gly Lys Thr Ile Asp Lys Gln Glu Met Ala Leu Leu Glu Glu Glu Arg 250 255 260	821
gtg aga tgg aga gca gtg cta acc cgt ctc att gct att gtg cag tca Val Arg Trp Arg Ala Val Leu Thr Arg Leu Ile Ala Ile Val Gln Ser 265 270 275 280	869
ctg gca gtt cgg aat ttg gct cta agg gga cac aca gaa aca ctg ttc Leu Ala Val Arg Asn Leu Ala Leu Arg Gly His Thr Glu Thr Leu Phe 285 290 295	917
aca tca tca aat ggg aat ttt ttg aaa gag gtt gaa ctg atg gcc agg Thr Ser Ser Asn Gly Asn Phe Leu Lys Glu Val Glu Leu Met Ala Arg 300 305 310	965
ttt gat ccc ata atg aaa gat cat ctt aac cgt gta tta aga gga aca Phe Asp Pro Ile Met Lys Asp His Leu Asn Arg Val Leu Arg Gly Thr 315 320 325	1013
gca agt cac aac agc tac ata ggc cat cat gtg cag aat gaa ctt att Ala Ser His Asn Ser Tyr Ile Gly His His Val Gln Asn Glu Leu Ile 330 335 340	1061
gat ttg ttg agc agc aaa atc cta tcc gct ata gtg gat gac atc aaa Asp Leu Leu Ser Ser Lys Ile Leu Ser Ala Ile Val Asp Asp Ile Lys 345 350 355 360	1109
aag gca aaa tat ttt tca ata att ctg gac tgc act ctg gat ata agc Lys Ala Lys Tyr Phe Ser Ile Ile Leu Asp Cys Thr Leu Asp Ile Ser 365 370 375	1157
cac aca gaa cag ttg tca gtt ata att aga gtg gtg tca ctg atg gag His Thr Glu Gln Leu Ser Val Ile Ile Arg Val Val Ser Leu Met Glu 380 385 390	1205
aag oct cag atc agg gaa cat ttt atg ggg ttt ttg gag gca gag gag Lys Pro Gln Ile Arg Glu His Phe Met Gly Phe Leu Glu Ala Glu Glu 395 400 405	1253
tcc aca ggc cag cac ttg gca tcc atg atc tta aac aga ctt gag gag Ser Thr Gly Gln His Leu Ala Ser Met Ile Leu Asn Arg Leu Glu Glu 410 415 420	1301
tta gga att tct ttt gaa gac tgc aga gga caa tca tat gat aat ggg Leu Gly Ile Ser Phe Glu Asp Cys Arg Gly Gln Ser Tyr Asp Asn Gly 425 430 435 440	1349
gca aat atg aaa ggc aaa aat aag gga gta caa gcc agg ctc tta gaa Ala Asn Met Lys Gly Lys Asn Lys Gly Val Gln Ala Arg Leu Leu Glu 445 450 455	1397
aag aat ccc cgt gct ctg ttt ttg cca tgc ggt gca cac aca ttg aat Lys Asn Pro Arg Ala Leu Phe Leu Pro Cys Gly Ala His Thr Leu Asn 460 465 470	1445
tta gtt gtg tgt gat got gct aag aga tct gtt gat gct atg agc tac Leu Val Val Cys Asp Ala Ala Lys Arg Ser Val Asp Ala Met Ser Tyr 475 480 485	1493
ttt ggt gtc ctg caa aag ott tac act tta ttt tca gcc tct gcc caa Phe Gly Val Leu Gln Lys Leu Tyr Thr Leu Phe Ser Ala Ser Ala Gln 490 495 500	1541
cga tgg gcc ata ctg aag agt cag gtg agc atc act cta aag tcg tgg Arg Trp Ala Ile Leu Lys Ser Gln Val Ser Ile Thr Leu Lys Ser Trp 505 510 515 520	1589
aca gaa aca agg tgg gag agc aaa atc aaa agc atc gag ccc atg agg Thr Glu Thr Arg Trp Glu Ser Lys Ile Lys Ser Ile Glu Pro Met Arg 525 530 535	1637

tac cag gga gct gca gtg aga gag gct tta ata gaa gtg aga gac aag Tyr Gln Gly Ala Ala Val Arg Glu Ala Leu Ile Glu Val Arg Asp Lys 540 545 550	1685
acc aaa gac cca gtt ata aag gct gag gcc cag tot ttg tot gaa gag Thr Lys Asp Pro Val Ile Lys Ala Glu Ala Gln Ser Leu Ser Glu Glu 555 560 565	1733
gta ggg tcg tac cgc ttc aac atc tgc aca gtc gta tgg cat gac att Val Gly Ser Tyr Arg Phe Asn Ile Cys Thr Val Val Trp His Asp Ile 570 575 580	1781
cta tct aca ata aag cat gtc agc aaa ctc atg cag tot cca aat atg Leu Ser Thr Ile Lys His Val Ser Lys Leu Met Gln Ser Pro Asn Met 585 590 595 600	1829
cat gtg gac cta gct gtg agt ctt ttg aag aag act gaa caa agt ctc His Val Asp Leu Ala Val Ser Leu Leu Lys Lys Thr Glu Gln Ser Leu 605 610 615	1877
cag agc tac agg gca aat ggc ttt gtg aat gca cag atg gca gcc aaa Gln Ser Tyr Arg Ala Asn Gly Phe Val Asn Ala Gln Met Ala Ala Lys 620 625 630	1925
gaa atg tgc aag gaa atg aat gtc gag gct att ttg aaa caa aaa aga Glu Met Cys Lys Glu Met Asn Val Glu Ala Ile Leu Lys Gln Lys Arg 635 640 645	1973
ata aga tcc aca aag tgc caa ttc tcg tat gaa tca cac gat gag cct Ile Arg Ser Thr Lys Cys Gln Phe Ser Tyr Glu Ser His Asp Glu Pro 650 655 660	2021
ttc agt gac gca ctt aaa aag ttg gag gtt gaa ttt ttc aat gtt gtt Phe Ser Asp Ala Leu Lys Lys Leu Glu Val Glu Phe Phe Asn Val Val 665 670 675 680	2069
gtt gat gaa gcc ttg tca gcc atc gcg gag agg ttt tcc aca ttg gaa Val Asp Glu Ala Leu Ser Ala Ile Ala Glu Arg Phe Ser Thr Leu Glu 685 690 695	2117
gtt gta caa aac aga ttt ggg gtt ttg acc aat ttc cca agc ctt gga Val Val Gln Asn Arg Phe Gly Val Leu Thr Asn Phe Pro Ser Leu Gly 700 705 710	2165
gac gag gag ctg acg gag caa tgc gag gca cta ggc aac ata ctc cat Asp Glu Glu Leu Thr Glu Gln Cys Glu Ala Leu Gly Asn Ile Leu His 715 720 725	2213
ttt gag aag aac tgg gat ttg gac agt aga gag ctt gtt cag gaa atc Phe Glu Lys Asn Trp Asp Leu Asp Ser Arg Glu Leu Val Gln Glu Ile 730 735 740	2261
aag aac ttg cct aac tta cca tca acg act cca agt ctc ctt gag ctc Lys Asn Leu Pro Asn Leu Pro Ser Thr Thr Pro Ser Leu Leu Glu Leu 745 750 755 760	2309
atc tct ttc atg tot gat aag gat cta tca gaa atc tat ccg aac ttt Ile Ser Phe Met Ser Asp Lys Asp Leu Ser Glu Ile Tyr Pro Asn Phe 765 770 775	2357
tgg act gct ctc agg att gca ctc acc ttg cca gtc act gtg gct caa Trp Thr Ala Leu Arg Ile Ala Leu Thr Leu Pro Val Thr Val Ala Gln 780 785 790	2405
gca gag agg agc ttt tca aaa cta aaa ttg atc aag tcg tac ctg agg Ala Glu Arg Ser Phe Ser Lys Leu Lys Leu Ile Lys Ser Tyr Leu Arg 795 800 805	2453
tca aca atg tca cag gag cga ctc act aac ctt gcc gtt gtt agc atc Ser Thr Met Ser Gln Glu Arg Leu Thr Asn Leu Ala Val Val Ser Ile 810 815 820	2501
aat cac tca gta ggg gag cag ata tca tat gat gat gtt att gac gag Asn His Ser Val Gly Glu Gln Ile Ser Tyr Asp Asp Val Ile Asp Glu 825 830 835 840	2549

ttt gca tca aga aag gct agg aag gtt agg ttt tag ttggtgtttt 2595
Phe Ala Ser Arg Lys Ala Arg Lys Val Arg Phe
845 850

ctgttattgt attggtgctg cagttatatt tatttttagcg tgtcatttgt gtgataaaag 2655

gtttgtgctt tataatattt attttatatt atttattcaa tattgagttt gattcaatat 2715

tttcttagct aactgtattt ttgccatgct 2745

<210> 17
<211> 851
<212> PRT
<213> Oryzias latipes

<400> 17

Met Glu Lys Lys Arg Ser Lys Pro Ser Gly Ala Gln Phe Arg Lys Lys
1 5 10 15

Arg Lys Glu Glu Glu Glu Lys Arg Asp Lys Glu Lys Gly Ala Leu Leu
20 25 30

Arg Tyr Phe Gly Ser Ser Thr Thr Ala Gln Asp Glu Thr Ser Thr Ser
35 40 45

Leu Pro Ala Ile Ser Ser Ala Thr Val Thr Val Ser Pro Pro Gln Asp
50 55 60

Glu Leu Pro Ser Thr Ser Ser Ala Thr His Val Val Pro Gln Leu Leu
65 70 75 80

Pro Glu Gln Ser Phe Asp Ser Glu Ala Glu Asp Val Val Pro Ser Thr
85 90 95

Ser Thr Gln Leu Glu Thr Ser Glu Met Pro Gly Asp Glu Thr Pro Leu
100 105 110

Thr Pro Thr Ala Glu Asp Gln Pro Leu Pro Thr Asp Pro Ala Lys Trp
115 120 125

Pro Ser Pro Leu Thr Asp Arg Ile Arg Met Glu Leu Val Arg Arg Gly
130 135 140

Pro Ser Ser Ile Pro Pro Asp Phe Val Phe Pro Arg Asn Asp Ser Asp
145 150 155 160

Gly Arg Ser Cys His His His Tyr Phe Arg Lys Thr Leu Val Ser Gly
165 170 175

Glu Lys Ile Ala Arg Thr Trp Leu Met Tyr Ser Lys Val Lys Asn Ser
180 185 190

Leu Phe Cys Phe Cys Cys Lys Leu Phe Ser Asn Lys Asn Ile Asn Leu
195 200 205

Thr Thr Ser Gly Thr Ala Asn Trp Lys His Ala Ser Thr Tyr Leu Thr
210 215 220

Ala His Glu Lys Ser Pro Glu His Leu Asn Cys Met Lys Ala Trp Lys
225 230 235 240

Glu Leu Ser Gly Arg Ile Arg Ser Gly Lys Thr Ile Asp Lys Gln Glu
 245 250 255
 Met Ala Leu Leu Glu Glu Glu Arg Val Arg Trp Arg Ala Val Leu Thr
 260 265 270
 Arg Leu Ile Ala Ile Val Gln Ser Leu Ala Val Arg Asn Leu Ala Leu
 275 280 285
 Arg Gly His Thr Glu Thr Leu Phe Thr Ser Ser Asn Gly Asn Phe Leu
 290 295 300
 Lys Glu Val Glu Leu Met Ala Arg Phe Asp Pro Ile Met Lys Asp His
 305 310 315 320
 Leu Asn Arg Val Leu Arg Gly Thr Ala Ser His Asn Ser Tyr Ile Gly
 325 330 335
 His His Val Gln Asn Glu Leu Ile Asp Leu Leu Ser Ser Lys Ile Leu
 340 345 350
 Ser Ala Ile Val Asp Asp Ile Lys Lys Ala Lys Tyr Phe Ser Ile Ile
 355 360 365
 Leu Asp Cys Thr Leu Asp Ile Ser His Thr Glu Gln Leu Ser Val Ile
 370 375 380
 Ile Arg Val Val Ser Leu Met Glu Lys Pro Gln Ile Arg Glu His Phe
 385 390 395 400
 Met Gly Phe Leu Glu Ala Glu Glu Ser Thr Gly Gln His Leu Ala Ser
 405 410 415
 Met Ile Leu Asn Arg Leu Glu Glu Leu Gly Ile Ser Phe Glu Asp Cys
 420 425 430
 Arg Gly Gln Ser Tyr Asp Asn Gly Ala Asn Met Lys Gly Lys Asn Lys
 435 440 445
 Gly Val Gln Ala Arg Leu Leu Glu Lys Asn Pro Arg Ala Leu Phe Leu
 450 455 460
 Pro Cys Gly Ala His Thr Leu Asn Leu Val Val Cys Asp Ala Ala Lys
 465 470 475 480
 Arg Ser Val Asp Ala Met Ser Tyr Phe Gly Val Leu Gln Lys Leu Tyr
 485 490 495
 Thr Leu Phe Ser Ala Ser Ala Gln Arg Trp Ala Ile Leu Lys Ser Gln
 500 505 510
 Val Ser Ile Thr Leu Lys Ser Trp Thr Glu Thr Arg Trp Glu Ser Lys
 515 520 525
 Ile Lys Ser Ile Glu Pro Met Arg Tyr Gln Gly Ala Ala Val Arg Glu
 530 535 540

Ala Leu Ile Glu Val Arg Asp Lys Thr Lys Asp Pro Val Ile Lys Ala
545 550 555 560

Glu Ala Gln Ser Leu Ser Glu Glu Val Gly Ser Tyr Arg Phe Asn Ile
565 570 575

Cys Thr Val Val Trp His Asp Ile Leu Ser Thr Ile Lys His Val Ser
580 585 590

Lys Leu Met Gln Ser Pro Asn Met His Val Asp Leu Ala Val Ser Leu
595 600 605

Leu Lys Lys Thr Glu Gln Ser Leu Gln Ser Tyr Arg Ala Asn Gly Phe
610 615 620

Val Asn Ala Gln Met Ala Ala Lys Glu Met Cys Lys Glu Met Asn Val
625 630 635 640

Glu Ala Ile Leu Lys Gln Lys Arg Ile Arg Ser Thr Lys Cys Gln Phe
645 650 655

Ser Tyr Glu Ser His Asp Glu Pro Phe Ser Asp Ala Leu Lys Lys Leu
660 665 670

Glu Val Glu Phe Phe Asn Val Val Val Asp Glu Ala Leu Ser Ala Ile
675 680 685

Ala Glu Arg Phe Ser Thr Leu Glu Val Val Gln Asn Arg Phe Gly Val
690 695 700

Leu Thr Asn Phe Pro Ser Leu Gly Asp Glu Glu Leu Thr Glu Gln Cys
705 710 715 720

Glu Ala Leu Gly Asn Ile Leu His Phe Glu Lys Asn Trp Asp Leu Asp
725 730 735

Ser Arg Glu Leu Val Gln Glu Ile Lys Asn Leu Pro Asn Leu Pro Ser
740 745 750

Thr Thr Pro Ser Leu Leu Glu Leu Ile Ser Phe Met Ser Asp Lys Asp
755 760 765

Leu Ser Glu Ile Tyr Pro Asn Phe Trp Thr Ala Leu Arg Ile Ala Leu
770 775 780

Thr Leu Pro Val Thr Val Ala Gln Ala Glu Arg Ser Phe Ser Lys Leu
785 790 795 800

Lys Leu Ile Lys Ser Tyr Leu Arg Ser Thr Met Ser Gln Glu Arg Leu
805 810 815

Thr Asn Leu Ala Val Val Ser Ile Asn His Ser Val Gly Glu Gln Ile
820 825 830

Ser Tyr Asp Asp Val Ile Asp Glu Phe Ala Ser Arg Lys Ala Arg Lys
835 840 845

Val Arg Phe
850

<210> 18
<211> 417
<212> DNA
<213> Artificial

<220>
<223> Description of the artificial sequence: VH region of anti-CD98 antibody

<220>
<221> CDS
<222> (1).. (417)

<400> 18
atg aag cac ctg tgg ttc ttc ctc ctg ctg gtg gcg gct ccc aga tgg 48
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15
gtc ctg tcc cag ctg cag ctg cag gag tgc ggc cca gga ctg gtg aag 96
Val Leu Ser Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys
20 25 30
cct tgc gag acc ctg tcc ctc acc tgc act gtc tct ggt ggc tcc atc 144
Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile
35 40 45
agc agt agt agt tac tac tgg ggc tgg atc cgc cag ccc cca ggg aag 192
Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
ggg ctg gag tgg att ggg agt atc tat tat agt ggg agt acc tac tac 240
Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr
65 70 75 80
aac ccg tcc ctc aag agt cga gtc acc ata tcc gta gac acg tcc aag 288
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
aac cag ttc tcc ctg aag ctg agc tct gtg acc gcc gca gac acg gct 336
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
gtg tat tac tgt gcg aga caa ggg acg ggg ctc gcc cta ttt gac tac 384
Val Tyr Tyr Cys Ala Arg Gln Gly Thr Gly Leu Ala Leu Phe Asp Tyr
115 120 125
tgg ggc cag gga acc ctg gtc acc gtc tcc tca 417
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135

<210> 19
<211> 139
<212> PRT
<213> Artificial

<220>
<223> Synthetic Construct

<400> 19

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15

Val Leu Ser Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys
20 25 30

Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile
35 40 45

Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60

Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr
65 70 75 80

Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95

Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110

Val Tyr Tyr Cys Ala Arg Gln Gly Thr Gly Leu Ala Leu Phe Asp Tyr
115 120 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135

<210> 20
<211> 120
<212> PRT
<213> Artificial

<220>
<223> Description of the artificial sequence: VH region of anti-CD98 antibody

<400> 20

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Gly Thr Gly Leu Ala Leu Phe Asp Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 21
<211> 387
<212> DNA
<213> Artificial

<220>
 <223> Description of the artificial sequence: VL region of anti-CD98 antibody

<220>
 <221> CDS
 <222> (1).. (387)

```

<400> 21
atg gaa acc cca gcg cag ctt ctc ttc ctc ctg cta ctc tgg ctc cca      48
Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro
1          5          10          15

gat acc acc gga gaa att gtg ttg acg cag tct cca ggc acc ctg tct      96
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
          20          25          30

ttg tct cca ggg gaa aga gcc acc ctc tcc tgc agg gcc agt cag agt     144
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
          35          40          45

gtt agc agc agc ttc tta gcc tgg tac cag cag aaa cct ggc cag gct     192
Val Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
          50          55          60

ccc agg ctc ctc atc tat ggt gca tcc agc agg gcc act ggc atc cca     240
Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
          65          70          75          80

gac agg ttc agt ggc agt ggg tct ggg aca gac ttc act ctc acc atc     288
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
          85          90          95

agc aga ctg gag cct gaa gat ttc gca gtg tat tac tgt cag cag tat     336
Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
          100          105          110

ggt agc tca cct cta ttc act ttc ggc cct ggg acc aaa gtg gat atc     384
Gly Ser Ser Pro Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile
          115          120          125

aaa
Lys
387

```

<210> 22
 <211> 129
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

```

<400> 22
Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro
1          5          10          15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
          20          25          30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
          35          40          45

Val Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
          50          55          60

Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
          65          70          75          80

```

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95

Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110

Gly Ser Ser Pro Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile
115 120 125

Lys

<210> 23
<211> 109
<212> PRT
<213> Artificial

<220>
<223> Description of the artificial sequence: VL region of anti-CD98 antibody

<400> 23

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95

Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105

<210> 24
<211> 420
<212> DNA
<213> Artificial

<220>
<223> Description of the artificial sequence: VH region of anti-TNF alpha antibody

<220>
<221> CDS
<222> (1)..(420)

<400> 24
atg gag ttg gga ctg agc tgg att ttc ctt ttg gct att tta aaa ggt 48
Met Glu Leu Gly Leu Ser Trp Ile Phe Leu Leu Ala Ile Leu Lys Gly
1 5 10 15

gtc cag tgt gag gtg cag ctg gtg gag tct ggg gga ggc ttg gta cag 96

Val	Gln	Cys	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln		
			20					25					30				
ccc	ggc	agg	tcc	ctg	aga	ctc	tcc	tgt	gcg	gcc	tct	gga	ttc	acc	ttt	144	
Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe		
		35					40					45					
gat	gat	tat	gcc	atg	cac	tgg	gtc	cgg	caa	gct	cca	ggg	aag	ggc	ctg	192	
Asp	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu		
		50				55					60						
gaa	tgg	gtc	tca	gct	atc	act	tgg	aat	agt	ggg	cac	ata	gac	tat	gcg	240	
Glu	Trp	Val	Ser	Ala	Ile	Thr	Trp	Asn	Ser	Gly	His	Ile	Asp	Tyr	Ala		
		65			70					75					80		
gac	tct	gtg	gag	ggc	cga	ttc	acc	atc	tcc	aga	gac	aac	gcc	aag	aac	288	
Asp	Ser	Val	Glu	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn		
				85					90					95			
tcc	ctg	tat	ctg	caa	atg	aac	agt	ctg	aga	gct	gag	gat	acg	gcc	gta	336	
Ser	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val		
			100					105					110				
tat	tac	tgt	gcg	aaa	gtc	tcg	tac	ctt	agc	acc	gcg	tcc	tcc	ctt	gac	384	
Tyr	Tyr	Cys	Ala	Lys	Val	Ser	Tyr	Leu	Ser	Thr	Ala	Ser	Ser	Leu	Asp		
		115				120						125					
tat	tgg	ggc	caa	ggt	acc	ctg	gtc	acc	gtc	tcg	tca					420	
Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser						
		130				135					140						

<210> 25
 <211> 140
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 25

Met	Glu	Leu	Gly	Leu	Ser	Trp	Ile	Phe	Leu	Leu	Ala	Ile	Leu	Lys	Gly
1				5					10					15	

Val	Gln	Cys	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln
			20					25					30		

Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe
		35				40						45			

Asp	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
	50					55					60				

Glu	Trp	Val	Ser	Ala	Ile	Thr	Trp	Asn	Ser	Gly	His	Ile	Asp	Tyr	Ala
	65				70					75					80

Asp	Ser	Val	Glu	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn
				85					90					95	

Ser	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val
			100					105					110		

Tyr	Tyr	Cys	Ala	Lys	Val	Ser	Tyr	Leu	Ser	Thr	Ala	Ser	Ser	Leu	Asp
		115					120					125			

Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser				
	130					135					140				

<210> 26
 <211> 121
 <212> PRT
 <213> Artificial
 <220>
 <223> Description of the artificial sequence: VH region of anti-TNF
 alpha antibody

<400> 26
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
 50 55 60
 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 27
 <211> 387
 <212> DNA
 <213> Artificial
 <220>
 <223> Description of the artificial sequence: VL region of anti-TNF
 alpha antibody

<220>
 <221> CDS
 <222> (1)..(387)

<400> 27
 atg gac atg agg gtc ccc gct cag ctc ctg ggg ctt ctg ctg ctc tgg 48
 Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Trp
 1 5 10 15
 ctc cca ggt gcc aga tgt gac atc cag atg acc cag tct cca tcc tcc 96
 Leu Pro Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
 20 25 30
 ctg tct gca tct gta ggg gac aga gtc acc atc act tgt cgg gca agt 144
 Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
 35 40 45
 cag ggc atc aga aat tac tta gcc tgg tat cag caa aaa cca ggg aaa 192
 Gln Gly Ile Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
 50 55 60

gcc cct aag ctc ctg atc tat gct gca tcc act ttg caa tca ggg gtc	240
Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val	
65 70 75 80	
cca tct cgg ttc agt ggc agt gga tct ggg aca gat ttc act ctc acc	288
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr	
85 90 95	
atc agc agc cta cag cct gaa gat gtt gca act tat tac tgt caa agg	336
Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg	
100 105 110	
tat aac cgt gca ccg tat act ttt ggc cag ggg acc aaa gtg gag atc	384
Tyr Asn Arg Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile	
115 120 125	
aaa	387
Lys	

<210> 28
 <211> 129
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 28

Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp	
1 5 10 15	
Leu Pro Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser	
20 25 30	
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser	
35 40 45	
Gln Gly Ile Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys	
50 55 60	
Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val	
65 70 75 80	
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr	
85 90 95	
Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg	
100 105 110	
Tyr Asn Arg Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile	
115 120 125	
Lys	

<210> 29
 <211> 107
 <212> PRT
 <213> Artificial

<220>
 <223> Description of the artificial sequence: VL region of anti-TNF
 alpha antibody

<400> 29

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 30

<211> 420

<212> DNA

<213> Artificial

<220>

<223> Description of the artificial sequence: VH region of anti-CD20 antibody

<220>

<221> CDS

<222> (1)..(420)

<400> 30

atg ggt tgg agc ctc atc ttg ctc ttc ctt gtc gct gtt gct acg cgt 48
Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg
1 5 10 15

gtc ctg tcc cag gta caa ctg cag cag cct ggg gct gag ctg gtg aag 96
Val Leu Ser Gln Val Gln Leu Gln Pro Gly Ala Glu Leu Val Lys
20 25 30

cct ggg gcc tca gtg aag atg tcc tgc aag gct tct ggc tac aca ttt 144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

acc agt tac aat atg cac tgg gta aaa cag aca cct ggt cgg ggc ctg 192
Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu
50 55 60

gaa tgg att gga gct att tat ccc gga aat ggt gat act tcc tac aat 240
Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn
65 70 75 80

cag aag ttc aaa ggc aag gcc aca ttg act gca gac aaa tcc tcc agc 288
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
85 90 95

aca gcc tac atg cag ctc agc agc ctg aca tct gag gac tct gcg gtc 336
Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
100 105 110

tat tac tgt gca aga tcg act tac tac ggc ggt gac tgg tac ttc aat 384
Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn
115 120 125

gtc tgg ggc gca ggg acc acg gtc acc gtc tct gca
 Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala
 130 135 140

420

<210> 31
 <211> 140
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 31

Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg
 1 5 10 15

Val Leu Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys
 20 25 30

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45

Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu
 50 55 60

Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn
 65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95

Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn
 115 120 125

Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala
 130 135 140

<210> 32
 <211> 121
 <212> PRT
 <213> Artificial

<220>
 <223> Description of the artificial sequence: VH region of anti-CD20
 antibody

<400> 32

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50	55	60	
Lys Gly Lys Ala Thr	Leu Thr Ala Asp Lys	Ser Ser Ser Thr Ala Tyr	
65	70	75	80
Met Gln Leu Ser	Ser Leu Thr Ser Glu Asp	Ser Ala Val Tyr Tyr Cys	
	85	90	95
Ala Arg Ser Thr	Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn	Val Trp Gly	
	100	105	110
Ala Gly Thr Thr	Val Thr Val Ser Ala		
	115	120	

<210> 33
 <211> 384
 <212> DNA
 <213> Artificial

 <220>
 <223> Description of the artificial sequence: VL region of anti-CD20 antibody

 <220>
 <221> CDS
 <222> (1)..(384)

 <400> 33

atg gat ttt cag gtg cag att atc agc ttc ctg cta atc agt gct tca	48
Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser	
1 5 10 15	
gtc ata atg tcc aga gga caa att gtt ctc tcc cag tct cca gca atc	96
Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile	
20 25 30	
ctg tct gca tct cca ggg gag aag gtc aca atg act tgc agg gcc agc	144
Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser	
35 40 45	
tca agt gta agt tac atc cac tgg ttc cag cag aag cca gga tcc tcc	192
Ser Ser Val Ser Tyr Ile His Trp Phe Gln Gln Lys Pro Gly Ser Ser	
50 55 60	
ccc aaa ccc tgg att tat gcc aca tcc aac ctg gct tct gga gtc cct	240
Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro	
65 70 75 80	
gtt cgc ttc agt ggc agt ggg tct ggg act tct tac tct ctc aca atc	288
Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile	
85 90 95	
agc aga gtg gag gct gaa gat gct gcc act tat tac tgc cag cag tgg	336
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp	
100 105 110	
act agt aac cca ccc acg ttc gga ggg ggg acc aag ctg gaa atc aaa	384
Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys	
115 120 125	

<210> 34
 <211> 128
 <212> PRT
 <213> Artificial

 <220>
 <223> Synthetic Construct

 <400> 34

Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15

Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
 20 25 30

Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
 35 40 45

Ser Ser Val Ser Tyr Ile His Trp Phe Gln Gln Lys Pro Gly Ser Ser
 50 55 60

Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro
 65 70 75 80

Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
 85 90 95

Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
 100 105 110

Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 115 120 125

<210> 35

<211> 106

<212> PRT

<213> Artificial

<220>

<223> Description of the artificial sequence: VL region of anti-CD20 antibody

<400> 35

Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
 1 5 10 15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
 20 25 30

His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
 35 40 45

Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
 50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
 65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
 85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 36

<211> 795

<212> DNA

<213> unknown

<220>
 <223> wild type neomycin resistant gene

<220>
 <221> CDS
 <222> (1).. (795)

<400> 36
 atg att gaa caa gat gga ttg cac gca ggt tct ccg gcc gct tgg gtg 48
 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val
 1 5 10 15
 gag agg cta ttc ggc tat gac tgg gca caa cag aca atc ggc tgc tct 96
 Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser
 20 25 30
 gat gcc gcc gtg ttc cgg ctg tca gcg cag ggg cgc ccg gtt ott ttt 144
 Asp Ala Ala Val Phe Arg Leu Ser Ala Ala Gln Gly Arg Pro Val Leu Phe
 35 40 45
 gtc aag acc gac ctg tcc ggt gcc ctg aat gaa ctg cag gac gag gca 192
 Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala
 50 55 60
 gcg cgg cta tcg tgg ctg gcc acg acg ggc gtt cct tgc gca gct gtg 240
 Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val
 65 70 75 80
 ctc gac gtt gtc act gaa gcg gga agg gac tgg ctg cta ttg ggc gaa 288
 Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu
 85 90 95
 gtg ccg ggg cag gat ctc ctg tca tct cac ctt gct cct gcc gag aaa 336
 Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys
 100 105 110
 gta tcc atc atg gct gat gca atg cgg cgg ctg cat acg ott gat ccg 384
 Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro
 115 120 125
 gct acc tgc cca ttc gac cac caa gcg aaa cat cgc atc gag cga gca 432
 Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala
 130 135 140
 cgt act cgg atg gaa gcc ggt ctt gtc gat cag gat gat ctg gac gaa 480
 Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu
 145 150 155 160
 gag cat cag ggg ctc gcg cca gcc gaa ctg ttc gcc agg ctc aag gcg 528
 Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala
 165 170 175
 cgc atg ccc gac ggc gag gat ctc gtc gtg acc cat ggc gat gcc tgc 576
 Arg Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys
 180 185 190
 ttg ccg aat atc atg gtg gaa aat ggc cgc ttt tct gga ttc atc gac 624
 Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp
 195 200 205
 tgt ggc cgg ctg ggt gtg gcg gac cgc tat cag gac ata gcg ttg gct 672
 Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala
 210 215 220
 acc cgt gat att gct gaa gag ctt ggc gcc gaa tgg gct gac cgc ttc 720
 Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Trp Ala Asp Arg Phe
 225 230 235 240
 ctc gtg ott tac ggt atc gcc got ccc gat tcg cag cgc atc gcc ttc 768
 Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe
 245 250 255
 tat cgc ott ott gac gag ttc ttc tga 795
 Tyr Arg Leu Leu Asp Glu Phe Phe
 260

<210> 37
 <211> 795
 <212> DNA
 <213> Artificial

<220>
 <223> modified neomycin resistant gene

<220>
 <221> CDS
 <222> (1).. (795)

<400> 37
 atg att gaa caa gat gga ttg cac gca ggt tct ccg gcc gct tgg gtg 48
 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val
 1 5 10 15
 gag agg cta ttc ggc tat gac tgg gca caa cag aca atc ggc tgc tct 96
 Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser
 20 25 30
 gat gcc gcc gtg ttc cgg ctg tca gcg cag ggg cgc ccg gtt ctt ttt 144
 Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe
 35 40 45
 gtc aag acc gac ctg tcc ggt gcc ctg aat gaa ctg caa gat gaa gcg 192
 Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala
 50 55 60
 gcg cga tta tcg tgg tta gcg acg acg ggg gta ccg tgt gcg gcg gta 240
 Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val
 65 70 75 80
 tta gat gta gta acg gaa gcg ggg cga gat tgg tta tta tta ggg gaa 288
 Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu
 85 90 95
 gta ccg ggg caa gat tta tta tcg tcg cat tta gcg ccg gcg gaa aaa 336
 Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys
 100 105 110
 gta tcg ata atg gcg gat gcg atg cga cga tta cat acg tta gat ccg 384
 Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro
 115 120 125
 gcg acg tgt ccg ttt gat cat caa gcg aaa cat cga ata gaa cga gcg 432
 Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala
 130 135 140
 cga acg cga atg gaa gcg ggg tta gta gat caa gat gat tta gat gaa 480
 Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu
 145 150 155 160
 gaa cat caa ggg tta gcg ccg gcg gaa tta ttt gcg cga tta aaa gcg 528
 Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala
 165 170 175
 cga atg ccg gat ggg gaa gat tta gta gta acg cat ggg gat gcg tgt 576
 Arg Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys
 180 185 190
 tta ccg aat ata atg gta gaa aat ggg cga ttt tcg ggg ttt ata gat 624
 Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp
 195 200 205
 tgt ggg cga tta ggg gta gcg gat cgt tat caa gat ata gcg tta gcg 672
 Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala
 210 215 220
 acg cga gat ata gcg gaa gaa tta ggg ggg gaa tgg gcg gat cga ttt 720
 Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe
 225 230 235 240
 tta gta tta tat ggg ata gcg gcg ccg gat tcg caa cga ata gcg ttt 768

Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe
 245 250 255
 tat cga tta tta gat gaa ttt ttt tga 795
 Tyr Arg Leu Leu Asp Glu Phe Phe
 260
 <210> 38
 <211> 795
 <212> DNA
 <213> artificial
 <220>
 <223> modified neomycin resistant gene
 <220>
 <221> CDS
 <222> (1).. (795)
 <400> 38
 atg att gaa caa gat gga ttg cac gca ggt tct ccg gcc gct tgg gtg 48
 Met Ile Glu Gln Asp Gly Leu His Ala Gln Ser Pro Ala Ala Trp Val
 1 5 10 15
 gag agg cta ttc ggc tat gac tgg gca caa cag aca atc ggc tgc tct 96
 Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser
 20 25 30
 gat gcc gcc gtg ttc cgg ctg tca gcg cag ggg cgc ccg gtt ctt ttt 144
 Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe
 35 40 45
 gta aaa acg gat tta tcg ggg gcg tta aat gaa tta caa gat gaa gcg 192
 Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala
 50 55 60
 gcg cga tta tcg tgg tta gcg acg acg ggg gta ccg tgt gcg gcg gta 240
 Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val
 65 70 75 80
 tta gat gta gta acg gaa gcg ggg cga gat tgg tta tta tta ggg gaa 288
 Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu
 85 90 95
 gta ccg ggg caa gat tta tta tcg tcg cat tta gcg ccg gcg gaa aaa 336
 Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys
 100 105 110
 gta tcg ata atg gcg gat gcg atg cga cga tta cat acg tta gat ccg 384
 Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro
 115 120 125
 gcg acg tgt ccg ttt gat cat caa gcg aaa cat cga ata gaa cga gcg 432
 Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala
 130 135 140
 cga acg cga atg gaa gcg ggg tta gta gat caa gat gat tta gat gaa 480
 Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu
 145 150 155 160
 gaa cat caa ggg tta gcg ccg gcg gaa tta ttt gcg cga tta aaa gcg 528
 Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala
 165 170 175
 cga atg ccg gat ggg gaa gat tta gta gta acg cat ggg gat gcg tgt 576
 Arg Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys
 180 185 190
 tta ccg aat ata atg gta gaa aat ggg cga ttt tcg ggg ttt ata gat 624
 Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp
 195 200 205
 tgt ggg cga tta ggg gta gcg gat cgt tat caa gat ata gcg tta gcg 672
 Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala
 210 215 220

acg cga gat ata gcg gaa gaa tta ggg ggg gaa tgg gcg gat cga ttt Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe 225 230 235 240	720
tta gta tta tat ggg ata gcg gcg ccg gat tgg caa cga ata gcg ttt Leu Val Leu Tyr 245 Ile Ala Ala Pro Asp 250 Ser Gln Arg Ile Ala Phe 255	768
tat cga tta tta gat gaa ttt ttt tga Tyr Arg Leu Leu Asp Glu Phe Phe 260	795
<210> 39	
<211> 795	
<212> DNA	
<213> artificial	
<220>	
<223> modified neomycin resistant gene	
<220>	
<221> CDS	
<222> (1).. (795)	
<400> 39	
atg att gaa caa gat gga ttg cac gca ggt tct ccg gcc gct tgg gtg Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val 1 5 10 15	48
gag agg cta ttt ggg tat gat tgg gcg caa caa acg ata ggg tgt tgg Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser 20 25 30	96
gat gcg gcg gta ttt cga tta tgg gcg caa ggg cga ccg gta tta ttt Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe 35 40 45	144
gta aaa acg gat tta tgg ggg gcg tta aat gaa tta caa gat gaa gcg Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala 50 55 60	192
gcg cga tta tgg tgg tta gcg acg acg ggg gta ccg tgt gcg gcg gta Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val 65 70 75 80	240
tta gat gta gta acg gaa gcg ggg cga gat tgg tta tta tta ggg gaa Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu 85 90 95	288
gta ccg ggg caa gat tta tta tgg tgg cat tta gcg ccg gcg gaa aaa Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys 100 105 110	336
gta tgg ata atg gcg gat gcg atg cga cga tta cat acg tta gat ccg Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro 115 120 125	384
gcg acg tgt ccg ttt gat cat caa gcg aaa cat cga ata gaa cga gcg Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala 130 135 140	432
cga acg cga atg gaa gcg ggg tta gta gat caa gat gat tta gat gaa Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu 145 150 155 160	480
gaa cat caa ggg tta gcg ccg gcg gaa tta ttt gcg cga tta aaa gcg Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala 165 170 175	528
cga atg ccg gat ggg gaa gat tta gta gta acg cat ggg gat gcg tgt Arg Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys 180 185 190	576
tta ccg aat ata atg gta gaa aat ggg cga ttt tgg ggg ttt ata gat	624

Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp	
195 200 205	
tgt ggg cga tta ggg gta gcg gat cgt tat caa gat ata gcg tta gcg	672
Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala	
210 215 220	
acg cga gat ata gcg gaa gaa tta ggg ggg gaa tgg gcg gat cga ttt	720
Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe	
225 230 235 240	
tta gta tta tat ggg ata gcg gcg ccg gat tgg caa cga ata gcg ttt	768
Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe	
245 250 255	
tat cga tta tta gat gaa ttt ttt tga	795
Tyr Arg Leu Leu Asp Glu Phe Phe	
260	

<210> 40
 <211> 649
 <212> PRT
 <213> Oryzias latipes
 <400> 40

Met Glu Glu Val Cys Asp Ser Ser Ala Ala Ala Ser Ser Thr Val Gln
1 5 10 15
Asn Gln Pro Gln Asp Gln Glu His Pro Trp Pro Tyr Leu Arg Glu Phe
20 25 30
Phe Ser Leu Ser Gly Val Asn Lys Asp Ser Phe Lys Met Lys Cys Val
35 40 45
Leu Cys Leu Pro Leu Asn Lys Glu Ile Ser Ala Phe Lys Ser Ser Pro
50 55 60
Ser Asn Leu Arg Lys His Ile Glu Arg Met His Pro Asn Tyr Leu Lys
65 70 75 80
Asn Tyr Ser Lys Leu Thr Ala Gln Lys Arg Lys Ile Gly Thr Ser Thr
85 90 95
His Ala Ser Ser Ser Lys Gln Leu Lys Val Asp Ser Val Phe Pro Val
100 105 110
Lys His Val Ser Pro Val Thr Val Asn Lys Ala Ile Leu Arg Tyr Ile
115 120 125
Ile Gln Gly Leu His Pro Phe Ser Thr Val Asp Leu Pro Ser Phe Lys
130 135 140
Glu Leu Ile Ser Thr Leu Gln Pro Gly Ile Ser Val Ile Thr Arg Pro
145 150 155 160
Thr Leu Arg Ser Lys Ile Ala Glu Ala Ala Leu Ile Met Lys Gln Lys
165 170 175
Val Thr Ala Ala Met Ser Glu Val Glu Trp Ile Ala Thr Thr Thr Asp
180 185 190
Cys Trp Thr Ala Arg Arg Lys Ser Phe Ile Gly Val Thr Ala His Trp
195 200 205

Ile Asn Pro Gly Ser Leu Glu Arg His Ser Ala Ala Leu Ala Cys Lys
 210 215 220
 Arg Leu Met Gly Ser His Thr Phe Glu Val Leu Ala Ser Ala Met Asn
 225 230 235 240
 Asp Ile His Ser Glu Tyr Glu Ile Arg Asp Lys Val Val Cys Thr Thr
 245 250 255
 Thr Asp Ser Gly Ser Asn Phe Met Lys Ala Phe Arg Val Phe Gly Val
 260 265 270
 Glu Asn Asn Asp Ile Glu Thr Glu Ala Arg Arg Cys Glu Ser Asp Asp
 275 280 285
 Thr Asp Ser Glu Gly Cys Gly Glu Gly Ser Asp Gly Val Glu Phe Gln
 290 295 300
 Asp Ala Ser Arg Val Leu Asp Gln Asp Asp Gly Phe Glu Phe Gln Leu
 305 310 315 320
 Pro Lys His Gln Lys Cys Ala Cys His Leu Leu Asn Leu Val Ser Ser
 325 330 335
 Val Asp Ala Gln Lys Ala Leu Ser Asn Glu His Tyr Lys Lys Leu Tyr
 340 345 350
 Arg Ser Val Phe Gly Lys Cys Gln Ala Leu Trp Asn Lys Ser Ser Arg
 355 360 365
 Ser Ala Leu Ala Ala Glu Ala Val Glu Ser Glu Ser Arg Leu Gln Leu
 370 375 380
 Leu Arg Pro Asn Gln Thr Arg Trp Asn Ser Thr Phe Met Ala Val Asp
 385 390 395 400
 Arg Ile Leu Gln Ile Cys Lys Glu Ala Gly Glu Gly Ala Leu Arg Asn
 405 410 415
 Ile Cys Thr Ser Leu Glu Val Pro Met Phe Asn Pro Ala Glu Met Leu
 420 425 430
 Phe Leu Thr Glu Trp Ala Asn Thr Met Arg Pro Val Ala Lys Val Leu
 435 440 445
 Asp Ile Leu Gln Ala Glu Thr Asn Thr Gln Leu Gly Trp Leu Leu Pro
 450 455 460
 Ser Val His Gln Leu Ser Leu Lys Leu Gln Arg Leu His His Ser Leu
 465 470 475 480
 Arg Tyr Cys Asp Pro Leu Val Asp Ala Leu Gln Gln Gly Ile Gln Thr
 485 490 495
 Arg Phe Lys His Met Phe Glu Asp Pro Glu Ile Ile Ala Ala Ala Ile
 500 505 510

Leu Leu Pro Lys Phe Arg Thr Ser Trp Thr Asn Asp Glu Thr Ile Ile
515 520 525

Lys Arg Gly Met Asp Tyr Ile Arg Val His Leu Glu Pro Leu Asp His
530 535 540

Lys Lys Glu Leu Ala Asn Ser Ser Ser Asp Asp Glu Asp Phe Phe Ala
545 550 555 560

Ser Leu Lys Pro Thr Thr His Glu Ala Ser Lys Glu Leu Asp Gly Tyr
565 570 575

Leu Ala Cys Val Ser Asp Thr Arg Glu Ser Leu Leu Thr Phe Pro Ala
580 585 590

Ile Cys Ser Leu Ser Ile Lys Thr Asn Thr Pro Leu Pro Ala Ser Ala
595 600 605

Ala Cys Glu Arg Leu Phe Ser Thr Ala Gly Leu Leu Phe Ser Pro Lys
610 615 620

Arg Ala Arg Leu Asp Thr Asn Asn Phe Glu Asn Gln Leu Leu Leu Lys
625 630 635 640

Leu Asn Leu Arg Phe Tyr Asn Phe Glu
645

<210> 41
<211> 600
<212> DNA
<213> artificial

<220>
<223> modified puromycin resistant gene

<220>
<221> CDS
<222> (1).. (600)

<400> 41
atg acg gaa tat aaa ccg acg gta cgt tta gcg acg cgt gat gat gta 48
Met Thr Glu Tyr Lys Pro Thr Val Arg Leu Ala Thr Arg Asp Asp Val
1 5 10 15

ccg cgt gcg gta cgt acg tta gcg gcg gcg ttt gcg gat tat ccg gcg 96
Pro Arg Ala Val Arg Thr Leu Ala Ala Ala Phe Ala Asp Tyr Pro Ala
20 25 30

acg cgt cat acg gta gat ccg gat cgt cat ata gaa cgt gta acg gaa 144
Thr Arg His Thr Val Asp Pro Asp Arg His Ile Glu Arg Val Thr Glu
35 40 45

tta caa gaa tta ttt tta acg cgt gta ggt tta gat ata ggt aaa gta 192
Leu Gln Glu Leu Phe Leu Thr Arg Val Gly Leu Asp Ile Gly Lys Val
50 55 60

tgg gta gcg gat gat ggt gcg gcg gta gcg gta tgg acg acg ccg gaa 240
Trp Val Ala Asp Asp Gly Ala Ala Val Ala Val Trp Thr Thr Pro Glu
65 70 75 80

tcg gta gaa gcg ggt gcg gta ttt gcg gaa ata ggt ccg cgt atg gcg 288
Ser Val Glu Ala Gly Ala Val Phe Ala Glu Ile Gly Pro Arg Met Ala
85 90 95

gaa tta tcg ggt tcg cgt tta gcg gcg caa caa caa atg gaa ggt tta 336
Glu Leu Ser Gly Ser Arg Leu Ala Ala Gln Gln Gln Met Glu Gly Leu

100	105	110			
tta gcg ccg cat cgt ccg aaa gaa ccg gcg tgg ttt tta gcg acg gta Leu Ala Pro His Arg Pro Lys Glu Pro Ala Trp Phe Leu Ala Thr Val	115	120	125	384	
ggt gta tcg ccg gat cat caa ggt aaa ggt tta ggt tcg gcg gta gta Gly Val Ser Pro Asp His Gln Gly Lys Gly Leu Gly Ser Ala Val Val	130	135	140	432	
tta ccg ggt gta gaa gcg gcg gaa cgt gcg ggt gta ccg gcg ttt tta Leu Pro Gly Val Glu Ala Ala Glu Arg Ala Gly Val Pro Ala Phe Leu	145	150	155	160	480
gaa acg tcg gcg ccg cgt aat tta ccg ttt tat gaa cgt tta ggt ttt Glu Thr Ser Ala Pro Arg Asn Leu Pro Phe Tyr Glu Arg Leu Gly Phe	165	170	175	528	
acg gta acg gcg gat gta gaa gta ccg gaa ggt ccg cgt acg tgg tgt Thr Val Thr Ala Asp Val Glu Val Pro Glu Gly Pro Arg Thr Trp Cys	180	185	190	576	
atg acg cgt aaa ccg ggt gcg tga Met Thr Arg Lys Pro Gly Ala	195			600	
<210> 42					
<211> 600					
<212> DNA					
<213> unknown					
<220>					
<223> wild type puromycin resistant gene					
<220>					
<221> CDS					
<222> (1).. (600)					
<400> 42					
atg acc gag tac aag ccc acg gtg cgc ctc gcc acc cgc gac gac gtc Met Thr Glu Tyr Lys Pro Thr Val Arg Leu Ala Thr Arg Asp Asp Val	1	5	10	15	48
ccc cgg gcc gta cgc acc ctc gcc gcc gcg ttc gcc gac tac ccc gcc Pro Arg Ala Val Arg Thr Leu Ala Ala Phe Ala Asp Tyr Pro Ala	20	25	30		96
acg cgc cac acc gtc gac ccg gac cgc cac atc gag cgg gtc acc gag Thr Arg His Thr Val Asp Pro Asp Arg His Ile Glu Arg Val Thr Glu	35	40	45		144
ctg caa gaa ctc ttc ctc acg cgc gtc ggg ctc gac atc ggc aag gtg Leu Gln Glu Leu Phe Leu Thr Arg Val Gly Leu Asp Ile Gly Lys Val	50	55	60		192
tgg gtc gcg gac gac ggc gcc gcg gtg gcg gtc tgg acc acg ccg gag Trp Val Ala Asp Asp Gly Ala Ala Val Ala Val Trp Thr Thr Pro Glu	65	70	75	80	240
agc gtc gaa gcg ggg gcg gtg ttc gcc gag atc ggc ccg cgc atg gcc Ser Val Glu Ala Gly Ala Val Phe Ala Glu Ile Gly Pro Arg Met Ala	85	90	95		288
gag ttg agc ggt tcc cgg ctg gcc gcg cag caa cag atg gaa ggc ctc Glu Leu Ser Gly Ser Arg Leu Ala Ala Gln Gln Gln Met Glu Gly Leu	100	105	110		336
ctg gcg ccg cac cgg ccc aag gag ccc gcg tgg ttc ctg gcc acc gtc Leu Ala Pro His Arg Pro Lys Glu Pro Ala Trp Phe Leu Ala Thr Val	115	120	125		384
ggc gtc tcg ccc gac cac cag ggc aag ggt ctg ggc agc gcc gtc gtg Gly Val Ser Pro Asp His Gln Gly Lys Gly Leu Gly Ser Ala Val Val	130	135	140		432

ctc ccc gga gtg gag gcg gcc gag cgc gcc ggg gtg ccc gcc ttc ctg Leu Pro Gly Val Glu Ala Ala Glu Arg Ala Gly Val Pro Ala Phe Leu 145 150 155 160	480
gag acc tcc gcg ccc cgc aac ctc ccc ttc tac gag cgg ctc ggc ttc Glu Thr Ser Ala Pro Arg Asn Leu Pro Phe Tyr Glu Arg Leu Gly Phe 165 170 175	528
acc gtc acc gcc gac gtc gag gtg ccc gaa gga ccg cgc acc tgg tgc Thr Val Thr Ala Asp Val Glu Val Pro Glu Gly Pro Arg Thr Trp Cys 180 185 190	576
atg acc cgc aag ccc ggt gcc tga Met Thr Arg Lys Pro Gly Ala 195	600

<210> 43
 <211> 600
 <212> DNA
 <213> artificial

<220>
 <223> modified puromycin resistant gene

<220>
 <221> CDS
 <222> (1).. (600)

<400> 43 atg acc gag tac aag ccc acg gta cgc tta gcg acc cgc gac gac gta Met Thr Glu Tyr Lys Pro Thr Val Arg Leu Ala Thr Arg Asp Asp Val 1 5 10 15	48
ccc cgg gcg gta cgc acc tta gcg gcg gcg ttc gcg gac tac ccc gcg Pro Arg Ala Val Arg Thr Leu Ala Ala Phe Ala Asp Tyr Pro Ala 20 25 30	96
acg cgc cac acc gta gac ccg gac cgc cac atc gag cgg gta acc gag Thr Arg His Thr Val Asp Pro Asp Arg His Ile Glu Arg Val Thr Glu 35 40 45	144
tta caa gaa tta ttc tta acg cgc gta ggg tta gac atc ggc aag gta Leu Gln Glu Leu Phe Leu Thr Arg Val Gly Leu Asp Ile Gly Lys Val 50 55 60	192
tgg gta gcg gac gac ggc gcg gcg gta gcg gta tgg acc acg ccg gag Trp Val Ala Asp Asp Gly Ala Ala Val Ala Val Trp Thr Thr Pro Glu 65 70 75 80	240
tcg gta gaa gcg ggg gcg gta ttc gcg gag atc ggc ccg cgc atg gcg Ser Val Glu Ala Gly Ala Val Phe Ala Glu Ile Gly Pro Arg Met Ala 85 90 95	288
gag tta tcg ggt tcg cgg tta gcg gcg cag caa cag atg gaa ggc tta Glu Leu Ser Gly Ser Arg Leu Ala Ala Gln Gln Met Glu Gly Leu 100 105 110	336
tta gcg ccg cac cgg ccc aag gag ccc gcg tgg ttc tta gcg acc gta Leu Ala Pro His Arg Pro Lys Glu Pro Ala Trp Phe Leu Ala Thr Val 115 120 125	384
ggc gta tcg ccc gac cac cag ggc aag ggt tta ggc tcg gcg gta gta Gly Val Ser Pro Asp His Gln Gly Lys Gly Leu Gly Ser Ala Val Val 130 135 140	432
tta ccc gga gta gag gcg gcg gag cgc gcg ggg gta ccc gcg ttc tta Leu Pro Gly Val Glu Ala Ala Glu Arg Ala Gly Val Pro Ala Phe Leu 145 150 155 160	480
gag acc tcg gcg ccc cgc aac tta ccc ttc tac gag cgg tta ggc ttc Glu Thr Ser Ala Pro Arg Asn Leu Pro Phe Tyr Glu Arg Leu Gly Phe 165 170 175	528
acc gta acc gcg gac gta gag gta ccc gaa gga ccg cgc acc tgg tgc Thr Val Thr Ala Asp Val Glu Val Pro Glu Gly Pro Arg Thr Trp Cys	576

180	185	190	
atg acc cgc aag ccc ggt gcg tga			600
Met Thr Arg Lys Pro Gly Ala			
195			
<210> 44			
<211> 600			
<212> DNA			
<213> artificial			
<220>			
<223> modified puromycin resistant gene			
<220>			
<221> CDS			
<222> (1).. (600)			
<400> 44			
atg acg gaa tat aaa ccg acg gta cgt tta gcg acg cgt gat gat gta			48
Met Thr Glu Tyr Lys Pro Thr Val Arg Leu Ala Thr Arg Asp Asp Val			
1 5 10 15			
ccg cgt gcg gta cgt acg tta gcg gcg gcg ttt gcg gat tat ccg gcg			96
Pro Arg Ala Val Arg Thr Leu Ala Ala Phe Ala Asp Tyr Pro Ala			
20 25 30			
acg cgt cat acg gta gat ccg gat cgt cat ata gaa cgt gta acg gaa			144
Thr Arg His Thr Val Asp Pro Asp Arg His Ile Glu Arg Val Thr Glu			
35 40 45			
tta caa gaa tta ttt tta acg cgt gta ggt tta gat ata ggt aaa gta			192
Leu Gln Glu Leu Phe Leu Thr Arg Val Gly Leu Asp Ile Gly Lys Val			
50 55 60			
tgg gta gcg gat gat ggt gcg gcg gta gcg gta tgg acg acg ccg gaa			240
Trp Val Ala Asp Asp Gly Ala Ala Val Ala Val Trp Thr Thr Pro Glu			
65 70 75 80			
tcg gta gaa gcg ggt gcg gta ttt gcg gaa ata ggt ccg cgt atg gcg			288
Ser Val Glu Ala Gly Ala Val Phe Ala Glu Ile Gly Pro Arg Met Ala			
85 90 95			
gaa tta tcg ggt tcg cgt tta gcg gcg caa caa caa atg gaa ggt tta			336
Glu Leu Ser Gly Ser Arg Leu Ala Ala Gln Gln Gln Met Glu Gly Leu			
100 105 110			
tta gcg ccg cat cgt ccg aaa gaa ccg gcg tgg ttt tta gcg acg gta			384
Leu Ala Pro His Arg Pro Lys Glu Pro Ala Trp Phe Leu Ala Thr Val			
115 120 125			
ggt gta tcg ccg gat cat caa ggt aaa ggt tta ggt tcg gcg gta gta			432
Gly Val Ser Pro Asp His Gln Gly Lys Gly Leu Gly Ser Ala Val Val			
130 135 140			
tta ccg ggt gta gaa gcg gcg gaa cgt gcg ggt gta ccg gcg ttt tta			480
Leu Pro Gly Val Glu Ala Ala Glu Arg Ala Gly Val Pro Ala Phe Leu			
145 150 155 160			
gaa acg tcg gcg ccg cgt aat tta ccg ttt tat gaa cgt tta ggt ttt			528
Glu Thr Ser Ala Pro Arg Asn Leu Pro Phe Tyr Glu Arg Leu Gly Phe			
165 170 175			
acg gta acg gcg gat gta gaa gta ccg gaa ggt ccg cgt acg tgg tgt			576
Thr Val Thr Ala Asp Val Glu Val Pro Glu Gly Pro Arg Thr Trp Cys			
180 185 190			
atg acg cgt aaa ccg ggt gcg tga			600
Met Thr Arg Lys Pro Gly Ala			
195			
<210> 45			
<211> 375			
<212> DNA			
<213> artificial			

<220>
 <223> modified zeocin resistant gene

<220>
 <221> CDS
 <222> (1).. (375)

<400> 45
 atg gcg aag tta acc tcg gcg gtt ccg gta tta acc gcg cgc gac gtc 48
 Met Ala Lys Leu Thr Ser Ala Val Pro Val Leu Thr Ala Arg Asp Val
 1 5 10 15
 gcg gga gcg gtc gag ttc tgg acc gac ccg tta ggg ttc tcg ccg gac 96
 Ala Gly Ala Val Glu Phe Trp Thr Asp Arg Leu Gly Phe Ser Arg Asp
 20 25 30
 ttc gta gag gac gac ttc gcg ggt gta gtc ccg gac gac gta acc tta 144
 Phe Val Glu Asp Asp Phe Ala Gly Val Val Arg Asp Asp Val Thr Leu
 35 40 45
 ttc atc tcg gcg gtc cag gac cag gta gta ccg gac aac acc tta gcg 192
 Phe Ile Ser Ala Val Gln Asp Gln Val Val Pro Asp Asn Thr Leu Ala
 50 55 60
 tgg gta tgg gta cgc gcc tta gac gag tta tac gcg gag tgg tcg gag 240
 Trp Val Trp Val Arg Gly Leu Asp Glu Leu Tyr Ala Glu Trp Ser Glu
 65 70 75 80
 gtc gta tcg acg aac ttc ccg gac gcc tcg ggg ccg gcg atg acc gag 288
 Val Val Ser Thr Asn Phe Arg Asp Ala Ser Gly Pro Ala Met Thr Glu
 85 90 95
 atc gcc gag cag ccg tgg ggg ccg gag ttc gcg tta cgc gac ccg gcg 336
 Ile Gly Glu Gln Pro Trp Gly Arg Glu Phe Ala Leu Arg Asp Pro Ala
 100 105 110
 gcc aac tgc gta cac ttc gta gcg gag gag cag gac tga 375
 Gly Asn Cys Val His Phe Val Ala Glu Glu Gln Asp
 115 120

<210> 46
 <211> 375
 <212> DNA
 <213> artificial

<220>
 <223> modified zeocin resistant gene

<220>
 <221> CDS
 <222> (1).. (375)

<400> 46
 atg gcg aaa tta acg tcg gcg gta ccg gta tta acc gcg cgt gat gta 48
 Met Ala Lys Leu Thr Ser Ala Val Pro Val Leu Thr Ala Arg Asp Val
 1 5 10 15
 gcg ggt gcg gta gaa ttt tgg acg gat cgt tta ggt ttt tcg cgt gat 96
 Ala Gly Ala Val Glu Phe Trp Thr Asp Arg Leu Gly Phe Ser Arg Asp
 20 25 30
 ttt gta gaa gat gat ttt gcg ggt gta gta cgt gat gat gta acc tta 144
 Phe Val Glu Asp Asp Phe Ala Gly Val Val Arg Asp Asp Val Thr Leu
 35 40 45
 ttt ata tcg gcg gta caa gat caa gta gta ccg gat aat acc tta gcg 192
 Phe Ile Ser Ala Val Gln Asp Gln Val Val Pro Asp Asn Thr Leu Ala
 50 55 60
 tgg gta tgg gta cgt ggt tta gat gaa tta tat gcg gaa tgg tcg gaa 240
 Trp Val Trp Val Arg Gly Leu Asp Glu Leu Tyr Ala Glu Trp Ser Glu
 65 70 75 80

gta gta tcg acg aat ttt cgt gat gcg tcg ggt ccg gcg atg acg gaa Val Val Ser Thr Asn Phe Arg Asp Ala Ser Gly Pro Ala Met Thr Glu 85 90 95	288
ata ggt gaa caa ccg tgg ggt cgt gaa ttt gcg tta cgt gat ccg gcg Ile Gly Glu Gln Pro Trp Gly Arg Glu Phe Ala Leu Arg Asp Pro Ala 100 105 110	336
ggt aat tgt gta cat ttt gta gcg gaa gaa caa gat tga Gly Asn Cys Val His Phe Val Ala Glu Glu Gln Asp 115 120	375
<210> 47	
<211> 1026	
<212> DNA	
<213> artificial	
<220>	
<223> modified hygromycin resistant gene	
<220>	
<221> CDS	
<222> (1).. (1026)	
<400> 47	
atg aaa aag cct gaa tta acc gcg acg tcg gta gag aag ttt tta atc Met Lys Lys Pro Glu Leu Thr Ala Thr Ser Val Glu Lys Phe Leu Ile 1 5 10 15	48
gaa aag ttc gac tcg gta tcg gac tta atg cag tta tcg gag ggc gaa Glu Lys Phe Asp Ser Val Ser Asp Leu Met Gln Leu Ser Glu Gly Glu 20 25 30	96
gaa tcg cgt gcg ttc tcg ttc gat gta gga ggg cgt gga tat gta tta Glu Ser Arg Ala Phe Ser Phe Asp Val Gly Gly Arg Gly Tyr Val Leu 35 40 45	144
cgt gta aat tcg tgc gcg gat ggt ttc tac aaa gat cgt tat gta tat Arg Val Asn Ser Cys Ala Asp Gly Phe Tyr Lys Asp Arg Tyr Val Tyr 50 55 60	192
cgt cac ttt gcg tcg gcg gcg tta ccg att ccg gaa gta tta gac att Arg His Phe Ala Ser Ala Ala Leu Pro Ile Pro Glu Val Leu Asp Ile 65 70 75 80	240
ggg gaa ttc tcg gag tcg tta acc tat tgc atc tcg cgc cgt gcg cag Gly Glu Phe Ser Glu Ser Leu Thr Tyr Cys Ile Ser Arg Arg Ala Gln 85 90 95	288
ggt gta acg ttg caa gac tta cct gaa acc gaa tta ccc gcg gta tta Gly Val Thr Leu Gln Asp Leu Pro Glu Thr Glu Leu Pro Ala Val Leu 100 105 110	336
cag ccg gta gcg gag gcg atg gat gcg atc gcg gcg gcg gat tta tcg Gln Pro Val Ala Glu Ala Met Asp Ala Ile Ala Ala Ala Asp Leu Ser 115 120 125	384
cag acg tcg ggg ttc ggc cca ttc gga ccg caa gga atc ggt caa tac Gln Thr Ser Gly Phe Gly Pro Phe Gly Pro Gln Gly Ile Gly Gln Tyr 130 135 140	432
act aca tgg cgt gat ttc ata tgc gcg att gcg gat ccc cat gta tat Thr Thr Trp Arg Asp Phe Ile Cys Ala Ile Ala Asp Pro His Val Tyr 145 150 155 160	480
cac tgg caa act gta atg gac gac acc gta tcg gcg tcg gta gcg cag His Trp Gln Thr Val Met Asp Asp Thr Val Ser Ala Ser Val Ala Gln 165 170 175	528
gcg tta gat gag tta atg tta tgg gcg gag gac tgc ccc gaa gta cgt Ala Leu Asp Glu Leu Met Leu Trp Ala Glu Asp Cys Pro Glu Val Arg 180 185 190	576
cac tta gta cac gcg gat ttc ggc tcg aac aat gta tta acg gac aat His Leu Val His Ala Asp Phe Gly Ser Asn Asn Val Leu Thr Asp Asn	624

195	200	205	
ggc cgc ata aca gcg gta att gac tgg tgc gag gcg atg ttc ggg gat Gly Arg Ile Thr Ala Val Ile Asp Trp Ser Glu Ala Met Phe Gly Asp 210 215 220			672
tgc caa tac gag gta gcg aac atc ttc ttc tgg cgt ccg tgg ttg gcg Ser Gln Tyr Glu Val Ala Asn Ile Phe Phe Trp Arg Pro Trp Leu Ala 225 230 235 240			720
tgt atg gag cag cag acg cgc tac ttc gag cgt cgt cat ccg gag tta Cys Met Glu Gln Gln Thr Arg Tyr Phe Glu Arg Arg His Pro Glu Leu 245 250 255			768
gcg gga tgc ccg cgt tta cgt gcg tat atg tta cgc att ggt ctt gac Ala Gly Ser Pro Arg Leu Arg Ala Tyr Met Leu Arg Ile Gly Leu Asp 260 265 270			816
caa tta tat cag tgc ttg gta gac ggc aat ttc gat gat gcg gcg tgg Gln Leu Tyr Gln Ser Leu Val Asp Gly Asn Phe Asp Asp Ala Ala Trp 275 280 285			864
gcg cag ggt cga tgc gac gcg atc gta cga tgc gga gcg ggg act gta Ala Gln Gly Arg Cys Asp Ala Ile Val Arg Ser Gly Ala Gly Thr Val 290 295 300			912
ggg cgt aca caa atc gcg cgc cgt tgc gcg gcg gta tgg acc gat ggc Gly Arg Thr Gln Ile Ala Arg Arg Ser Ala Ala Val Trp Thr Asp Gly 305 310 315 320			960
tgt gta gaa gta tta gcg gat tgc gga aac cga cgc ccc tgc act cgt Cys Val Glu Val Leu Ala Asp Ser Gly Asn Arg Arg Pro Ser Thr Arg 325 330 335			1008
ccg cgt gcg aag gaa tag Pro Arg Ala Lys Glu 340			1026
 <210> 48 <211> 1026 <212> DNA <213> artificial			
 <220> <223> modified hygromycin resistant gene			
 <220> <221> CDS <222> (1).. (1026)			
 <400> 48			
atg aaa aaa ccg gaa tta acg gcg acg tgc gta gaa aaa ttt tta ata Met Lys Lys Pro Glu Leu Thr Ala Thr Ser Val Glu Lys Phe Leu Ile 1 5 10 15			48
gaa aaa ttt gat tgc gta tgc gat tta atg caa tta tgc gaa ggt gaa Glu Lys Phe Asp Ser Val Ser Asp Leu Met Gln Leu Ser Glu Gly Glu 20 25 30			96
gaa tgc cgt gcg ttt tgc ttt gat gta ggt ggt cgt ggt tat gta tta Glu Ser Arg Ala Phe Ser Phe Asp Val Gly Gly Arg Gly Tyr Val Leu 35 40 45			144
cgt gta aat tgc tgt gcg gat ggt ttt tat aaa gat cgt tat gta tat Arg Val Asn Ser Cys Ala Asp Gly Phe Tyr Lys Asp Arg Tyr Val Tyr 50 55 60			192
cgt cat ttt gcg tgc gcg gcg tta ccg ata ccg gaa gta tta gat ata Arg His Phe Ala Ser Ala Ala Leu Pro Ile Pro Glu Val Leu Asp Ile 65 70 75 80			240
ggt gaa ttt tgc gaa tgc tta acg tat tgt ata tgc cgt cgt gcg caa Gly Glu Phe Ser Glu Ser Leu Thr Tyr Cys Ile Ser Arg Arg Ala Gln 85 90 95			288

ggt gta acg tta caa gat tta ccg gaa acg gaa tta ccg gcg gta tta Gly Val Thr Leu Gln Asp Leu Pro Glu Thr Glu Leu Pro Ala Val Leu 100 105 110	336
caa ccg gta gcg gaa gcg atg gat gcg ata gcg gcg gcg gat tta tcg Gln Pro Val Ala Glu Ala Met Asp Ala Ile Ala Ala Asp Leu Ser 115 120 125	384
caa acg tcg ggt ttt ggt ccg ttt ggt ccg caa ggt ata ggt caa tat Gln Thr Ser Gly Phe Gly Pro Phe Gly Pro Gln Gly Ile Gly Gln Tyr 130 135 140	432
acg acg tgg cgt gat ttt ata tgt gcg ata gcg gat ccg cat gta tat Thr Thr Trp Arg Asp Phe Ile Cys Ala Ile Ala Asp Pro His Val Tyr 145 150 155 160	480
cat tgg caa acg gta atg gat gat acg gta tcg gcg tcg gta gcg caa His Trp Gln Thr Val Met Asp Asp Thr Val Ser Ala Ser Val Ala Gln 165 170 175	528
gcg tta gat gaa tta atg tta tgg gcg gaa gat tgt ccg gaa gta cgt Ala Leu Asp Glu Leu Met Leu Trp Ala Glu Asp Cys Pro Glu Val Arg 180 185 190	576
cat tta gta cat gcg gat ttt ggt tcg aat aat gta tta acg gat aat His Leu Val His Ala Asp Phe Gly Ser Asn Asn Val Leu Thr Asp Asn 195 200 205	624
ggt cgt ata acg gcg gta ata gat tgg tcg gaa gcg atg ttt ggt gat Gly Arg Ile Thr Ala Val Ile Asp Trp Ser Glu Ala Met Phe Gly Asp 210 215 220	672
tcg caa tat gaa gta gcg aat ata ttt ttt tgg cgt ccg tgg tta gcg Ser Gln Tyr Glu Val Ala Asn Ile Phe Phe Trp Arg Pro Trp Leu Ala 225 230 235 240	720
tgt atg gaa caa caa acg cgt tat ttt gaa cgt cgt cat ccg gaa tta Cys Met Glu Gln Gln Thr Arg Tyr Phe Glu Arg Arg His Pro Glu Leu 245 250 255	768
gcg ggt tcg ccg cgt tta cgt gcg tat atg tta cgt ata ggt tta gat Ala Gly Ser Pro Arg Leu Arg Ala Tyr Met Leu Arg Ile Gly Leu Asp 260 265 270	816
caa tta tat caa tcg tta gta gat ggt aat ttt gat gat gcg gcg tgg Gln Leu Tyr Gln Ser Leu Val Asp Gly Asn Phe Asp Asp Ala Ala Trp 275 280 285	864
gcg caa ggt cgt tgt gat gcg ata gta cgt tcg ggt gcg ggt acg gta Ala Gln Gly Arg Cys Asp Ala Ile Val Arg Ser Gly Ala Gly Thr Val 290 295 300	912
ggt cgt acg caa ata gcg cgt cgt tcg gcg gcg gta tgg acg gat ggt Gly Arg Thr Gln Ile Ala Arg Arg Ser Ala Ala Val Trp Thr Asp Gly 305 310 315 320	960
tgt gta gaa gta tta gcg gat tcg ggt aat cgt cgt ccg tcg acg cgt Cys Val Glu Val Leu Ala Asp Ser Gly Asn Arg Arg Pro Ser Thr Arg 325 330 335	1008
ccg cgt gcg aaa gaa tga Pro Arg Ala Lys Glu 340	1026

Fig. 1





Fig. 2

Fig. 3




Fig. 4





Fig. 5

Fig. 6





Fig. 7


Fig. 8

Fig. 9




Fig. 10





Fig. 11


Fig. 12

Fig. 13